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Abstract
The majority of hepatocellular carcinomas (HCCs) develop in a setting of chronic inflamma-
tion, which is accompanied by the persistent activation of macrophages and long-lasting in-
filtration of lymphocytes into the liver. Inflammatory microenvironments comprise a battery
of cytokines and growth factors that stimulate liver regeneration but also favour malignant
transformation and support neoplastic growth. One important group of inflammatory media-
tors present within this inflammatory microenvironment are IL-6-type cytokines which induce
a growth-promoting transcriptional program by activating signal transducer and activator of
transcription 3 (STAT3). While the expression of STAT3 target genes supports cellular sur-
vival and stimulates proliferation, STAT3 activation might also play an important role in
the regulation of cellular metabolism. STAT3 induces the expression of the metabolic key
regulator hypoxia-inducible factor-1α (HIF-1α) which orchestrates the regulation of hundreds
of target genes, many of which play key roles in the adaptation of cellular metabolism to low
oxygen tension. Both, aberrant STAT3 signalling and HIF-1α expression are associated with
cancer development and progression. While aberrant STAT3 expression drives cellular prolif-
eration, the particular impact of STAT3-mediated HIF-1α induction on cellular metabolism
under normoxic conditions remained to be elucidated. Thus we aimed to determine whether
IL-6 type cytokines induce changes within central carbon metabolism that would support the
metabolic requirements of carcinogenesis.
In this work, we used the IL-6-type cytokine Oncostatin M (OSM) to induce HIF-1α ex-
pression under normoxic conditions in HCC cell lines and in immortalized hepatocytes. We
performed stable-isotope assisted metabolomics to decipher whether OSM-induced HIF-1α
results in a hypoxia-like metabolic phenotype and thus has the ability to promote neoplastic
growth.
We found that short-term OSM treatments induced metabolic reprogramming in immortal-
ized hepatocytes while the metabolism of HCC cell lines remained unaffected. OSM-mediated
changes within central carbon metabolism were characterized by a reduced pyruvate dehy-
drogenase complex activity, thus a diminished entry of glucose-derived carbon into the TCA
cycle and an increased reductive glutamine metabolism. We provided evidence that OSM-
mediated metabolic changes in immortalized hepatocytes were HIF-1α-dependent and that
the HIF-1α target gene pyruvate dehydrogenase kinase 1 plays an essential role. Although
OSM-induced HIF-1α protein levels under normoxia were comparable to those observed un-
der hypoxia, OSM-mediated metabolic reprogramming was less pronounced.
While cellular metabolism of HCC cell lines was unaffected by short-term OSM treatments,
we showed that chronic OSM exposure leads to drastic metabolic changes in the HCC cell
line JHH-4. Chronic OSM treatment in JHH-4 cells did not induce HIF-1α, suggesting that
the metabolic effects are HIF-1α independent. Chronic OSM stimulation did not effect PDC
activity while reductive glutamine metabolism to generate lipogenic citrate was induced,
iv
pointing towards OSM-induced changes in fatty acid metabolism.
Our results reveal that inflammatory conditions, which frequently coincide with HCC devel-
opment and progression, might assist carcinogenesis by regulating growth promoting changes
in cellular metabolism.
v
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Chapter 1
Introduction
1.1 Inflammation promotes hepatocellular carcinoma devel-
opment
Chronic inflammation precedes 70% to 90% of all hepatocellular carcinomas (HCCs), which
indicates that inflammatory conditions promote malignant growth [El-Serag and Rudolph,
2007]. Chronic hepatitis B and C virus infections, amongst other causes, induce liver cirrhosis
which is accompanied by a continuous activation of liver resident macrophages, the Kupffer
cells, and long-lasting infiltration of lymphocytes [El-Serag and Rudolph, 2007, Fausto, 1999].
This condition stimulates hepatocyte regeneration while driving hepatocarcinogenesis and is
accompanied by the production of cytokines, chemokines and growth factors that support
proliferation [Fausto, 1999]. In addition, activated immune cells secrete reactive oxygen
species (ROS) and nitrogen oxide species (NOS) which increase mutagenesis and thereby can
lead to the activation of oncogenes and/or inactivation of tumour suppressor genes [Sakurai
et al., 2008].
Primary liver cancer is the fifth most common cancer, causing approximately 600,000 deaths
each year, and is the third most common cause of cancer-related death worldwide [El-Serag
and Rudolph, 2007, Parkin, 2001]. The vast majority (85% to 90%) of primary liver cancers
are HCCs which preferentially develop within an inflammatory microenvironment [El-Serag
and Rudolph, 2007]. The observation that chronic inflammation drives cancer development
and progression dates back to 1863 where Rudolf Virchow observed that cancer predominantly
develops at sites of inflammation (reviewed in [Balkwill and Mantovani, 2001, Mantovani
et al., 2008]. 150 years later, 15% of all cancers are attributed to chronic infection and
inflammation while tumour-promoting inflammation is now considered a hallmark of cancer
[Hanahan and Weinberg, 2011, Kuper et al., 2000].
While numerous signalling cascades are described to be involved in HCC development and
1
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progression, an important role has been attributed to the signal transducer and activator of
transcription 3 (STAT3) (reviewed in [Aravalli et al., 2008]) (Section 1.2).
1.2 The implication of STAT3 in cancer developpment
The transcription factor STAT3 is activated in 50-90% of primary human tumours and in
numerous cancer cell lines [Garcia et al., 2001, Ma et al., 2004, Mora Linda et al., 2002, Xu
et al., 2005]. Growing evidence indicates that STAT3-induced gene transcription plays a key
role in inflammation-mediated tumorigenesis and inflammation-stimulated tumour progres-
sion [Bollrath et al., 2009, Catlett-Falcone et al., 1999, Grivennikov et al., 2009, Kortylewski
et al., 2009, Kujawski et al., 2008, Mantovani et al., 2008]. Constitutive STAT3 activation
results either from genetic alterations or extrinsic stimuli such as chemicals, carcinogens and
infection [Arredondo et al., 2006, Bronte-Tinkew et al., 2009, Chan et al., 2004, Ernst et al.,
2008, Gao et al., 2007, Gu et al., 2007, Olcaydu et al., 2009, Samavati et al., 2009, Sano
et al., 2005, Spannbauer and Trautwein, 2009]. Since STAT3 oncogenic mutations are rare in
malignant liver cancer, it is most probable that growth factors and cytokines within the in-
flammatory microenvironment are responsible for aberrant STAT3 activation [He and Karin,
2011] (Section 1.3).
1.3 STAT3 activation by IL-6-type cytokines
STAT3-mediated transcription is commonly induced by cytokines, growth factors and car-
cinogens (reviewed in [Aggarwal et al., 2009]). Cytokines that activate STAT3 include the
family of Interleukin-6 (IL-6)-type cytokines which is composed of IL-6, interleukin-11 (IL-11),
leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNPF),
cardiotrophin 1 (CT-1) and cardiotrophin-like cytokine (CLCF-1) (reviewed in [Heinrich
et al., 1998]). IL-6-type cytokines initiate the Janus kinase (JAK)-STAT3 signalling cas-
cade through ligand-induced membrane receptor homo- or heterodimerization (Figure 1.1).
Dimeric IL-6-type cytokine receptors are composed of glycoprotein 130 (gp130) and a ligand
specific subunit (reviewed in [Heinrich et al., 1998]) (Figure 1.1). IL-6 signals via a gp130
homodimer while CNPF, LIF and CT-1 recruit gp130-LIF receptor (LIFR) heterodimers and
OSM requires gp130-LIFR or gp130-OSM receptor (OSMR) heterodimers [Davis et al., 1993,
Gearing et al., 1992, Ichihara et al., 1997, Murakami et al., 1993, Pennica et al., 1995]. IL-11
signals via gp130-IL-11 receptor (IL11R) complexes [Robb et al., 1996].
Ligand-mediated receptor activation leads to the phosphorylation of receptor-associated JAKs
(Figure 1.1). In turn, JAKs phosphorylate tyrosine residues on the cytoplasmic tail of the
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Figure 1.1: IL-6-type cytokine-mediated JAK/STAT3 signalling. Immune cells se-
crete IL-6-type cytokines which bind their surface receptors on target cells. As a consequence,
the receptors homo- or heterodimerize which brings the JAKs bound to the receptor in close
proximity and leads to their transphosphorylation. In turn, activated JAKs phosphorylate
the cytosolic part of the receptor which leads to the docking and subsequent phosphorylation
of STAT3. Phosphorylated STAT3 molecules dimerize and translocate to the nucleus where
they act as transcriptional regulators. A subset of STAT3 target genes and their respective
functions are listed (adapted from [Yu et al., 2009]). JAK-STAT3 signalling is negatively
regulated by SOCS and PIAS which respectively interfere with signal transduction and tran-
scriptional activity of STAT3. JAK Janus kinase, STAT3 signal transducer and activator of
transcription 3, SOCS suppressor of cytokine signaling, PIAS protein inhibitor of activated
STAT.
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receptor and thereby recruit STAT3. Consequently, STAT3 is phosphorylated and thereby ac-
tivated [Hemmann et al., 1996, Stahl et al., 1995]. Phosphorylated STAT3 molecules dimerize
and translocate to the nucleus where they regulate the expression of genes involved in cel-
lular survival, proliferation, invasion, angiogenesis and metastasis (reviewed in [Aggarwal
et al., 2009, Frank, 2007]) (Figure 1.1). Canonical IL-6-type cytokine signalling occurs via
STAT3, however, in parallel other signalling cascades such as the mitogen-activated protein
kinase (MAPK) pathway and the phosphatidylinositide 3-kinase (PI3K)/protein kinase B
(PKB)/mechanistic target of rapamycin (mTOR) pathways are also induced (reviewed in
[Dey et al., 2013, Hermanns, 2015]).
STAT3 signalling is tightly regulated by protein tyrosine phosphatases (PTPs), the protein
inhibitor of activated STAT (PIAS) and the suppressor of cytokine signalling (SOCS) (re-
viewed in [Shuai and Liu, 2003] (Figure 1.1). PTPs carry out tyrosine dephosphorylations
within the components of the JAK/STAT3 signalling pathway and thereby regulate its ac-
tivity (reviewed in [Yang et al., 2004]. SOCS binds JAKs and the cytokine receptor and
compete with STAT signalling while PIAS interferes with the capacity of STAT to bind DNA
(reviewed in [Carow and Rottenberg, 2014, Shuai and Liu, 2005]). In addition, cytokine sig-
nalling is inhibited by receptor internalization [Wang and Fuller, 1994].
1.3.1 The IL-6-type cytokine Oncostatin M
Activated monocytes and macrophages are the primary source of OSM in vivo: it is released
upon stimulation with Toll-like-receptor ligands or prostaglandins while T-cells and dendritic
cells also secrete OSM [Ganesh et al., 2012, Zarling et al., 1986]. OSM primarily activates
STAT3 signalling and in parallel induces PI3K, STAT1, extracellular signal-regulated kinase
(ERK) and Jun amino-terminal kinase (JNK) pathways [Faris et al., 1996]. In the liver, Kupf-
fer cells secrete OSM along with other IL-6-type cytokines and thereby initiate the secretion
of acute phase proteins which are part of the innate non-specific immune response [Richards
et al., 1992]. Furthermore, OSM regulates fetal liver development, liver regeneration, hepatic
cell differentiation and hematopeisis [Kamiya et al., 1999, Miyajima et al., 2000, Nakamura
et al., 2004].
OSM was considered as an anticancer drug because it inhibits the proliferation of various
cancer cell lines including melanoma, glioma, hepatoma, neuroblastoma, lung and breast
cancer [Halfter et al., 1998, Horn et al., 1990, Klausen et al., 2000, Zarling et al., 1986].
However, preclinical studies were not completed, most probably due to OSM-induced side
effects [Richards, 2013]. Moreover, the effects of OSM on proliferation are pleiotropic, while
it inhibits growth in some cell lines it stimulates proliferation in others such as in Kaposi’s
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sarcoma cells [Nair et al., 1992].
1.4 The implication of STAT3 in HCC
Aberrant STAT3 activation occurs in 60% of HCCs and is associated with aggressive cancer
and a poor prognosis [Calvisi et al., 2006, He et al., 2010]. Although it is clear that consti-
tutive STAT3 activation is involved in HCC, the exact mechanisms remain to be elucidated.
60% of benign liver adenomas harbour small in-frame deletions within the gp130 subunit of
the IL-6-type cytokine receptor that lead to constitutive STAT3 activation. HCC, however,
only develops when the gp130 deletion is combined with an activating mutation in β-catenin
[Spannbauer and Trautwein, 2009]. Since STAT3 oncogenic mutations are rare in HCC, it is
most probable that growth factors and cytokines within the inflammatory microenvironment
are responsible for STAT3 activation [He and Karin, 2011].
Pro-inflammatory cytokines, such as IL-6 and OSM, can establish a pro-carcinogenic mi-
croenvironment by activating STAT3 [Mantovani et al., 2008]. Indeed, cirrhotic liver tissue
contains high levels of OSM while high IL-6 concentrations in serum promote the develop-
ment of hepatocellular carcinoma in patients with hepatitis B [Wong et al., 2009, Znoyko
et al., 2005]. Moreover, patients with HCC have increased IL-6 and OSM serum levels [Gi-
annitrapani et al., 2006, Liang et al., 2012]. According to data from the Human Proteome
Atlas, OSM is not present in healthy liver tissue, while moderate levels are detected in HCC
tissue slices [Uhle´n et al., 2015]. Mouse models also point towards STAT3 and IL-6 as impor-
tant mediators in HCC development. In mice, HCC can be induced by diethylnitrosamine
(DEN). DEN-induced HCC is characterized by IL-6-mediated persistent STAT3 activation
[Naugler et al., 2007]. However, when HCC is induced by DEN in STAT3 deficient mice, less
mice developed the disease and tumours are generally smaller [He et al., 2010]. Interestingly,
DEN-induced liver damage can be dampened by OSM [Hamada et al., 2007]. Furthermore,
inhibition of STAT3 in HCC cells impairs cell proliferation and induces apoptosis in vitro and
in xenograft models [Sun et al., 2008].
Cellular transformation is a multi-step process that drives progressive malignant transfor-
mation described as hallmarks of cancer. These hallmarks include sustained proliferative
signalling, the evasion of growth suppressors, resistance to cell death, replicative immortality,
induction of angiogenesis, activation of invasion and metastasis, evading immune destruction
and reprogramming of energy metabolism [Hanahan and Weinberg, 2000, 2011]. The effect of
STAT3 on most hallmarks of cancer has been intensively studied over the last years, however
little is known so far about STAT3-mediated effects on cellular metabolism.
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1.5 The metabolic effects of STAT3
STAT3 regulates the expression of genes that are involved in cellular metabolism. STAT3
suppresses gluconeogenesis by blocking the transcription of phosphoenolpyruvate carboxyk-
inase 1 (PEPCK) and the catalytic subunit of glucose-6-phosphatase (G6PC) [Inoue et al.,
2004, Ramadoss et al., 2009]. Furthermore, STAT3 upregulates miR-23a which targets G6PC
and thereby further reduces gluconeogenetic rates [Bo Wang, Shuhao Hsu, Wendy Frankel
and Jacob, 2013]. While STAT3 downregulates gluconeogenesis it enhances glycolysis by up-
regulating hexokinase 2 (HK2) and phosphofructokinase 1 (PFK-1) [Ando et al., 2010]. Apart
from its impact on glycoysis, STAT3 also interferes with mitochondrial respiration. While
transcriptionally active STAT3 is phosphorylated on tyrosine 705, mitochondrial STAT3 is
phosphorylated on serine 727 and regulates the activity of complexes I and II within the elec-
tron transport chain [Wegrzyn et al., 2009]. Mitochondrial STAT3 is furthermore thought
to support oncogenic transformation and promote cancer growth [Gough et al., 2009, Zhang
et al., 2013].
Little is known about the effects of OSM on cellular metabolism. OSM was described to up-
regulate the expression of the low density lipoprotein receptor (LDLR) in the liver, suggesting
its potential involvement in cholesterol metabolism [Grove et al., 1991]. Another study de-
scribes the involvement of OSM in the regulation of fatty acid metabolism [Zhou et al., 2007].
OSM stimulation in HepG2 HCC cells results in the upregulation of acyl-CoA synthase long-
chain family (ACSL) members 3 and 5 and thereby stimulates β-oxidation [Zhou et al., 2007].
However, the effect of OSM on fatty acid metabolism was mediated by OSM-induced ERK
and not STAT3 signalling [Zhou et al., 2007].
Recent studies have revealed an interesting crosstalk between STAT3 and the metabolic key
regulator hypoxia-inducible factor 1-α (HIF-1α) and indicate that IL-6-type cytokines might
have unforeseen roles in the regulation of cellular metabolism (Section 1.6.2.1)
1.6 Hypoxia-inducible factor 1-α
HIF-1 is a basic loop-helix-loop transcription factor that regulates the expression of hundreds
of genes, many of which code for metabolic enzymes that play key roles in the adaptation
of cellular metabolism to low oxygen tension (Figure 1.2)[Allen et al., 2006, Chi et al., 2006,
Vengellur et al., 2003, Wang et al., 1995]. It is composed of α and β subunits that regulate the
transcription of genes containing the hypoxia response consensus sequences 5’- RCGTG-3’
[Wenger et al., 2005]. The HIF-α subunit has three different isoforms: HIF-1α [Semenza and
Wang, 1992], HIF-2α [Ema et al., 1997] and HIF-3α [Gu et al., 1998]. The HIF-β subunit
exists as two isoforms: HIF-1β and HIF-2β. The best studied complex and the most relevant
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Figure 1.2: HIF-1 target genes. HIF-1 regulates to the expression of hundreds of
target genes and thereby regulates various cellular processes. A subset of HIF-1 target
genes is shown. ADM adrenomedullin, AK9 adenylate kinase 9, AMF autocrine motility
factor, BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3, CA9 carbonic anhy-
drase IX, CDKN1A cyclin-dependent kinase inhibitor 1A, COL5A1 collagen, type V,
alpha 1, CP ceruloplasmin, DDIT4 DNA-damage-inducible transcript 4, DEC deleted in
oesophageal cancer, ENG endoglin, ENO1 enolase 1, EPO erythropoietin, ETS-1 E26
transformation-specific 1, FN1 fibronectin 1, GAPDH glyceraldehyde-3-phosphate dehy-
drogenase, GLUT1 glucose transporter 1, GPI glucose-6-phosphate isomerase, HK1 hexok-
inase 1, HK2 hexokinase 2, IGF2 insulin-like growth factor 2, IGFBP1 insulin-like growth
factor binding protein 1, KRT keratin, LDHA lactate dehydrogenase A, LEP leptin, LRP1
low density lipoprotein receptor-related protein 1, MDR multi-drug resistant, MET MET
proto-oncogene, receptor tyrosine kinase, MIC2 CD99 molecule, MMP2 matrix metal-
lopeptidase 2, NOS2 nitric oxide synthase 2, NR4A1 nuclear receptor subfamily 4, group
A, member 1, NT5E 5’-nucleotidase, ecto, P4HA1 prolyl 4-hydroxylase, alpha polypeptide
I, PAI1 serpin peptidase inhibitor member 1, PFKFB3 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3, PFKL phosphofructokinase, liver, PGK1 phosphoglycerate kinase 1,
PKM pyruvate kinase muscle isozyme, TF transferrin, TFRC transferrin receptor, TGF
transforming growth factor, TGM2 transglutaminase 2, TPI triosephosphate isomerase,
UPAR urokinase plasminogen activator receptor, VEGF vascular endothelial growth fac-
tor A, VIM vimentin (adapted from [Semenza, 2003]).
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to this work is HIF-1, composed of a HIF-1α and a HIF-1β subunit.
HIF-1 activation contributes to a wide range of human cancers, where HIF-1 expression corre-
lates with increased tumour aggressiveness, therapeutic resistance and mortality (reviewed in
[Brahimi-Horn and Pouysse´gur, 2004, Quintero et al., 2004, Semenza, 2003]). HIF-1 regulates
angiogenesis, stem cell maintenance, metabolic reprogramming, autocrine growth factor sig-
nalling, epithelial to mesenchymal transition, invasion, metastasis and resistance to radiation
and chemotherapy (reviewed in [Semenza, 2003, 2012, Sturek, 2011]).
1.6.1 Oxygen-dependent HIF-1α induction
HIF-1 was first purified in 1995 and found to upregulate erythropoietin (EPO) production in
response to low oxygen tension [Wang et al., 1995, Wang and Semenza, 1995]. The stability
of the HIF-1α subunit is tightly regulated by oxygen availability, while the HIF-1β subunit is
continuously expressed. Under normoxia, the HIF-1α protein has a half-life of only 5 minutes
as it undergoes oxygen-dependent degradation via the ubiquitin-proteasome pathway [Huang
et al., 1998, Moroz et al., 2009]. In the presence of oxygen, prolyl hydroxylase dioxygenases
(PHDs) catalyse the hydroxylation of HIF-1α on two proline residues (Pro402 and Pro564)
(Figure 1.3) [Bruick and Mcknight, 2001, Epstein et al., 2001, Ivan et al., 2001, Jaakkola
et al., 2001]. Mammalian cells express 4 PHD isoforms, out of which, PHD1, PHD2 and
PHD3 hydroxylate the HIFα subunit (reviewed in [Fong and Takeda, 2008]. PHD2 has a
higher affinity for HIF-1α while PHD1 and PHD3 more efficiently hydroxylate HIF-2α (re-
viewed in [Appelhoff et al., 2004]). Upon proline hydroxylation, HIF-1α binds to the von
Hippel-Lindau (VHL) tumour suppressor which is complexed to elongin B and C. VHL acts
as an E3 ubiquitin ligase which adds ubiquitin residues to HIF-1α and thereby tags it for
proteasomal degradation (Figure 1.3) [Cockman et al., 2000, Maxwell et al., 1999, Stickle
et al., 2004].
A second level of HIF-1α regulation is managed by the factor inhibiting HIF (FIH). FIH hy-
droxylates HIF-1α on an asparaginyl residue (Asp803) located within the carboxy-terminal
transactivation domain (Figure 1.3). Thereby FIH prevents protein-protein interactions be-
tween the HIF-1α transactivation domain and transcriptional co-regulators such as p300 and
the CREB binding protein (CBP) (Figure 1.3) [Masson et al., 2012, Stolze et al., 2004]. Both
PHDs and FIH are members of the iron- and α-ketoglutarate-dependent family of dioxyge-
nases, using oxygen to hydroxylate their substrates and, in parallel, oxidize and decarboxy-
late α-ketoglutarate to succinate [Schofield and Zhang, 1999]. The Arrest-defective protein
1 (ARD1) acetylates HIF-1α on lysine 532 and thereby enhances the interaction with VHL
and thus supports HIF-1α degradation [Jeong et al., 2002] (Figure 1.3).
Under hypoxic conditions, PHDs and FIH are inhibited by the lack of oxygen leading to HIF-
1α stabilization in the cytoplasm, dimerization with HIF-1β and translocation to the nucleus
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Figure 1.3: Mechanisms of HIF-1α stabilization. (A) HIF-1α is composed of 4 do-
mains. The basic helix-loop-helix (bHLH) and the Per-Arnt-Sim (PAS) are involved in
complex dimerization and DNA binding. The N- and C-terminal transactivation domains
(TAD-N, TAD-C) regulate the transcriptional activity of HIF-1α. O2-dependent HIF-1α
hydroxylation is regulated by PHDs (proline 402 and 564) and by FIH (asparagine 803).
FIH-mediated hydoxylation prevents the interaction between HIF-1α and transcriptional
co-regulators p300 and CBP. ARD1 acetylates HIF-1α on lysine 532 within the TAD-N do-
main and enhances the interaction with VHL and thus HIF-1α degradation (adapted from
[Semenza, 2012]. (B) Under normoxic conditions, PDHs and FIH catalyze HIF-1α hydrox-
ylation. Hydroxylation on prolines 402 and 564 lead to the binding of VHL and subsequent
proteasomal degradation. PHDs can be inhibited by the TCA cycle intermediates fumarate
and succinate and HIF-1α can be stabilized. Low oxygen tension or high levels of succinate
and fumarate result in HIF-1α stabilization, dimerization with HIF-β and translocation to the
nucleus. PHD Prolyl hydroxylaes, SDH succinate dehydrogenase, α-KG α-ketoglutarate,
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where the assembled HIF-1 regulates the expression of numerous genetic targets [Jiang et al.,
1996, Mole et al., 2009, Ortiz-Barahona et al., 2010, Semenza et al., 1994, Wang and Semenza,
1995, Xia et al., 2009] (Figure 1.2, 1.3). Another mode of PHD inactivation under hypoxia
might be mediated by ROS generated by the mitochondria under oxygen limitation [Brunelle
et al., 2005, Guzy et al., 2005, Mansfield et al., 2005].
1.6.2 Oxygen-independent HIF-1α induction
HIF-1α induction under normoxic conditions either results from genetic alterations or cy-
tokine and growth factor signalling.
The tumor suppressor VHL is involved in the degradation process of HIF-1α under normoxic
conditions (Figure 1.3). Loss of expression or mutations in its binding domain lead to low-
affinity interactions with HIF-1α which consequently is stabilized [Clifford et al., 2001, Krieg
et al., 2000]. Mutations within fumarate hydratase (FH) and succinate dehydrogenase (SDH)
lead to accumulation of succinate and fumarate which consequently inhibit PHD-mediated
HIF-1α prolyl-hydroxylation. [Hewitson et al., 2007, Isaacs et al., 2005, Pollard et al., 2007,
Selak et al., 2005] (Figure 1.3).
HIF-1α expression can be induced by a variety of cytokines and growth factors (epidermal
growth factor (EGF), fibroblast growth factor 2 (FGF2), hepatocyte growth factor (HGF),
insulin-like growth factor 1 and 2 (IGF), interleukin-1β (IL-1β), insulin, prostaglandin E2,
transforming growth factor α (TGF-α), TGF-β, thrombin, and tumor necrosis factor α (TNF-
α)) via MAPK and PI3K signal transduction pathways [Fukuda et al., 2002, Laughner et al.,
2001, Treins et al., 2002].
In addition, STAT3 was shown to actively regulate HIF-1α expression (Section 1.6.2.1).
1.6.2.1 Interactions between STAT3 and HIF-1α
Drastic evidence suggests that also STAT3-dependent signalling interferes with HIF-1α.
HIF-1α is a direct STAT3 target gene [Vollmer et al., 2009] and IL-6-type cytokines (OSM,
IL-6, IL-1β,TNF-α) upregulate HIF-1α which translates into increased HIF-1α protein levels
even under normoxic conditions in HCC cells and immortalized hepatocytes [Vollmer et al.,
2009]. Among all IL-6-type cytokines, OSM induces the stongest HIF-1α expression, which
is the reason why we studied its role in this work. OSM-induced HIF-1α is an active tran-
scription factors that upregulates reporter genes and the endogenous target genes VEGF
and serpin peptidase inhibitor member 1 (PAI) [Vollmer et al., 2009]. In contrast to hypoxia,
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OSM-induced HIF-1α is solely dependent on STAT3-mediated upregulation and not on mech-
anisms that interfere with HIF-1α stability [Vollmer et al., 2009].
Demaria et al. showed that constitutive STAT3 activation in mouse embryonic fibroblasts
(MEFs) induces HIF-1α under normoxic conditions. In turn, HIF-1α upregulates glycolytic
genes and induces aerobic glycolysis [Demaria et al., 2012]. In response to constitutive STAT3
activation, complex IV and V within the electron transfer chain were downregulated, however
in a HIF-1α independent fashion [Demaria et al., 2010]. In further work, Demaria et al. show
that constitutive STAT3 expression can serve as a first hit in carcinogenesis where STAT3-
mediated HIF-1α induction supports cellular proliferation by inducing high glycolytic rates
[Demaria et al., 2012].
Furthermore, STAT3 is not only required for cytokine-induced HIF-1α activity but is also
essential for basal HIF-1α expression under normoxia and under hypoxia [Niu et al., 2008,
Xu et al., 2005]. In addition, STAT3 and HIF-1α can interact on protein level, where STAT3
binds the C-terminal domain of HIF-1α and thereby stabilizes it [Jung et al., 2008, Niu et al.,
2008]. STAT3 and HIF-1α cooperatively act on gene transcription. STAT3 binds to HIF-1
target gene promoters where it interacts with HIF-1α and helps to recruit transcriptional co-
activators such as CBP, p300 and RNA polymerase II [Jung et al., 2005, Pawlus et al., 2014a].
1.6.3 The transcriptional and metabolic consequences of HIF-1α stabiliza-
tion under hypoxia
The transcription factor HIF-1 regulates the expression of a large variety of genes (Figure
1.2). Mole et al. have performed genome-wide chromatin immunopreciptitation (ChIP) of
HIF-1 and correlated their results with transcript profiling. They identified 546 HIF-1α
binding sides in the genome that mapped 394 different gene loci in MCF-7 cells [Mole et al.,
2009]. Xia et al. also identified several hundred direct HIF-1 target genes in HepG2 cells
and described a high enrichment of genes that facilitate the metabolic adaptation to hypoxia
[Xia et al., 2009]. Oritz-Barahona et al. have combined phylogenetic footprinting with tran-
scription profiling meta-analysis to identify HIF-1 target genes. In this work over 200 high
confidence HIF-1 target genes are identified [Ortiz-Barahona et al., 2010]. Further investi-
gations by Scho¨del et al. using high-resolution genome-wide mapping of HIF-1 binding sites
lead to the identification of high-confidence binding sides [Schoedel et al., 2011]. Apart from
direct gene regulation, HIF-1 also regulates microRNAs and chromatin modifying enzymes
[Crosby et al., 2009, Wu et al., 2011, Xia et al., 2009].
HIF-1 targets a large group of genes that code for metabolic genes which play key roles in
the adaptation of cellular metabolism to low oxygen tension [Allen et al., 2006, Chi et al.,
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Figure 1.4: The effects of HIF-1α on glycolysis. A large functional group of HIF-
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regulates the expression of glucose transporters ((GLUT) and thereby glucose uptake is
increased. HIF-1α induces the expression of all glycolytic genes and thereby enhances the
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is enhanced and the entry of pyruvate into the TCA cycle inhibited. HK hexokinase, PGI
glucosephosphate isomerase, PFK phosphofructo kinase, ALDO aldolase, TPI triosephos-
phate isomerase, GAPDH glyceraldehyde-3-phosphate dehydrogenase, PGK phosphoglyc-
erate kinase, PGAM phosphoglycerate mutase, ENO enolase, PK pyruvate kinase, PDC
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2006, Vengellur et al., 2003]. HIF-1α activation under hypoxic conditions serves two main
metabolic purposes: the stimulation of energy production via glycolysis and the downregula-
tion of mitochondrial respiration.
HIF-1 upregulates the expression of the glucose transporters 1 and 3 (GLUT1, GLUT3) and
thereby increases cellular glucose uptake (Figure 1.4) [Maxwell et al., 1997, Wang et al.,
2001]. Furthermore, HIF-1 upregulates all enzymes that concordantly break down glucose
into pyruvate (Figure 1.4) [Iyer et al., 1998, Seagroves et al., 2001, Semenza et al., 1994].
Glycolytic rates are largely regulated by substrate and product availabilities where increased
glucose availability leads to increased glucose breakdown.
Under normoxic conditions, pyruvate enters the mitochondria while reduced nicotinamide
adenine dinucleotide (NADH) is shuttle through the malate-aspartate or 3-phosphoglycerate
shuttle into the mitochondria. Pyruvate is converted to acetyl-coA by the pyruvate dehydro-
genase complex (PDC) and further oxidized to generate NADH and reduced flavin adenine
dinucleotide (FADH2), both of which finally donate electrons to the electron transfer chain.
The electrons are then transferred to molecular oxygen to generate water and a proton gradi-
ent that serves the generation of adenosine 5’-triphosphate (ATP). Under hypoxia, however,
mitochondria cannot function properly due to a lack of oxygen and therefore NADH and
pyruvate accumulate. HIF-1 upregulates the expression of lactate dehydrogenase (LDH) that
converts pyruvate and NADH into lactate and NAD+ (Figure 1.4). The resulting lactate
can then be secreted from the cells via the HIF-1 induced monocarboxylate transporter 4
(MCT4) [Firth et al., 1995]. This mechanism removes the excess of lactate from the cell and
regenerates NAD+ which is required for further glycolytic activities (Figure 1.4).
Furthermore, HIF-1α prevents the entry of pyruvate into the tricarboxylic acid (TCA) cycle
and thereby reduces cellular respiration. HIF-1α upregulates pyruvate dehydrogenase kinase
1 (PDK1) which phosphorylates and thereby inactivates PDC and thus prevents the decar-
boxylation of pyruvate to acetyl-coA (Figure 1.4). PDC inactivation reduces cellular oxygen
consumption and decreases ROS generation [Kim et al., 2006, Papandreou et al., 2006, Roche
et al., 2001].
Under hypoxia, the deviation of the glycolytic flux towards lactate production results in a
depleted mitochondrial citrate pool. Citrate, however, is an indispensable precursor for fatty
acid synthesis. Under hypoxic conditions, cells use glutamine to replenish the intracellular
citrate pool and thereby sustain fatty acid synthesis (Figure 1.5). In cells, where HIF-1 is
stabilized, the vast majority of citrate is generated using reductive glutamine metabolism
[Metallo et al., 2011, Wise et al., 2011]. For this type of metabolism, glutamine is converted
to α-ketoglutarate which is carboxylated to isocitrate by isocitrate dehydrogenase 2 (IDH)
and then converted to citrate (Figure 1.5) [Des Rosiers et al., 1995, Metallo et al., 2011,
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Yoo et al., 2008]. Glutamine-derived citrate can then serve as carbon source for fatty acid
synthesis and thereby ensure cellular proliferation under hypoxic condition [Gameiro et al.,
2013, Metallo et al., 2011]. A study has recently identified a mechanism by which HIF-1
actively participates in the shift from oxidative to reductive glutamine metabolism [Sun and
Denko, 2014]. They show that HIF-1 activation results in a drastically reduced activity of
α-ketoglutarate dehydrogenase (α-KGDH) [Sun and Denko, 2014]. HIF-1 seems to induce
ubiquitinylation and subsequent proteolysis of the E1 subunit of α-KGDH and thereby inac-
tivating this enzyme [Sun and Denko, 2014]. Increased α-ketoglutarate to citrate ratios under
hypoxia trigger reductive glutamine metabolism by mass action [Fendt et al., 2013].
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1.7 The metabolism of proliferating cells
Proliferating cells largely depend on a glycolytic metabolism even under normoxic conditions
and in absence of HIF-1 activation. In the 1920s, Otto Warburg discovered that cancer cells
consume higher amounts of glucose and secrete more lactate when compared to normal cells.
This phenomena is known as the ”Warburg effect” or ”aerobic glycolysis”. Aerobic glycolysis
describes the fact that cancer cells have high glycolytic rates and secrete most of the glucose
derived-carbon as lactate despite the fact that oxygen is present and oxidative phosphoryla-
tion would be an option (Figure 1.6) [Warburg, 1928, 1956]. In normal tissues approximately
10% of the ATP is generated by glycolysis while 90% of the ATP is generated via oxidative
phosphorylation within the mitochondria (Figure 1.6). In tumour sections, however, 50% of
the cellular energy is produced by glycolysis with the remaining being generated by oxidative
phosphorylation [Warburg, 1956]. This is one of the reasons why Otto Warburg hypothesized
that cancer cells harbour defects in their mitochondrial metabolism which are compensated
by aeorobic glycolysis [Warburg, 1956]. Later, it was discovered that not only cancer cells
but proliferating cells in general depend on aerobic glycolysis (Figure 1.6). In proliferating
lymphocytes, for example, about 90% of glucose-derived carbon is converted to lactate [Wang
et al., 1976]. Numerous cancer cell lines have now been investigated in detail and no defects
within oxidative phosphorylation were identified (reviewed in [Moreno-Sa´nchez et al., 2007]).
This observation shows that aerobic glycolysis is not a result of a defective mitochondrial
metabolism but a metabolic feature of proliferating cells [Brand et al., 1992, Fabiano and
Qiu, 2015, Hedeskov, 1968, Wang et al., 1976]. In rare cases, however, mutations in the TCA
cyle enzymes SDH and FH indeed can lead to severe metabolic consequences and tumour
development. Mutations in SDH lead to the development of familial paraganglioma and can
cause pheochromocytoma [Astuti et al., 2001, Baysal, 2000, Niemann and Mu¨ller, 2000] while
mutations in FH lead to papillary renal cancer [Tomlinson et al., 2002].
1.8 The Warburg effect
The reason behind aerobic glycolysis in proliferating cells is still not fully elucidated, but
widely discussed and an intense field of investigation. It is hypothesized that high glycolytic
rates provide advantages required for cellular proliferation (Figure 1.6). While high glycolytic
rates produce more ATP than oxidative phosphorylation, it is thought that the requirements
of proliferating cells go beyond high ATP production, as these cells strongly depend on
biosynthetic precursors to support high proliferation rates (Figure 1.6) [Pfeiffer et al., 2001].
Glucose-derived carbon serves as precursor for the generation of intermediates that can be
used in biosynthetic pathways including ribose sugars for nucleotide synthesis, glycerol and
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Figure 1.6: Glucose metabolism in resting and proliferating cells. Quiescent cells (left) have
basal level of glycolysis. Glucose is converted to pyruvate, which is then oxidized within the
TCA cycle. The majority of the ATP (green stars) in resting cells is generated by oxidative
phosphoryaltion. In proliferating cells, the high influx of glucose results in high levels of ATP
generated by glycolysis and decreased NAD+/NADH ratios. Most of the pyruvate is con-
verted by to lactate by lactate dehydrogenase (LDH) which is subsequently secreted. The
conversion of pyruvate to lactate regenerates NAD+ and thereby keeps glycolysis running.
Some pyruvate enters the TCA cycle where it is used for fatty acid synthesis to support pro-
liferation rather than for oxidative phosphorylation. Citrate is exported into the cytoplasm
and is cleaved by ATP citrate lyase (ACL) to form acetyl-CoA. In turn acetyl-coA is used
by fatty acid synthase (FAS) to generate fatty acids while oxaloacetate (OA) is converted
to malate (Mal) and pyruvate (adapted from [DeBerardinis et al., 2008]. MDH malate
dehydrogenase, ME malic enzyme. Green lines represent the glucose flux in resting cells and
red lines represent the glucose flux in proliferating cells
citrate for lipogenesis and non-essential amino-acids (Figure 1.6) [DeBerardinis et al., 2008].
It is however surprising that so much glucose-derived carbon is discarded by generating high
amounts of lactate although it could be further oxidized and increase ATP yields [DeBer-
ardinis et al., 2008]. Possibly, under aerobic glycolysis, the velocity of glycolysis outpaces
the maximal velocity of oxidative phosphoryation so that pyruvate must be eliminated using
a high flux mechanism [Curi et al., 1988]. While the velocity of the oxidation of pyruvate
and its subsequent entry into the TCA cycle seems outpaced by high glycolytic rates, the
velocity of biosyntetic pathways could be maximized [DeBerardinis et al., 2008]: high-flux
metabolic pathways, such as glycolysis, branch into low flux metabolic pathways such as
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pathways involved in macromolecule synthesis. By increasing the flux through glycolysis the
entry of glucose-derived carbon into low flux metabolic pathways could be optimized and
thereby push the synthesis of molecular precursors for macromolecule synthesis [Newsholme
et al., 1985].
Glycolytic genes are frequently upregulated in cancer [Altenberg and Greulich, 2004]. In
particular a specific isoform of pyruvate kinase (PK) regulates the metabolic switch from
oxidative phosphorylation to aerobic glycolysis in proliferating cells. PK regulates the last
step in glycolysis by converting phosphoenolpyruvate and ADP to pyruvate and ATP. PK
exists in four isoforms: the L and the R isoforms are expressed in the liver and in red blood
cells, the M1 isoform is expressed in most adult tissues and the M2 isoform is expressed
during embryonic development [Jurica et al., 1998]. Many tumour cells exclusively express
pyruvate kinase muscle isozyme 2 (PKM2) [Dombrauckas et al., 2005, Mazurek et al., 2005].
While the PKM1 isoform is constitutively active, the PKM2 isoform relies on the allosteric
regulation by the upstream metabolite fructose-1,6-bisphosphate: low levels of fructose-1,6-
bisphosphate render PKM2 inactive while high levels of fructose-1,6-bisphosphate activate
PKM2 [Jurica et al., 1998]. This particular allosteric regulation of the PKM2 isoform allows
the accumulation of glycolytic intermediates and their channelling into biosynthetic path-
ways which branch off from glycolysis. Switching PK expression from the M2 back to the
M1 isoform was shown to reverse the Warburg effect and correlate with reduced ability to
form tumours in vivo [Christofk et al., 2008]. A recent study uncovered the importance of
PKM2 in normal proliferating cells; in MEFs loss of PKM2 results in PKM1 expression and
proliferation arrest [Lunt et al., 2015]. The expression of PKM1 leads to impaired nucleic
acid biosynthesis and thereby hinders cell proliferation [Lunt et al., 2015].
PKM2 can form tetramers, which are enzymatically active, or dimers which are enzymati-
cally inactive. While tumours show high levels of PKM2 dimers, normal proliferating cells
mainly express PKM2 tetramers [Mazurek, 2011]. Destabilization of PKM2 tetamers can
occur upon growth factor signalling, the interaction with oncoproteins and in the presence
of ROS via a number of mechanisms including tyrosine phosphorylation, association with ty-
rosine phosphopeptides or oxidation [Anastasiou et al., 2011, Christofk et al., 2008, Hitosugi
et al., 2009]. As a consequence of decreased PKM2 enzymatic activity, cell proliferation is
enhanced. This can be partly explained by the diversion of glycolytic intermediates from
catabolic to anabolic processes [Anastasiou et al., 2011, Vander Heiden et al., 2009]. Apart
from the metabolic consequences of PKM2 expression, PKM2 dimers seem to have indepen-
dent roles in the nucleus. Among other examples, PKM2 dimers were shown to interact with
STAT3 in the nucleus. PKM2 can phosphorylate STAT3 on tyrosine 705 and thereby induces
the transcription of STAT3 target genes [Gao et al., 2012].
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Figure 1.7: Glutamine metabolism in proliferating cells. In proliferating cells, citrate
is used to generate fatty acids. The eﬄux of citrate from the TCA cycle results in the loss
of oxaloacetate (OA). OA anaplerosis is governed by the complex glutamine metabolism.
In the cytosol, glutamine donates nitrogen to purines and pyrimidines, which result in the
formation of glutamate. In turn, glutamate donates its amino groups to α-ketoacids and
α-ketoglutarate (α-KG) which can enter the mitochondria. Glutamine can also be directly
converted to glutamate in the mitochondria by phosphate-dependent glutaminase (PDG)
and mitochondrial glutamate is converted to α-KG by glutamate dehydrogenase (GDH) or
aminotransferases. For TCA cycle anaplerosis, α-KG enters the TCA cycle and forms OA.
On the other hand, glutamine-derived α-KG can be converted to citrate and fuel fatty acid
synthesis (adapted from [DeBerardinis et al., 2008]. LDH lactate dehydrogenase, ME malic
enzyme.
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The TCA cycle is a hub for biosynthesis and plays key roles in providing proliferating cells
with biosynthetic precursors. While in resting cells most of the carbon entering the TCA
cycle yields in ATP production, in proliferating cells most of the carbon is used for biosyn-
thesis rather than ATP production. In proliferating cells, this results in an eﬄux of carbon
from the TCA towards biosynthetic pathways. One example consists in the generation of
fatty acids and cholesterol from mitochondrial citrate to meet the high demand for the gen-
eration of membranes (Figure 1.6). In the TCA cycle citrate is generated from oxaloacetate
that is condensed with acetyl-coA by CS. Mitochondrial citrate is then shuttled from the
mitochondria to the cyctoplasm. In the cytoplasm, citrate is cleaved to oxaloacetate and
acetyl-coA which is used by fatty acid synthase (FAS) to synthesize lipids. The remaining
oxaloacetate is then reduced to malate by malate dehydrogenase (MDH), utilizing the low
cytosolic NAD+/NADH ratio. Malate can either be transported back into the mitochondria
via the malate/citrate antiport or converted to pyruvate by malic enzyme (ME), generating
NADPH that further supports fatty acid synthesis (reviewed in [DeBerardinis et al., 2008]).
The export of mitochondrial citrate to synthesize fatty acids is crucial to sustain cellular
proliferation. The two enzymes, ATP citrate lyase (ACL) and FAS, which are involved in
this process, are induced in proliferating cells where their activity is required for proliferation
[Bauer et al., 2005, Hatzivassiliou et al., 2005, Kuhajda et al., 1994, Pizer et al., 1996]. The
depletion of the mitochondrial citrate pool results in a truncated TCA cycle [Hatzivassiliou
et al., 2005, Parlo and Coleman, 1984a]. Despite the drastic eﬄux of glucose-derived carbon
from the TCA cycle into fatty-acid synthesis and other biosynthetic precursor pathways, cells
must sustain an equal influx to resupply the TCA cycle with oxaloacetate. One enzyme that
can refuel the TCA cycle is pyruvate carboxylase (PC). PC generates oxaloacetate directly
from pyruvate in an ATP dependent reaction. PC activity is of substantial importance in
cells with a truncated TCA cycle. In SDH-deficient cells, PC replenishes the TCA cycle with
oxaloacetate which keeps the TCA cycle running but also ensures the synthesis of aspartate
which is an indispensable precursor for the synthesis of proteins, nucleotides and the amino
acids arginine and asparagine [Lussey-Lepoutre et al., 2015]. Another alternative of TCA
cycle anaplerosis is to use amino acids, in particular glutamine. Replenishment of oxaloac-
etate in the TCA cycle can be assured by glutaminolysis. For this, glutamine is taken up by
the cell and converted to glutamate. Glutamate is then further oxidized to α-ketoglutarate
which is fuelled into the TCA cycle and thereby produces oxaloactetate. In recent years,
however it has become more and more clear that glutamine can also be used to generate
citrate via a mechanism that is known as ”reductive glutamine metabolism” [Holleran et al.,
1995]. Under reductive conditions, α-ketoglutarate is carboxylated to isocitrate by isocitrate
dehydrogenase 1 (IDH1) and converted to citrate [Des Rosiers et al., 1995, Yoo et al., 2008].
Glutamine derived citrate can then serve as carbon source for fatty acid synthesis [Holleran
et al., 1995]. Reductive glutamine metabolism is essential for tumour cells with defective
mitochondria as they count on this mechanism as a major pathway to generate citrate which
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provides the carbon necessary for acetyl-CoA synthesis [Mullen et al., 2011]. Reductive glu-
tamine metabolism is IDH1 dependent and is active in most cell lines under normal culturing
condition, and required for cell proliferation under hypoxic conditions [Gameiro et al., 2013,
Metallo et al., 2011].
1.9 Metabolomics
The knowledge about signal transduction, gene transcription and protein induction and
protein-protein interaction is getting more detailed and complex while databases that docu-
ment findings are growing. Transcripomic and proteomic approaches deliver valuable infor-
mation on gene and protein expression under certain experimental conditions. Metabolomic
approaches help to define if the observed changes in expression levels also translate into
a metabolic phenotype. mRNA levels do not necessarily correlate with increased protein
abundance [Gygi et al., 1999], translated proteins might or might not be active, such as
for example PKM2 (Section 1.8) [Schwab, 2003]. Consequently, drawing conclusions about
metabolic changes from transcriptomic and proteomic datasets alone might result in incorrect
assumptions and conclusions.
Originally metabolomics was used to identify and quantify metabolites while the application
of 13C-labelled tracers now also allows to study metabolic fluxes through networks (Section
1.9.3) [Haverkorn van Rijsewijk et al., 2011, Noguchi et al., 2009]. Metabolomics is a high-
throughput technique and can be applied to various sample types including cells, tissues
and body fluids. The field of metabolomics can be separated into targeted and non-targeted
metabolomics (reviewed in [Hiller et al., 2010]). Targeted metabolomics concentrates on a
set of known metabolites while non-targeted metabolomics tries to derive information about
all detectable, known and unknown metabolites.
1.9.1 Metabolomics workflow
The study of cellular metabolism is generally composed of three steps that include (1) sample
preparation, (2) analytical metabolite detection and (3) computational data analysis. The
first step in a metabolomics experiment is the preparation of the sample. The turnover
rate of metabolites is very high thus the first step in sample processing includes quenching
of cellular metabolism with ice-cold methanol:water mixtures [Spura et al., 2009]. Thereby
the tertiary structures of enzymes is disrupted and heat-sensitive metabolites are stabilized
[Villas-Boˆas et al., 2005]. The next step consists in a liquid-liquid extraction, generally using
chloroform/methanol/water mixtures to separate polar and non-polar metabolites and clear
the sample from DNA, RNA and proteins (reviewed in [Sapcariu et al., 2014]).
Extracted metabolites can then be separated by chromatography, including gas- or liquid
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[Koek et al., 2006] chromatography and identified by mass spectrometry (reviewed in [Lei
et al., 2011, Want et al., 2005]) or NMR [Holmes et al., 1998]. In this thesis, we used
gas chromatography (GC) couple to mass spectrometry (MS) and thus I will briefly intro-
duce these two techniques. To make a sample suitable for separation by GC it needs to be
volatile. Therefore polar hydrogen groups within metabolites such as hydroxyl (-OH), pri-
mary amine(-NH2), carboxyl (-COOH) or carbonyl(-CO-) groups are chemically substituted
by derivatization agents [Kanani et al., 2008].
Once derivatized, metabolites are separated by gas chromatography and subsequently ionized
by electron impact ionization under vacuum to form positive radicals. Formed radicals are
highly unstable and further fragment. The fragmentation of metabolites results in a charac-
teristic pattern that is recorded by MS.
1.9.2 Mass isotopomer distribution
In MS, fragment ions are separated according to their mass over charge ratios. The mass
spectrum of each metabolite is composed of different fragment ions each of which is composed
of an isotopomer cluster [Wegner et al., 2013]. An isotopomer cluster results from the natu-
ral occurrence of stable isotopes and in the context of stable-isotope assisted metabolomics
from the incorporation of labelled carbon sources. An example is depicted in figure 1.8.
This metabolite is composed of two carbon atoms and concordantly results in three mass
istopomers: the mass isotopomer M0 is only composed of unlabelled carbon; the mass iso-
topomer M1 contains one 13C atom at either position; M2 is in this case the heaviest mass
isotopomer and only contains 13C carbon atoms (Figure 1.8 A). The mass spectrum of a
given fragment always reflects the complex mixture of all mass istopomers, those that occur
naturally and those introduced with tracers (Figure 1.8 B). The relative abundance of each
mass isotopomer within a mass spectrum is termed mass isotopomer distribution (MID) and
can be calculated by solving the following linear equation systems:
A · f = I
where A is the matrix to correct for the natural abundance of heavy isotopes, f is the vector
containing the fractional abundance of each mass isotopmer and I is the vector that contains
the signal intensities for each isotomer measured by GC-MS [Hiller et al., 2011] (Figure 1.8 B).
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1.9.3 Metabolic flux analysis
Using metabolic flux analysis, intracellular metabolic fluxes can be quantified under the as-
sumption that the system is in a metabolic steady-state. To resolve changes in intracellular
fluxes 13C-labelled tracers are introduced into the system. Various 13C-labelled tracers exist
and their application largely depends on which metabolic pathway is targeted [Metallo et al.,
2009]. In stable-isotope assisted metabolomics experiments, 13C-labelled carbon sources are
fed into the system and the labelled carbon atoms are redistributed to other metabolites
within a metabolic network. Once the system has reached an isotopic and metabolic steady-
state, which assumes constant intracellular fluxes and labelling patterns, the distribution of
the labelled carbons within metabolites can be measured by MS or NMR.
Changes in intracellular fluxes can then be estimated based on the mass isotopomer distri-
bution (MID). Here I give two examples. One of the tracers that we used throughout this
project is [13C6]glucose (Figure 1.9). Besides others, we used this tracer to study the entry of
glucose-derived carbon into the TCA cycle. [13C6]glucose is metabolized through glycolysis
and generates [13C3]pyruvate. [
13C3]pyruvate can enter the TCA cycle via PDC activity which
oxidatively decarboxylates [13C3]pyruvate and thereby generates [
13C2]acetyl-coA and NADH.
[13C2]acetyl-coA is then condensed with unlabelled oxaloacetate to form [
13C2]citrate. The
relative abundance of [13C2]citrate or M2 citrate directly reflects PDC activity. [
13C3]pyruvate
can also be fuelled into the TCA cycle via the anaplerotic reaction mediated by PC. PC activ-
ity carboxylates [13C3]pyruvate and thereby generates [
13C3]oxaloacetate. Due to its chemical
instability, oxaloacetate is not detectable in most metabolomics experiments while the MID of
aspartate can serve as a surrogate for oxaloacetate in asparate free medium [Buescher et al.,
2015, Zimmermann et al., 2014]. Further, if [13C3]oxaloacetate is used within the TCA cycle
it will combine with unlabelled (coming from fatty acid degradation) or labelled (coming
from PDC activity) acetyl-coA to generate [13C3]citrate and [
13C5]citrate, respectively. Thus
[13C5]citrate or M5 citrate reflects the combined activity of PDC and PC (Figure 1.9). PC
activity can also be inferred from M3 malate, M3 aspartate and M3 fumarate. Since the
before mentioned mass isotopomers can also result from cycling through the TCA, it is rec-
ommended to compare M3 malate, M3 aspartate and M3 fumarate to M3 succinate [Buescher
et al., 2015]. This comparison allows to infer the proportion of carbon within the TCA cycle
that results from TCA cycle anaplerosis by PC [Buescher et al., 2015].
Apart from stable-isotope assisted metabolomics, other methods exist to measure PDC and
PC activities [Kerr et al., 1987, Sheu et al., 1981]. A commonly used diagnostic method to
determine PDC activity is to measure the production of 14CO2 from 1-
14C-pyruvate [Kerr
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Figure 1.8: Mass isotopomer distribution. (A) A molecule composed of two carbon
atoms give rise to different mass isotopomers. Mass isotopomers result from the natural
occurrence of 13C and, in the case of stable-isotope assisted metabolomics, from the incorpo-
ration of 13C from labelled tracers. The mass spectra is depicted along with the corresponding
mass isotopomer (grey circles = 12C, red/green circles = 13C). (B) Only one mass spectrum
is measured for a complex mixture of mass isotopomers and the relative abundance of each
mass isotopomer can be calculated by solving a linear equation system. In this example 50%
of the molecule contains unlabelled carbon (M0), 25% contains one 13C atom (M1) and the
remaining 25% is labelled on two carbon atoms (M2) (adapted from [Hiller et al., 2011]).
et al., 2012]. While this assay is relatively time consuming, it does not require enzyme pu-
rification nor mitochondrial extracts, thus crude cell or tissue samples are suitable for this
method [Kerr et al., 2012]. The first step in this assay is the optional activation of PDC by
incubating cells or tissues with dichloroacetate or phosphatases, respectively, leading to the
dephosphorylation and thus full activation of PDC. The second step consists in the incuba-
tion of the crude cell or tissue extracts with 1-14C-pyruvate in the presence of pyrophosphate
and coenzyme A [Kerr et al., 2012]. The activity of PDC can then be derived from the
production of 14CO2 which is measured using a liquid scintillation counter [Kerr et al., 2012].
As an alternative, a variety of manufactures now offer kits to determine PDC activity which
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consist of enzyme-linked immunosorbent assays and subsequent colorimetric detection. A
frequently used diagnostic method to determine the activity of PC in crude cell extracts is
based on the carboxylation of pyruvate with 14CO2. This reaction leads to the formation
of oxaloacetate and subsequently citrate when CS and acetyl-coA are present [Atkin et al.,
1979]. This method is insensitive towards interfering reactions that compete for pyruvate,
while it has the disadvantage to be based on the usage of radioactive and volatile 14CO2
[Kerr et al., 2012]. PC activity is calculated based on the fixation of 14CO2 measured using
a liquid scintillation counter [Kerr et al., 2012]. Furthermore the activity of PC in crude
extracts can be assayed using spectrophotometric techniques. Various ready-to-use reagents
are commercially available or can be prepared in-house [Scrutton and White, 1974, Warren
and Tipton, 1974].
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Figure 1.9: Mass isotopomer distributions from [13C6]glucose. MIDs resulting from PC
(in green) and PDC (in blue) activities are depicted for all TCA cycle intermediates. PDC
Pyruvate dehydrogenase complex, CS Citrate synthase, ACO Aconitase, IDH Isocitrate
dehydrogenase, α-KGDH α-Ketoglutarate dehydrogenase, SCS Succinate synthase, SDH
Succinate dehydrogenase, FH Fumarate hydratase, MDH Malate dehydrogenase, OA Ox-
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The other tracer that we used throughout this study is [13C5]glutamine by which oxidative
and reductive glutamine metabolism can be profiled. In both cases, [13C5]glutamine is con-
verted to α-[13C5]ketoglutarate. Under oxidative conditions α-[
13C5]ketoglutarate undergoes
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decarboxylation within the TCA cycle and thereby generates [13C4]succinyl-CoA which is fur-
ther metabolized through the TCA cycle resulting in [13C4]oxaloacetate. [
13C4]oxaloacetate
then condenses with unlabelled acetyl-coA to form [13C4]citrate. When glutamine is metab-
olized in a reductive manner [13C5]α-ketoglutarate is carboxylated to form [
13C5]isocitrate
and subsequently [13C5]citrate (Figure 1.10).
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Figure 1.10: Mass isotopomer distributions from [13C5]glutamine. MIDs resulting from
oxidative (in red) and reductive (in purple) glutamine metabolism are depicted for all TCA
cycle intermediates. PDC Pyruvate dehydrogenase complex, CS Citrate synthase, ACO
Aconitase, IDH Isocitrate dehydrogenase, α-KGDH α-Ketoglutarate dehydrogenase, SCS
Succinate synthase, SDH Succinate dehydrogenase, FH Fumarate hydratase, MDH Malate
dehydrogenase, OA Oxaloacetate
1.10 Aims and scope of the thesis
The fact that inflammation promotes neoplastic growth is known since Rudolf Virchow made
this observation in 1863. While numerous cancers develop in an inflammatory microenviron-
ment, liver cancer is one of the most striking examples. Virtually all HCCs are preceded and
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accompanied by chronic inflammatory conditions that promote its development and support
its progression. A large body of evidence shows that the combination of ROS, cytokines and
growth factors, released by immune cells within the inflammatory microenvironment, drive
neoplastic growth by increasing mutagenesis rates and by supporting cellular survival and
proliferation. In conjunction with growth-promoting stimuli, proliferating cells have a high
demand of biomass precursors such as: amino acids for protein synthesis, nucleotides for DNA
replication and fatty acids for the generation of cellular membranes.
This study was designed based on the observation that IL-6-type cytokines increase the
expression of the metabolic key regulator HIF-1α on mRNA and protein level in a STAT3-
dependent manner. While the metabolic consequences of HIF-1α stabilization under hypoxic
conditions were well understood, the particular impact of cytokine-mediated HIF-1α induc-
tion under normoxic growth conditions remained to be elucidated. IL-6-type cytokines such
as IL-6 and OSM were shown to be implicated into HCC development and progression while
the observation that these cytokines can upregulate HIF-1α suggested an interesting and so
far unstudied interplay with cellular metabolism.
The aim of this thesis was to elucidate whether the induction of HIF-1α by IL-6-type cy-
tokines results in similar changes within central carbon metabolism than hypoxia itself.
While numerous studies showed that growth factors and cytokines can upregulate HIF-1α
under normoxic conditions, it remained to be studied whether this also results in a metabolic
phenotype. In the larger context, our findings should show how inflammatory conditions,
such as present during HCC development and progression modulate cellular metabolism and
determine whether cytokine-mediated HIF-1α induction plays a crucial role in this context.
To simulate an inflammatory environment, we used the IL-6-cytokine OSM which plays an
important role during HCC promotion and development while it also induced a strong re-
sponse in terms of HIF-1α induction in vitro. To study whether OSM stimulation in HCC
cells promotes a hypoxia-like metabolic phenotype in cells we treated different HCC cells and
immortalized hepatocytes with OSM, cultured them under hypoxia and subjected them to a
combinatorial treatment. We studied the metabolic consequences of these treatments on the
cellular metabolome using a targeted stable-isotope assisted metabolomics approach.
Chapter 2
Material and Methods
Unless specified differently, buffers and dilutions were prepared in water.
Only ultrapure water was used (resistivity (25◦C) > 18.18 MΩcm).
All solvents were of the highest purity grade available.
Technical details on experiments done by our collaborator Dr. Andreas Zimmer can be found
in [Battello et al., 2016].
2.1 Cell culture and reagents
HCC cells and immortalized hepatocytes were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) (D5796, Sigma Aldrich) supplemented with 10% fetal bovine serum (FBS)
(PAA or Invitrogen). Cells were cultured at 37 ◦C in a humidified atmosphere at 5% CO2
(Sanyo). Detailed information on the cell lines is given in table 2.1. For routine culture, cells
were maintained in cell culture flasks (Thermo Fisher Scientific) and grown to 90% confluency
before splitting. To do this, old cell culture medium was gently removed and cells washed
with 1x Dulbecco’s phosphate-buffered saline (DPBS) (Gibco). Trypsin (Life Technologies)
was added to fully cover cell monolayers and flasks were incubated for 5-10 min at 37 ◦C
in a humidified atmosphere at 5% CO2. Trypsin was inactivated with complete cell culture
medium and cells were resuspended to get a single cell suspension. An adequate volume of
the cell suspension was transferred into a new cell culture flask and supplemented with fresh
growth medium (splitting ratios are depicted in table 2.1).
Human OSM M (227 a. a., Peprotech) was reconstituted in 1x DPBS containing 0.1% bovine
serum albumin (Sigma Aldrich) to a concentration of 100 ng/µl and stored at -80◦C.
Hypoxia treatments were carried in a hypoxia chamber (Jacomex) at 1% O2 and 37
◦C in
a humidified atmosphere at 5% CO2. Cell culture media was incubated under hypoxia 24 h
27
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prior to each experiment.
Table 2.1: Overview on HCC cell lines and immortalized hepatocytes.
Name Tumour / Stage Morphology Age Gender Ethnicity Splitting ratio Supplier Catalog No.
HepG2/C3A HCC epithelial 15 male Caucasian 1:3 ATCC CRL-10741
Hep-3B HCC epithelial 8 male Afro-american 1:3 DSMZ ACC 93
HepG2 HCC epithelial 15 male Caucasian 1:3 ATCC HB-8065
HLE undifferentiated HCC - 68 male - 1:8 JCRB JCRB0404
HLF undifferentiated HCC - 68 male - 1:8 JCRB JCRB0405
HuH-7 well differentiated HCC epithelial-like 57 male Asian 1:4 JCRB JCRB0403
JHH-4 HCC epithelial-like 51 male Asian 1:4 JCRB JCRB0435
PH5CH1 immortalized hepatocytes epithelial - - Asian 1:3 [Ikeda et al., 1998] -
PH5CH7 immortalized hepatocytes epithelial - - Asian 1:3 [Ikeda et al., 1998] -
PH5CH8 immortalized hepatocytes epithelial - - Asian 1:3 [Ikeda et al., 1998] -
PLC/PRF/5 hepatoma epithelial - - - 1:3 ATCC CRL-8024
SK-HEP-1 adenocarcinoma epithelial 52 male Caucasian 1:4 ATCC HTB-52
SNU-387 pleomorphic HCC, grade IV/V epithelial 41 female Asian 1:6 ATCC CRL-2237
SNU-423 pleomorphic HCC, grade III/IV epithelial 40 male Asian 1:6 ATCC CRL-2238
SNU-449 HCC , grade II-III/IV epithelial 52 male Asian 1:6 ATCC CRL-2234
SNU-475 HCC , grade II-IV/V epithelial 43 male Asian 1:6 ATCC CRL-2236
2.2 Stable isotope labelling experiments
One vial of DMEM 5030 (Sigma Aldrich) and 3.7 g of sodium bicarbonate were reconstituted
1 l of water. The pH was adjusted to 7.4 with 5 M hydrogen chloride (Sigma Aldrich), the
medium was sterile filtered through a Millex-GV 0.22 µm filter unit (Merck Millipore) and
stored at 4 ◦C.
This basic labelling medium was supplemented with 10% dialysed FBS (Invitrogen). For
stable isotope labelling experiments with a uniformly labelled glucose tracer, the labelling
medium was supplemented with 25 mM [13C6]glucose (Campro Scientific) and 4 mM glu-
tamine (Sigma Aldrich). For isotope labelling experiments with uniformly labelled glutamine,
basic labelling medium was supplemented with 25 mM glucose (Sigma Aldrich) and 4 mM
[13C5] glutamine (Campro Scientific). The pH was adjusted to 7.4 with 1 M hydrogen chloride
and the complete labelling medium was sterile filtered through a 0.22 µm Steriflip GP filter
unit (Merck Millipore) and stored at 4 ◦C.
2.3 siRNA-mediated silencing of PDK1 and HIF-1α
Small interfering RNA (siRNA)-mediated silencing of PDK1 and HIF-1α was performed by
reverse transfection and was based on the recommended RNAiMAX protocol from the man-
ufacturer (Invitrogen). siRNA sequences, suppliers and catalogue numbers are depicted in
table 2.2. 5 nmol of the PDK1 and non-targeting control siRNA were reconstituted in 250 µl
of RNAse free water (Santa Cruz) to create a stock solution of 20 µM. The HIF-1α siRNA
was reconstituted in 330 µl of RNAse free water to create a stock solution of 10 µM. SiRNAs
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were stored in aliquots at -80 ◦C.
For the siRNA-mediated HIF-1α knockdown, 2 µl of 10 µM siRNA was diluted in 200 µl
1x Opti-MEM I (Gibco by Life Technologies) and gently mixed by inversion. 3 µl of Lipo-
fectamine RNAiMAX (Invitrogen) were added and the solution was mixed by inverting the
tube. For siRNA-mediated PDK1 knockdown, 1 µL of 20 µM siRNA was diluted in 200 µl
1x Opti-MEM I (Gibco, Thermo Scientific) and gently mixed by inversion. 2.5 µl of Lipo-
fectamine RNAiMAX (Invitrogen) were added and the solution was mixed by inversion. The
transfection solution was incubated for 20 min at room temperature and transferred into
a 12-well cell culture plate (Thermo Fisher Scientific). The 12-well cell culture plate was
gently agitated back and forth until the entire growth surface was covered with transfection
solution and incubated for another 5 min at room temperature. PH5CH clones were seeded
at a density of 95 000 cells/well in a volume of 800 µl directly onto the transfection mix. A
pool of non-targeting siRNAs was used as control (table 2.2). The final concentration of all
siRNAs was 20 nM. Cells were grown for 6-24 h at 37 ◦C in a humidified atmosphere at 5%
CO2 and the medium was replaced with fresh growth medium.
Table 2.2: siRNA sequences
Gene Target sequence(s) Supplier Catalogue Number
Human HIF-1α 5’-CUG AUG ACC AGC AAC UUG A-3’ Santa Cruz sc-35561
Human PDK1 5’-GAU CAG AAA CCG ACA CAA U-3’ Darmacon D-001810-10-20
5’-GCC AGA AUG UUC AGU ACU U-3’
5’-GCA UAA AUC CAA ACU GCA A-3’
5’-CAA AGG AAG UCC AUC UCA U-3’
non-targeting siRNA 5’-UGG UUU ACA UGU CGA CUA A-3’ Darmacon L-005019-00-0005
5’-UGG UUU ACA UGU UGU GUG A-3’
5’-UGG UUU ACA UGU UUU CUG A-3’
5’-UGG UUU ACA UGU UUU CCU A-3’
2.3.1 OSM stimulation
2.3.2 Short-term OSM stimulation
All experiments were carried out in 12-well cell culture plates. Cells were seeded in a volume
of 750 µl at the seeding densities indicated in table 2.3 and grown for 24 h at 37◦C in a
humidified atmosphere at 5% CO2. Normal growth medium was gently removed and cells
were washed once with 1 ml 1x DPBS. 750 µl of labelling medium was added per well. Cells
were either left untreated or stimulated with 50 ng/ml OSM for the indicated periods of time.
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Table 2.3: Cell seeding densities for stable isotope labelling experiments
Cell line Seeding density (cells/cm2)
PH5CH clones 25 000
HepG2 50 000
HepG2/C3A 50 000
JHH-4 15 000
Sk-Hep1 25 000
2.3.3 Long-term OSM stimulation
On day one PH5CH8 and JHH-4 cells were plated at 60 000 cells/well and 45 000 cells/well
respectively, in 12-well cell culture plates. Cells were grown for 8 h at 37 ◦C in a humidified
atmosphere at 5% CO2. Cell culture media was replaced with fresh cell culture medium
with or without 25 ng/ml OSM and cells were grown for 24 h. On the subsequent days,
cell culture medium was replaced and the OSM stimulation refreshed. On day four, the cell
culture medium was replaced with labelling medium with or without 25 ng/ml OSM. 24
hours later, intracellular metabolites and proteins were extracted. Cells were furthermore
transferred into a T25 cell culture flasks and grown over the weekend. Control cells were left
untreated and stimulated cells were grown in the presence of 25 ng/ml OSM. On day seven
of the experiment, cells were reseeded as previously described. The experimental scheme is
depicted in Figure 2.1
2.4 Extraction of intracellular metabolites
The extraction of intracellular metabolites was performed on cells grown in 12-well cell culture
plates. The cell culture media was gently removed and cells were washed once with 1 ml 0.9%
NaCl (w/v) (Sigma Aldrich). Cellular metabolism was quenched with 200 µL of -20 ◦C 100%
methanol (Sigma Aldrich). 200 µL of 4 ◦C water was added containing 1 µg/ml pentanedioic-
d6 acid (C/D/N Isotopes Inc.) as an internal standard. The cells were scraped off the plate
and transferred into 1.5 ml reaction tubes containing 200 µL -20 ◦C 100% chloroform (Sigma
Aldrich). Extracts were incubated in a Thermomixer for 20 min at 4 ◦C and under continuous
shaking at 1400 rpm (Eppendorf). Cell extracts were centrifuged for 5 min at 4 ◦C and 21 000
xg in a benchtop centrifuge (Eppendorf 5424R or 5415R). Centrifugation resulted in phase
separation, where the upper phase contains polar metabolites, the interphase is composed
of DNA, RNA and proteins and the lower phase contains non-polar metabolites. 200 µL of
the polar phase were transferred into GC glass vials (Chromatographie Zubehr Trott) and
dried in a refrigerated rotary vacuum evaporator (Labconco). Dried metabolite extracts were
stored at -80 ◦C until further processing.
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Figure 2.1: Experimental scheme of the long-term OSM stimulation.
For hypoxia experiments, the first two extraction steps were carried out inside the hypoxia
chamber. Cells were washed with hypoxic 0.9% NaCl (w/v), quenched then taken out of the
hypoxia chamber and intracellular metabolites extracted as described bellow.
2.5 Medium preparation for GC-MS analysis
The cell culture medium was transferred into a 1.5 ml reaction tube and centrifuged at 300
xg for 5 min at room temperature in a benchtop centrifuge. The supernatant was transferred
into a fresh 1.5 ml reaction tube and stored at -80 ◦C until further processing. For the
calibration curve, cell culture medium (D5796, Sigma Aldrich) was spiked with 8 mM lactic
acid (Sigma Aldrich) and 0.4 mM glutamate and diluted to 1:32 in serial dilution steps of 1:2.
Extracellular metabolites from medium samples were extracted using ice-cold extraction fluid
(8+1 methanol/water) containing the internal standard [13C5]ribitol (Omicron Biochemicals,
Inc.) at a concentration of 1 µg/ml. 20 µl of medium was mixed with 180 µl ice-cold extraction
fluid, vortexed for 10 s and centrifuged at 21 000 xg for 5 min at 4 ◦C in a benchtop centrifuge.
50 µl of medium extracts were transferred to GC glass vials and dried in a refrigerated rotary
vacuum evaporator.
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2.6 Cell counting
Cell culture medium was gently removed from cells grown in 12-well cell culture plates. Cells
were washed once with 1 ml 1x DPBS and 200 µL of trypsin was added into each well
to disperse the cells. Cell culture plates were incubated for 7 min at 37 ◦C in a humidified
atmosphere at 5% CO2. Trypsin was inactivated with 400 µL of complete cell culture medium.
Cells were resuspended to single cell suspension and transferred into sample cups (Vi-Cell,
Beckman Coulter). Cell viability and count was determined on a cell viability analyser (Vi-
Cell, Beckman Coulter).
2.7 GC-MS analysis
Metabolite derivatization was performed using a Multi Purpose Sampler (Gerstel).
Dried polar intracellular metabolites were dissolved in 15 µl of 2% methoxyamine hydrochlo-
ride (w/v)(Sigma Aldrich) in pyridine (Sigma Aldrich) and incubated 60 min at 55 ◦C under
continuous shaking. An equal volume of N-tert-butyldimethylsilyl-N-methyltriuoroacetamide
(Restek) was added and incubated for 60 min at 55 ◦C under continuous shaking.
GC-MS analysis was carried out on a Agilent 7890A gas chromatograph coupled to an Agilent
5975C inert XL mass selective detector (Agilent Technologies). 1 µl sample was injected into
a split/splitless inlet, operating in splitless mode at 270 ◦C . The GC was equipped with a 5
m DuraGuard capillary column and a 30 m (I.D. 250 µm, film 0.25 µm) DB-35MS analytical
column (Agilent J&W GC Column). Helium was used as carrier gas at a constant flow rate
of 1 ml/min. The GC oven temperature was held at 100 ◦C for 2 min and increased to 300
◦C at 10 ◦C/min and held for 4 min. The total run time of one sample was 26 min. The
transfer line temperature was set to 280 ◦C. The MS was operating under electron ionization
at 70 eV. The MS source was held at 230 ◦C and the quadrupole at 150 ◦C. The detector was
operated in selected ion mode (SIM) and details on SIM parameters can be found in table
2.4.
Dried extracellular metabolites were dissolved in 15 µl of 2% methoxyamine hydrochloride
(w/v) in pyridine and incubated 60 min at 40 ◦C under continuous shaking. An equal volume
of N-Methyl-N-(trimethylsilyl)trifluoroacetamide (Sigma Aldrich) was added and the samples
were incubated at 40 ◦C for 30 min under continuous shaking. 1 µL of sample was injected
into a split/splitless inlet, operating in splitless mode at 270 ◦C. GC oven temperature was
held at 90 ◦C for 1 min and increased to 300 ◦C by 15 ◦C/min for 8 min to 320 ◦C. The total
run time of one sample was 24.3 min.
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Table 2.4: GC-MS analysis: Details on the SIM method
Comound Sum Formula Ions Exact ion Dwell time (ms) RT (min) Carbon atoms MID size
Pyruvic acid 1MeOX 1TBDMS C6H12O3NSi 174-180 0 15 6.82 3 4
Lactic acid 2TBDMS C11H25O3Si2 261-267 0.1 15 8.99 3 4
Alanine 2TBDMS C11H26NO2Si2 260-266 0.1 15 9.51 3 4
Glycine 2TBDMS C10H24NO2Si2 246-252 0.1 15 10.02 2 3
Succinic acid 2TBDMS C12H25O4Si2 289-296 0.1 15 12.66 4 5
Fumaric acid 2TBDMS C12H23O4Si2 287-294 0.1 15 12.79 4 5
Serine 3TBDMS C17H40NO3Si3 390-396 0.2 15 14.18 3 4
Methionine 2TBDMS C13H30NO2SSi2 320-328 0.2 10 14.8 5 6
2-Oxoglutaric acid 1MeOX 2TBDMS C14H28NO5Si2 346-354 0.2 10 15.47 5 6
Malic acid 3TBDMS C18H39O5Si3 419-426 0.2 15 15.69 4 5
Aspartic acid 3TBDMS C18H40NO4Si3 418-425 0.2 15 16.1 4 5
Glutamatic acid 3TBDMS C19H42NO4Si3 432-440 0.3 10 17.19 5 6
Glutamine 3TBDMS C19H43N2O3Si3 431-439 0.3 10 18.85 5 6
Citric acid 4TBDMS C26H55O7Si4 591-600 0.3 10 19.81 6 7
2.8 GC-MS data analysis
All GC-MS chromatograms were processed using the MetaboliteDetector software [Hiller
et al., 2009]
2.8.1 Mass isotopomer distribution analysis
MIDs were determined from samples measured in SIM. The monitored fragments contained
the full carbon backbone of the respective metabolite and the provided sum formula was used
to correct for natural isotope abundance. GC-MS raw data files were converted to netCDF
format (GC/MSD ChemStation Software, Agilent) and imported into MetaboliteDetector.
The retention time was used for chromatogram alignment and metabolites were identified
using an in-house library. Software settings for compound identification and MID calculation
are depicted in supplemental tables B.1 and B.2. Chemical formulas for MID determination
are given in table 2.4 and were taken from [Wegner et al., 2014].
Weighted carbon contribution was calculated with the following formula:
1
n ·
n∑
i=1
Mi · i
where n is the number of carbons of the molecule of interest and Mi the i
th mass isotopomer.
2.8.2 Relative quantification of metabolites
Chromatograms were processed as described in 2.8.1 and metabolites were quantified using
the batch quantification wizard (Supplemental table B.2).
For relative quantification of intracellular metabolites from samples measured in SIM, the
signal intensities of metabolites were divided by the signal intensity of the internal standard
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pentanedioic-d6 acid, which accounts for variations during metabolite extraction and GC-MS
measurements. Furthermore, signal intensities were divided by cell count, to account for
variations in the cell number.
For relative quantification of extracellular metabolites, signal intensities were normalized to
the cell number.
2.9 Reverse transcription and quantitative PCR procedure
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the man-
ufacturer’s instructions. 500 ng of total RNA were reverse transcribed using SuperScript
III reverse transcriptase (Invitrogen) in a final volume of 20 µl according to manufacturer’s
recommendations and diluted with 180 µl PCR-grade water (Sigma Aldrich). qPCR was
performed on a LightCycler 480 (Roche) in a total volume of 20 µl containing 1 µl cDNA,
5 pmol of each forward and reverse primer (Eurogentec), 10 µl iTaq Universal SYBR Green
Supermix (Bio-Rad) and PCR-grade water. qPCRs were performed on samples from bio-
logical triplicates and each sample was measured in technical duplicates. Primer sequences
are depicted in table 2.5. Thermal cycling conditions for all qPCR assays consisted of an
initial enzyme activation step at 95 ◦C for 15 min, followed by 40 cycles of 30 s of denatura-
tion at 95 ◦C, annealing at 60 ◦C and elongation at 72 ◦C. The threshold crossing value of
each transcript was normalized to the housekeeping gene L27 and relative quantification was
performed using the comparative Ct method.
Table 2.5: Primer sequences
Gene Symbol Primer Sequence
Human HIF-1α Forward 5’-CGT TCC TTC GAT CAG TTG TC-3’
Reverse 5’-TCA GTG GTG GCA GTG GTA GT-3’
Human PDK1 Forward 5’-GCA CTC TTT ATT GTT TGG TGG-3’
Reverse 5’-ACG CCT AGC ATT TTC ATA GC-3’
Human L27 Forward 5’-CTG GTG GCT GGA ATT GAC-3’
Reverse 5’-ACA GAG TAC CTT GTG GGC-3’
2.10 Western blots
Protein extraction was performed on cells grown in 12-well cell culture plates. Cells were
washed once with 1 ml 1x DPBS and lysed with 60 µl M-PER lysis buffer (Thermo Scien-
tific) supplemented with 1 x protease inhibitors (Roche). Cells were scraped off the plate
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and transferred into 1.5 ml reaction tubes. Protein extracts were incubated 30 min at 4◦C
under continuous shaking at 1400 rpm. Protein extracts were centrifuged at 21 000 xg for 5
min at 4◦C in a benchtop centrifuge and the supernatant was used for western blot analysis.
Protein extracts were quantified on a Nanodrop spectrophotometer (Thermo Scientific) and
protein extracts containing 10 µg of protein were diluted 1:3 with 4 x Laemmli sample buffer
(Thermo Scientific) supplemented with 10% β-mercaptoethanol (v/v) (Sigma Aldrich). Pro-
teins were denatured for 5 min at 95 ◦C, centrifuged down at 21 000 xg and at 4◦C in a
benchtop centrifuge and kept on ice.
Sodium dodecyl sulfate polyacrylamide gels were pored in-house and were composed of a 3%
acrylamide stacking and 10% acrylamide separating gel. 5 mL stacking gel solution contained
500 µl acrylamide/bis-acrylamide (29:1) (Sigma Aldrich), 1.25 ml 0.5 M tris-hydrogen chlo-
ride (Sigma Aldrich) at pH 6.8, 50 µl 10 % sodium dodecyl sulfate (w/v) (Sigma Aldrich),
3.15 ml water, 50 µl freshly prepared 10 % ammonium persulfate (w/v) (Sigma Aldrich)
and 7 µl tetramethylethylenediamine (Sigma Aldrich). 10 mL separating gel solution was
composed of 3.3 µl acrylamide/bis-acrylamide (29:1), 2.5 ml 1.5 M tris-hydrogen chloride at
pH 8.8, 100 µl 10 % sodium dodecyl sulfate (w/v), 4 ml water, 100 µl freshly prepared 10 %
ammonium persulfate (w/v) and 14 µl tetramethylethylenediamine (Sigma Aldrich).
Protein extracts and 5 µl Precision Plus Kaleidoscope protein standard were loaded on the
gel. Proteins were separated for 15 min at 90 V and then for 60 min at 120 V in a Mini-
Protean Tetra System (Biorad) electrophoresis chamber filled with a running buffer composed
of 25 mM tris-base at pH 8.3 (Sigma Aldrich), 0.2 M glycine (Sigma Aldrich), 0.1% sodium
dodecyl sulfate (w/v).
Gels were washed once for 5 min in water and proteins were transferred on a polyvinylidene
fluoride membrane with a pore size of 0.45 µm (Merck). Therefore, the membrane was ac-
tivated for 1 min with 100% methanol. All components of the western blot stack i.e. the
gel, the membrane, the Whatman paper (GE Healthcare Life Sciences ) were wet in transfer
buffer composed of 25 mM tris-base at pH 8.3 (Sigma Aldrich), 0.2 M glycine (Sigma Aldrich)
and 20% methanol (Sigma Aldrich) before being assembled. Proteins were transferred onto
the membrane in a Criterion Blotter (Biorad) filled with transfer buffer for 1 h at 90 V.
Membranes were washed once in tris-buffered saline-tween (TBS-T) (20 mM tris-hydrochloride,
0.4 mM sodium chloride (Sigma Aldrich), 0.1% Tween (v/v) (Sigma Aldrich), pH 7.6) and
blocked in 10% BSA (w/v) (Sigma Aldrich) in TBS-T for 1 h at room temperature and 50
rpm. Primary antibodies were diluted in 5% BSA (w/v) in TBS-T (refer to table 2.6) and
blots were incubated with the primary antibody over night at 4 ◦C under continuous rotation
at 50 rpm. Blots were washed three times for 5 min with TBS-T. The secondary horse reddish
peroxidase-coupled antibodies (Cell signalling) were diluted 1:5000 in TBS-T containing 5%
skim milk (w/v) (Sigma Aldrich) and the membranes were incubated at room temperature
for 1 h under continuous rotation at 50 rpm. Blots were washed three times for 5 min with
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TBS-T and ECL signals were detected on a Odyssey imaging system (LI-COR Biosciences)
as previously described [Haan and Behrmann, 2007]
Table 2.6: Antibody dilutions and suppliers
Primary antibody Supplier Catalogue Number Species Dilution
HIF-1α BD Transduction Laboratories 610958 mouse 1:500
PDK1 Enzo ADI-KAP-PK112 rabbit 1:1000
pSTAT3 (pTyr705) Cell signaling D3A7 rabbit 1:1000
STAT3 Cell signaling 12640 rabbit 1:1000
pPDH-E1alpha (pSer232) Millipore AP1063 rabbit 1:1000
pPDH-E1alpha (pSer300) Millipore ABS194 rabbit 1:1000
pPDH-E1alpha (pSer293) Millipore ABS204 rabbit 1:10000
alpha-tubulin ThermoFisher scientific PA1-38814 rabbit 1:5000
2.11 Statistical analysis
Each experiment was done in biological triplicates and each triplicate consisted of three wells
per condition. Statistical significance was determined using two-tailed Student’s t-test where
* denotes P6 0.05, ** denotes P6 0.01, and *** denotes P6 0.001. Error bars represent the
standard deviation.
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This study was based on the observation that the IL-6 type cytokine OSM upregulates HIF-1α
on mRNA and protein level under normoxic conditions in HCC cell lines and in immortal-
ized hepatocytes [Vollmer et al., 2009]. While HIF-1α is known to orchestrate the metabolic
response to hypoxia, the metabolic consequences of HIF-1α induction by the inflammatory
cytokine OSM under normoxia remained to be elucidated. Thus, we investigated whether
OSM can induce a hypoxia-like metabolic phenotype via HIF-1α upregulation under nor-
moxic conditions.
First, we studied hypoxia-mediated metabolic effects in two HCC cell lines (HepG2 and JHH-
4) and in immortalized hepatocytes (PH5CH8). Next, we studied the metabolic effects of
OSM under normoxic conditions and compared hypoxia-mediated metabolic changes with
those induced by OSM. Based on the observation that OSM treatment can further increase
HIF-1α levels under hypoxia, we investigated whether a combinatorial treatment can also
boost metabolic effects [Vollmer et al., 2009].
We found that OSM can indeed induce hypoxia-like metabolic changes in immortalized hep-
atocytes, while cellular metabolism of HCC cells remained unaffected although HIF-1α was
upregulated. OSM-mediated metabolic effects in PH5CH8 cells where less pronounced than
those observed under hypoxia, despite the fact that HIF-1α protein levels were similar. Fur-
thermore, a combined treatment of OSM and hypoxia did not result in a stronger metabolic
phenotype. Then we validated, that OSM-mediated metabolic reprogramming is mediated
via HIF-1α and showed that the HIF-1α target gene PDK1 plays a crucial role in this con-
text.
In order to simulate chronic exposure to inflammatory cytokines in PH5CH8 and JHH-4
cell lines, we performed long-term OSM stimulations. Chronic OSM treatment strengthened
OSM-induced metabolic reprogramming of PH5CH8 cells and induced HIF-1α independent
metabolic effects in the HCC cell line JHH-4.
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These results consist of our contribution to the TANDEM project entitled: ”Effects of inflam-
matory cytokines and hypoxia on cancer metabolism in a systems approach”. This project
was carried out in collaboration with Dr. Claude Haan and Dr. Andreas Zimmer (Signal
transduction group, Life Science Research Unit, University of Luxembourg). While we con-
ducted the metabolic profiling, our collaborators contributed valuable information on gene
and protein regulation. Wherever appropriate, I will state our collaborators contributions to
the figures and findings. While the majority of the results was published recently [Battello
et al., 2016] (supplements C), I will describe and discuss our results in more detail and elab-
orate on findings from unpublished experiments.
3.1 Effects of hypoxia on cellular metabolism of HCC cells
and immortalized hepatocytes
HIF-1α is the key regulator of the cell’s response to hypoxia. HIF-1α stabilization under hy-
poxic conditions results in the transcription of numerous target genes, a multitude of which
code for metabolic enzymes [Mole et al., 2009, Ortiz-Barahona et al., 2010]. To study the
metabolic effects of HIF-1α stabilization under hypoxia we performed stable-isotope assisted
metabolomics. We cultured HepG2, JHH-4 and PH5CH8 cell lines for 36 h under normoxia
(18.6% O2) or hypoxia (1%O2) and used uniformly labelled glucose ([
13C6]glucose) and uni-
formly labelled glutamine ([13C5]glutamine) to profile central carbon metabolism.
3.1.1 Hypoxia reduces glucose-derived carbon entry into the TCA cycle
The majority of carbon within central metabolism is derived from glucose and glutamine.
Glucose is metabolized through glycolysis to generate pyruvate. Pyruvate can be decarboxy-
lated to acetyl-coA to be further oxidized within the TCA cycle or converted to lactate and
excreted from the cell. Glutamine is converted to α-ketoglutarate which undergoes oxidative
decarboxylation within the TCA cycle or reductive carboxylation to generate lipogenic cit-
rate. Other carbon sources that contribute to the carbon pool are degradation products from
fatty, amino and nucleic acids. By using [13C6]glucose and [
13C5]glutamine, we can calculate
relative carbon contributions to the metabolites of central carbon metabolism which reflect
the relative proportion of glucose- or glutamine-derived carbon within a given metabolite.
First, we were interested to acquire a general overview of glucose- and glutamine-derived car-
bon contributions to central carbon metabolism in HepG2 and JHH-4 HCC cell lines and in
PH5CH8 immortalized hepatocytes grown under control conditions (18.6% O2). Therefore,
we analysed glucose- and glutamine-derived carbon contribution to (1) pyruvate and lactate
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as representatives for glycolysis, (2) the amino acids serine and glycine and (3) the TCA cycle
intermediates: citrate, α-ketoglutarate, succinate, fumarate, malate and aspartate.
Glucose-derived carbon accounts for the majority (70-90%) of carbon within glycolysis as
could be derived from pyruvate and lactate (Figure 3.1 A-C). Glutamine-derived carbon and
carbon derived from unlabelled sources contributed to glycolysis to lesser extend (Figure 3.1
A-C). Within the TCA cycle, glucose-derived carbon contributed 25-50% of the carbon in
citrate (Figure 3.1 A-C) and 5-25% of the carbon in the other intermediates. Furthermore,
35-50% of the carbon within the TCA cycle was derived from glutamine while 10-15% came
from other carbon sources (Figure 3.1 A-C).
The general distribution of glucose- and glutamine-derived carbon in HCC cell lines and im-
mortalized hepatocytes might reflect the typical metabolic features of proliferating cells. The
contribution of glucose-derived carbon to the TCA cycle metabolites is relatively low, while
compensated by carbon coming from glutamine. However, it remains difficult to draw final
conclusions as we did not profile the metabolism of non-proliferating hepatocytes. Neverthe-
less, our observations underlined the importance of glutamine as carbon source in proliferating
hepatocytes and HCC cell lines which is the case for proliferating cells in general [DeBerar-
dinis et al., 2008].
Although the distribution of glucose- and glutamine-derived carbon within central carbon
metabolism was comparable, cell lines exhibited differences. In HepG2 cells, for example, we
measured that glucose- and glutamine-derived carbon contributed equally to serine while in
JHH-4 and PH5CH8 cell lines, glucose-derived carbon contribution to serine was only 10%.
This suggests differences, either in serine uptake rates from the cell culture medium or a
different influx of glucose-derived carbon into serine and glycine synthesis. Furthermore, we
observed that in HepG2 cells, the contribution of glucose-derived carbon to citrate and other
TCA cycle intermediates was much higher when compared to JHH-4 and PH5CH8 cells. This
observation might be explained by their high PC activity (Figure 3.2 E).
Under hypoxia, we observed that cellular metabolism undergoes drastic changes in terms
of glucose- and glutamine-derived carbon contributions to TCA cycle metabolites. We ob-
served that the relative contribution of glucose-derived carbon to TCA cycle drops drastically
while the contribution of glutamine-derived carbon, and other unlabelled sources, increased
(Figure 3.1 A-C). Under low oxygen tension and for all cell lines, the synthesis of citrate,
α-ketoglutarate and succinate became almost entirely independent of carbon coming from
glucose, providing evidence for that glucose-derived carbon entry into the TCA cycle is dras-
tically altered.
Taken together we observed that in immortalized hepatocytes and HCC cells the metabolic
adaptation to hypoxia goes hand in hand with a drastic decrease in glucose-derived car-
bon to the TCA cycle while glutamine-derived carbon is used as a substitute to synthesize
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Figure 3.1: Hypoxia-mediated changes in glucose- and glutamine-derived carbon
contributions. HCC cell lines (HepG2, JHH-4) and immortalized hepatocytes (PH5CH8)
were grown for 36 h under normoxia (N) (18.6% O2) or under hypoxia (H) (1%O2) in presence
of [13C6]glucose or [
13C5]glutamine. Relative carbon contributions from glucose, glutamine
and other (unlabelled) carbon sources to serine (Ser), glycine (Gly), pyruvate (Pyr), lactate
(Lac), citrate (Cit), α-ketoglutarate (α-KG), succinate (Suc), fumarate (Fum), malate (Mal)
and aspartate (Asp) were calculated for (A) HepG2, (B) JHH-4 and (C) PH5CH8.
TCA cycle metabolites. These results demonstrate that the entry of pyruvate into the TCA
cycle is prohibited while glutamine ensures the generation of numerous metabolites under hy-
poxic conditions. Our results are in agreement with the classical hypoxia-mediated metabolic
changes that have been described in numerous cell lines [Fendt et al., 2013, Filipp et al., 2012,
Metallo et al., 2011, Scott et al., 2011].
3.1.2 Metabolic consequences of hypoxia on glucose and glutamine metabolism
To profile the activity of PDC and PC, the two enzymes that link glycolysis and the TCA cy-
cle, we applied [13C6]glucose. When [
13C6]glucose is metabolized via glycolysis, [
13C3]pyruvate
is generated. By oxidative decarboxylation, PDC generates [13C2]acetyl-CoA (Figure 3.2 A).
Then, CS catalyzes the condensation of [13C2]acetyl-CoA and unlabelled oxaloacetate and
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thereby generates [13C2]citrate (Figure 3.2 A). Thus, the abundance of M2 citrate mass iso-
topologues represents PDC activity (Figure 3.2 A). Pyruvate can also enter the TCA cycle via
PC which regulates TCA cycle anaplerosis and is implicated into gluconeogenesis. Further,
PC catalyzes the carboxylation of [13C3]pyruvate and generates [
13C3]oxaloacetate (Figure
3.2 B). CS condenses [13C3]oxaloacetate with unlabelled acetyl-CoA derived from β-oxidation
of fatty acid, or with [13C2]acetyl-CoA derived from PDC activity and generates [
13C3]- or
[13C5]citrate, respectively (Figure 3.2 B,C). Thus, the relative abundance of M3 citrate mass
isotopologues reflects PC activity while the fraction of M5 citrate mass isotopologues rep-
resents the combined activity of PC and PDC (Figure 3.2 B, C). By analysing the relative
fractions of M2, M3 and M5 isotopologues of citrate we can distinguish PDC and PC me-
diated reactions and draw conclusions about their respective activities. To avoid bias from
general mass isotopomer enrichment, we normalized the abundance of citrate isotopologues
to the abundance of M3 lactate isotopologues.
In line with the differential contribution of glucose-derived carbon to citrate (Figure 3.1 A-C),
we detected different PDC and PC activities in the cell lines (Figure 3.2 D-F). We found that
PDC activity was lowest in HepG2 cells, while it was similar in PH5CH8 and JHH-4 cells
(Figure 3.2 D). This suggests that the relative pyruvate flux through PDC was lower in HepG2
cells when compared to JHH-4 and PH5CH8 (Figure 3.2 D). Furthermore, we observed that
the relative activity of PC was variable between cell lines, where HepG2 cells exposed the
highest and PH5CH8 the lowest fraction of M3 citrate mass isotopologues (Figure 3.2 E). This
suggested that TCA cycle anaplerosis, which is regulated by PC, was differently regulated
in the cell lines. Together, our data indicated that the three cell lines have different relative
PDC and PC activities, which might be explained by different expressions levels, distinct
activation states and/or allosteric regulation (Figure 3.2 D-E). Despite different PDC and
PC activities, the majority of pyruvate entered the TCA cycle via PDC as reflected by a 6
to 30 times higher abundance of M2 citrate isotopologues as compared to M3 citrate.
Under hypoxia, we found that in all cell lines the fraction of M2, M3 and M5 citrate isotopo-
logues strongly decreased. This shows that PDC and PC were less active and that the glucose
flux into the TCA cycle was drastically dampened (Figure 3.2 D-F). Inhibited glucose-derived
carbon entry into the TCA cycle is a metabolic consequence of hypoxia and is mediated by
HIF-1α. HIF-1α upregulates the protein kinase PDK1 and downregulates the pyruvate dehy-
rogenase phosphatase catalytic subunit 2 (PDP2) thereby leading to PDC phosphorylation
and consequently inhibition [Kim et al., 2006, Liou et al., 2001]. We measured significant
PDK1 upregulation and PDP2 downregulation under hypoxia in all cell lines (Supplemental
figure A.2 A-F and A.3 A-C). PDK1 upregulation translated in PDC phosphorylation on
all three serine residues (Supplemental figure A.2 A-F and A.3 A-C). Furthermore, under
hypoxia, we detected significantly decreased PC activity which might be due to reduced PC
expression or allosteric regulation. HIF-1 can indeed bind the promoter region of PC while it
remains elusive if this stimulates or represses PC expression [Schoedel et al., 2011]. Moreover,
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PC is allosterically regulated by acetyl-coA. Since acetyl-coA synthesis is drastically inhibited
under hypoxia, PC activity might consequently be dampened.
To study glutamine metabolism, we employed a [13C5]glutamine tracer. By applying this
tracer we can distinguish oxidative and reductive glutamine metabolism. Under oxidative
conditions, [13C5]glutamine undergoes oxidation within the TCA cycle and [
13C4]citrate
is generated (Figure 3.2 C). However, if glutamine is metabolized in a reductive manner,
[13C5]glutamine generates [
13C5]citrate (Figure 3.2 C). Therefore, M4 and M5 citrate iso-
topologues represent the oxidative and reductive glutamine metabolism, respectively. To
avoid bias from a different glutamine influx into the TCA cycle, the relative abundance of
M4 and M5 citrate isotopologues was normalized to the abundance of the M5 glutamate
isotopologues.
Similar to our observation for glucose metabolism, the different cell lines exhibit differences in
the relative fractions of the M4 and M5 citrate isotopologues under normoxia suggesting a cell
line to cell line specific distribution of glutamine within central carbon metabolism (Figure
3.2 F-G). We found that the fraction of M5 citrate was almost equal in HepG2 and PH5CH8
cells, while JHH-4 cells metabolized much less glutamine in a reductive manner (Figure 3.2
F-G). Concerning the oxidative metabolism of glutamine, we detected the highest fraction of
M4 citrate in JHH-4 cells, an intermediate fraction in PH5CH8 cells and the lowest abun-
dance of M4 citrate isotopologues in HepG2 (Figure 3.2 F-G). This suggested that the relative
proportion of glutamine that was either used for decarboxylation within the TCA cycle or
the generation of lipogenic citrate varied between the cell lines. However, we observed that
in all cell lines, the majority of glutamine was metabolized oxidatively, as reflected by the
abundance of the M4 citrate isotopologues that was 2 to 7 times higher than the abundance
of the M5 citrate isotopologues (Figure 3.2 F-G).
Under hypoxia, the fraction of the M5 citrate isotopologues increased while the abundance
of the M4 citrate isotopologues decreased in all cell lines (Figure 3.2 F-G). This suggests
that under hypoxia, reductive carboxylation of α-ketoglutarate increases while oxidative α-
ketoglutarate decarboxylation decreases. Under hypoxic conditions, the majority of glutamine
was metabolized in a reductive manner as reflected by a 6 to 8 times higher fraction of the
M5 citrate isotopologues as compared to abundance of the M4 citrate isotopologues (Figure
3.2 F-G).
In the HCC cells lines HepG2 and JHH-4 and in the immortalized hepatocytes PH5CH8,
hypoxia reduced oxidation of glucose- and glutamine-derived carbon within the TCA cycle
while reductive glutamine metabolism was increased. These observations are in-line with
other studies that investigated the metabolic consequences of hypoxia and show that HIF-
1α stabilization results in the upregulation of PDK1 which consequently inhibits PDC by
phosphorylation [Kim et al., 2006]. As a result, the entry of pyruvate into the TCA cycle
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Figure 3.2: Hypoxia-mediated changes in glucose and glutamine metabolism in
HCC cell lines and immortalized hepatocytes. HepG2 and JHH-4 HCC cell lines
and PH5CH8 immortalized hepatocytes were grown for 36 h under normoxia (18.6% O2)
(Ctrl) or under hypoxia (1%O2) in the presence of [
13C6]glucose or [
13C5]glutamine. (A-C)
Carbon atom transitions for pyruvate carboxylase (PC) and pyruvate dehydrogenase com-
plex (PDC) activities, from a [13C6]glucose tracer. (D) PDC activity determined from the
M2 citrate isotopologues normalized to the M3 lactate isotopologues, from [13C6]glucose.
(E) PC activity determined from the M3 citrate isotopologues normalized to the M3 lac-
tate isotopologues, from [13C6]glucose. (F) M5 isotopologues of citrate reflecting the com-
bined carbon contribution of PC and PDC normalized to the M3 lactate isotopologues,
from [13C6]glucose. (G) Carbon atom transitions for oxidative and reductive glutamine
metabolism, from [13C5]glutamine. (H) Reductive glutamine contribution to citrate, deter-
mined by the ratio of the M5 isotopologues of citrate to M5 isotopologues of glutamate, from
[13C5]glutamine. (I) Oxidative glutamine contribution to citrate, determined by the ratio of
the M4 isotopologues of citrate to the M5 isotopologues of glutamate, from [13C5]glutamine.
Error bars indicate the standard deviation and are calculated from at least two independent
replicates. Statistical significance between control and the treatment was determined by a
two-tailed t-test where * denotes P6 0.05, ** denotes P6 0.01, and *** denotes P6 0.001.
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is prohibited and consequently less citrate is generated from glucose while the generation of
lipogenic citrate becomes dependent on reductive carboxylation of glutamine [Fendt et al.,
2013, Metallo et al., 2011].
3.2 OSM-mediated metabolic effects in HCC cell lines and
immortalized hepatocytes
In the previous section, I have presented HIF-1α-mediated metabolic effects under hypoxia
in HCC cell lines and in immortalized hepatocytes. As expected, HIF-1α stabilization un-
der hypoxic conditions results in metabolic reprogramming of cellular metabolism. Since the
pro-inflammatory cytokine OSM induces HIF-1α upregulation on mRNA and protein level
under normoxia, we hypothesized that OSM will induce a hypoxia-like metabolic phenotype
under normoxic conditions [Vollmer et al., 2009]. To investigate the metabolic effects of OSM-
mediated HIF-1α induction under normoxic conditions in hepatocellular carcinoma cells and
immortalized hepatocytes we performed stable-isotope assisted metabolomics. We stimu-
lated HepG2, JHH-4 and PH5CH8 for 36 h with 50 ng/mL OSM or left the cells untreated
and incubated them under normoxia (18.6% O2). To profile central carbon metabolism, we
employed [13C6]glucose and [
13C5]glutamine.
3.2.1 Effects of OSM on glucose- and glutamine-derived carbon contribu-
tion to central carbon metabolism
Unlike hypoxia, OSM-stimulation did not effect glucose- nor glutamine-derived carbon contri-
butions to citrate in the HCC cell lines HepG2 and JHH-4 (Figure 3.3 A, B). Solely in HepG2
cells, glucose-derived carbon contribution to serine and glycine was mildly reduced suggesting
a decreased glucose flux to one-carbon metabolism or an increased uptake of serine from cell
culture medium (Figure 3.3 A). Interestingly, in HepG2 cells a reduction of glucose-derived
carbon to serine and glycine was also observed under hypoxia (Figure 3.1 A). Whereas OSM
treatment had no typical hypoxia-like metabolic effects in HCC cells, we detected a significant
decrease in glucose-derived carbon contribution to citrate in OSM-stimulated PH5CH8 cells
(Figure 3.3 C). In line with this result, we observed an increased contribution of glutamine-
derived carbon to citrate (Figure 3.3 C).
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Figure 3.3: OSM-mediated changes in carbon contributions in HCC cells and
immortalized hepatocytes. HepG2, JHH-4 hepatocellular carcinoma cells and PH5CH8
immortalized hepatocytes were left untreated (C) or stimulated with 50 ng/mL OSM (O)
for 36 h under normoxia in presence of [13C6]glucose or [
13C5]glutamine. Relative carbon
contributions from glucose, glutamine and other (unlabelled) carbon sources to serine (Ser),
glycine (Gly), pyruvate (Pyr), lactate (Lac), citrate (Cit), α-ketoglutarate (α-KG), succinate
(Suc), fumarate (Fum), malate (Mal) and aspartate (Asp) were calculated for (A) HepG2,
(B) JHH-4 and (C) PH5CH8 cells. Error bars represent the standard deviation.
3.2.2 Effects of OSM on glucose and glutamine metabolism
Next, we studied the entry of glucose-derived carbon into the TCA cycle. Therefore we anal-
ysed the abundance of the M2 and M3 mass isotopologues of citrate, reflecting PDC and PC
activity, respectively (Figure 3.4 A-B). Correlating with our finding that OSM had no effect
on the glucose-derived carbon contribution to citrate in HepG2 and JHH-4 HCC cell lines,
the fraction of the M2 and M3 citrate isotopologues remained unaffected (Figure 3.4 D-E).
Furthermore, we studied oxidative and reductive glutamine metabolism which is reflected by
the fraction of the M4 and M5 citrate isotopologues generated from [13C5]glutamine (Figure
3.4 C). As illustrated by unchanged fractions of M4 and M5 citrate isotopologues in these
cells, OSM treatment did not effect glutamine metabolism (Figure 3.4 F-G).
However in PH5CH8 cells, we detected a significant decrease in the abundance of the M2
citrate isotopologues pointing towards decreased PDC activity (Figure 3.4 D). In conjunction
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with decreased PDC activity, PH5CH8 cells secreted significantly more lactate when com-
pared to untreated cells (Supplemental figure A.1). Furthermore, we observed a significantly
decreased oxidative glutamine metabolism while reductive glutamine metabolism through
IDH1 was increased by OSM stimulation (Figure 3.4 F-G).
Based on the fact that under hypoxia HIF-1α mediates metabolic reprogramming via PDK1
up- and PDP2 downregulation, we analysed the expression of these two genes after OSM
treatment in PH5CH8 cells. We detected a significant upregulation of PDK1 on mRNA and
protein level while PDP2 expression remained unaffected (Supplemental figure A.3 A-C).
Although hypoxia and OSM treatment induced similar levels of PDK1 mRNA expression,
PDK1 protein expression was stronger after hypoxia (Supplemental figure A.3 A-C). Intrigu-
ingly, OSM-induced PDK1 upregulation did not translate into enhanced PDC phosphoryla-
tion which might be explained by the fact that PDP2 is not downregulated (Supplemental
figure A.3 A-C).
To conclude, we observed that OSM stimulation did not induce hypoxia-like metabolic changes
in the HCC cell lines HepG2 and JHH-4. In PH5CH8 immortalized hepatocytes, however,
the stimulation triggered a hypoxia-like metabolic phenotype which was way less pronounced
than the one induced by hypoxia. Moreover when we applied a combinatorial treatment of
OSM and hypoxia in PH5CH8 cells, we did not observe further hypoxia-mediated metabolic
effects (Supplemental figure A.4).
3.2.3 OSM-mediated HIF-1α upregulation in hepatoma and hepatic cells
Based on our observation that OSM induced a hypoxia-like metabolic phenotype in immortal-
ized hepatocytes but not in HCC cell lines, we studied HIF-1α mRNA and protein expression
upon OSM treatment in HepG2 and JHH-4 hepatocellular carcinoma cells and compared
those to the expression in PH5CH81. Therefore, we analysed HIF-1α mRNA and protein
expression levels after 8, 12, 24 and 36 h of OSM treatment, hypoxia (1% O2) or a combina-
torial treatment.
In PH5CH8 cells, HIF-1α mRNA and protein expression was upregulated after OSM treat-
ment over the full length of the timecourse (Figure 3.5 A-C). 36 h after the treatment,
OSM- and hypoxia-induced HIF-1α protein expression reached equal levels (Figure 3.5 B-
C). Despite the fact that hypoxia- and OSM-induced HIF-1α protein expression was similar,
hypoxia-mediated effects on cellular metabolism were much stronger than those mediated
by OSM under normoxia (Figure 3.2 and figure 3.4). This suggests that in PH5CH8 cells,
OSM-induced HIF-1α is either less active or that other factors influence metabolism under
hypoxic conditions.
1The data in this section has been generated by our collaborator Dr. Andreas Zimmer
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Figure 3.4: OSM-mediated changes in glucose and glutamine metabolism in
hepatoma cells and immortalized hepatocytes. HepG2 and JHH-4 HCC cell lines
and PH5CH8 immortalized hepatocytes were treated for 36 h with 50 ng/mL OSM under
normoxia (18.6% O2) (OSM) or left untreated and grown in the presence of [
13C6]glucose
or [13C5]glutamine. (A-C) Carbon atom transitions for pyruvate carboxylase (PC) and
pyruvate dehydrogenase complex (PDC) activities, [13C6]glucose. (D) PDC activity deter-
mined from the M2 citrate isotopologues normalized to the M3 lactate isotopologues, from
[13C6]glucose. (E) PC activity determined from the M3 citrate isotopologues normalized
to the M3 lactate isotopologues, from [13C6]glucose. (F) M5 isotopologues of citrate re-
flecting the combined carbon contribution of PC and PDC normalized to the M3 lactate
isotopologues, from [13C6]glucose. (G) Carbon atom transitions for oxidative and reductive
glutamine metabolism, [13C5]glutamine. (H) Reductive glutamine contribution to citrate,
determined by the ratio of the M5 isotopologues of citrate to the M5 isotopologues of glu-
tamate, from [13C5]glutamine. (I) Oxidative glutamine contribution to citrate, determined
by the ratio of the M4 isotopologues of citrate to the M5 isotopologues of glutamate, from
[13C5]glutamine. Error bars indicate the standard deviation and are calculated from at least
two independent replicates. Statistical significance between control and the treatment was
determined by a two-tailed t-test where * denotes P6 0.05, ** denotes P6 0.01, and ***
denotes P6 0.001.
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Figure 3.5: The effect of OSM on HIF-1α expression in PH5CH8 immortalized
hepatocytes and HepG2 and JHH-4 hepatoma cells. HepG2, JHH-4 and PH5CH8
cells were treated with 50 ng/ml OSM, hypoxia (1% O2), or a combinatorial treatment for 8,
12, 24 and 36 h. (A) qPCR on HIF-1α mRNA expression. The fold change was calculated
relative to the untreated control. Error bars represent the standard deviation of three bio-
logical replicates. (B) Western Blot on HIF-1α . α-Tubulin was used as a loading control,
and one representative blot for α-Tubulin is shown. S. Exp. = short exposure; L. Exp. =
long exposure. (C) Quantification of HIF-1α protein levels in HepG2 and PH5CH8 cells.
Error bars indicate the standard deviation and are calculated from at least three independent
replicates. Statistical significance between control and the treatment was determined by a
two-tailed t-test where * denotes P6 0.05, ** denotes P6 0.01, and *** denotes P6 0.001.
Figure published in [Battello et al., 2016] This data was kindly provided by Dr. Andreas
Zimmer.
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In HepG2 cells, HIF-1α mRNA was upregulated by OSM treatment under normoxia over
the entire time course (Figure 3.5 A). However, increased mRNA levels did not translate
into increased HIF-1α protein levels at later stimulation time points. In HepG2 cells, OSM-
mediated HIF-1α protein induction peaks between 8 and 12 h and decreases between 24 and
36 h (Figure 3.5 B-C). This suggests that OSM-induced HIF-1α proteins underwent degra-
dation under normoxia at longer stimulation time points. Interestingly, we observed that a
combinatorial treatment of OSM and hypoxia over 24 and 36 h led to higher HIF-1α protein
levels than hypoxia alone. Thus, OSM-induced HIF-1α proteins probably underwent oxygen-
dependent degradation, while they were stabilized under hypoxic conditions and thus further
increased HIF-1α protein levels. While OSM stimulation under hypoxia further increased
HIF-1α protein expression, we did not detect a more pronounced hypoxic metabolic pheno-
type (Supplemental figure A.4).
In JHH-4 cells, OSM-mediated HIF-1α mRNA upregulation was transient and very mild,
reaching a maximum between 8 and 12 h (Figure 3.5 A) while HIF-1α protein levels were
barely detectable and remained unaffected by OSM treatment (Figure 3.5 B-C). This obser-
vation implied that in JHH-4 cells, HIF-1α protein expression cannot be induced by OSM-
mediated STAT3 activation.
Based on the finding that OSM-induced HIF-1α upregulation is transient in HepG2 cells we
screened 11 HCC cell lines and 2 non-neoplastic hepatocyte cell lines, 8 hours and 36 hours
after OSM treatment or exposure to hypoxia (1% O2). In 10 out of 13 cell lines, we detected
HIF-1α protein induction within the first 8 hours after stimulation, whereas after 36 hours,
we detected OSM-induced HIF-1α in 5 out of 13 cell lines (Figure 3.5 D). In almost all cell
lines we observed a continuous and strong HIF-1α induction by hypoxia (Figure 3.5 D).
In summary, these data suggested that OSM-mediated HIF-1α protein induction is transient
and restricted to early stimulation time-points in many HCC cell lines. Based on this find-
ing the question rises whether cytokine-induced HIF-1α induction is required for metabolic
reprogramming at early stimulation time points.
3.2.4 OSM does not induce metabolic changes in HepG2-C3A and SK-
Hep1 HCC cells despite HIF-1α induction
Based on the previously described results, we aimed to study the effects of OSM on the
metabolism of HepG2-C3A and SK-Hep1 HCC cell lines since we detected a strong induction
of HIF-1α protein over the whole period of OSM treatment (Figure 3.6 A, F ). Therefore,
we stimulated HepG2-C3A and SK-Hep1 cells for 8 and 36 hours with 50 ng/mL OSM and
conducted metabolic tracer experiments using [13C6]glucose and [
13C5]glutamine. Our results
show that, strong OSM-mediated HIF-1α protein inductions did not result in drastic activity
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Figure 3.6: OSM-mediated metabolic effects in Sk-Hep1 and HepG2-C3A HCC
cell lines. Sk-Hep1 and HepG2-C3A HCC cell lines were stimulated for 8 and 36 h with 50
ng/mL OSM or left untreated and grown in the presence of [13C6]glucose or [
13C5]glutamine.
(A) Westernblot on HIF-1α. (B, G) PDC activity determined from the M2 citrate isotopo-
logues normalized to the M3 lactate isotopologues, from [13C6]glucose. (C, H) PC activity
determined from the M3 citrate isotopologues normalized to the M3 lactate isotopologues,
from [13C6]glucose. (D, I) Reductive glutamine contribution to citrate, determined by the
ratio of M5 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine.
(E, J) Oxidative glutamine contribution to citrate, determined by the ratio of the M4 iso-
topologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine. Error bars
indicate the standard deviation and are calculated from at least two independent replicates.
Statistical significance was determined by a two-tailed t-test. * denotes P6 0.05, ** denotes
P6 0.01, and *** denotes P6 0.001. Westernblots were generated by our collaborator Dr.
Andreas Zimmer
changes of PDC and PC (Figure 3.6 B-C, G-H). Furthermore, we did not observe hypoxia-like
metabolic changes within glutamine metabolism (Figure 3.6 D-E, I-J). Solely in HepG2-C3A
cells we detected a decreased abundance of M5 citrate isotopologues pointing towards a de-
creased reductive glutamine metabolism after a 36 h OSM treatment. This effect was the
contrary to what we would have expected from HIF-1α and furthermore was not observed
after a 8 h OSM stimulation (Figure 3.6 D-E, I-J).
These results demonstrated that despite its induction, HIF-1α did not induce hypoxia-like
metabolic changes within central carbon metabolism in the HCC cell lines HepG2-C3A and
Sk-Hep. These data suggest that OSM-induced HIF-1α might either be fully inactive un-
der the given conditions or participate in the regulation of cellular functions other than the
metabolism.
3.2.5 OSM-mediated metabolic effects in PH5CH8 cells are concentration
dependent
Based on our finding that OSM treatment leads to a hypoxia-like metabolic phenotype in
PH5CH8 cells, we studied if these effects are concentration dependent. For that purpose,
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we stimulated PH5CH8 cells with 10, 25 and 50 ng/mL OSM for 36 h. In line with a dose
dependent increase of HIF-1α protein levels (Figure 3.7 A), we observed that the strength of
the metabolic effects is indeed dependent on the concentration (Figure 3.7 B-E). While OSM-
mediated metabolic effects on PDC activity (Figure 3.7 B) and on glutamine metabolism
(Figure 3.7 D-E) were strongest with the highest OSM concentration, significant changes in
glucose and glutamine metabolism could already be detected with 10 ng/mL OSM.
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Figure 3.7: OSM-mediated metabolic changes in PH5CH8 are concentration-
dependent. PH5CH8 immortalized hepatocytes were stimulated for 36 h with 10, 25 and 50
ng/mL OSM or left untreated and grown in the presence of [13C6]glucose or [
13C5]glutamine.
(A) Western blot on HIF-1α. (B) PDC activity determined from the M2 citrate isotopo-
logues normalized to the M3 lactate isotopologues, from [13C6]glucose. (C) PC activity de-
termined from the M3 citrate isotopologues normalized to the M3 lactate isotopologues, from
[13C6]glucose. (D) Reductive glutamine contribution to citrate, determined by the ratio of
the M5 isotopologues of citrate to the M5 isotopologues of glutamate, from [13C5]glutamine.
(E) Oxidative glutamine contribution to citrate, determined by the ratio of the M4 isotopo-
logues of citrate to the M5 isotopologues of glutamate, from [13C5]glutamine. Error bars
indicate the standard deviation and are calculated from at least two independent replicates.
Statistical significance between control and the treatment was determined by a two-tailed
t-test. * denotes P6 0.05, ** denotes P6 0.01, and *** denotes P6 0.001.
3.2.6 OSM-mediated metabolic effects in PH5CH8 cells are HIF-1α de-
pendent
To verify that the hypoxia-like metabolic effects observed in OSM-stimulated PH5CH8 cells
are indeed dependent on HIF-1α we performed an siRNA-mediated HIF-1α knockdown
in OSM-treated PH5CH8 cells under normoxia and hypoxia and profiled central carbon
metabolism with [13C6]glucose and [
13C5]glutamine
2.
Silencing HIF-1α under normoxia already effected the metabolism of unstimulated PH5CH8
cells. We observed that upon HIF-1α knockdown PC activity increased while PDC activity
remained unaffected (Figure 3.8 A-B). At the same time we observed a very mild increase
2The data in this section was generated by Carole Goebel as part of her Master thesis
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Figure 3.8: The metabolic effects of HIF-1α silencing on the OSM-induced
hypoxia-like metabolic phenotype in PH5CH8. A siRNA-mediated HIF-1α knock-
down (siHIF-1α) was performed in PH5CH8 cells grown under normoxia or hypoxia. A
non-targeting siRNA (siCtrl) was used as control. PH5CH8 cells were stimulated for 36
h with 50 ng/mL OSM or left untreated and grown in the presence of [13C6]glucose or
[13C5]glutamine. (A) The enzymatic activity of PDC determined from the M2 citrate iso-
topologues normalized to the M3 lactate isotopologues, from [13C6]glucose. (B) PC activity
determined from the M3 citrate isotopologues normalized to the M3 lactate isotopologues,
from [13C6]glucose. (D) Reductive glutamine metabolism, determined by the ratio of the M5
isotopologues of citrate to the M5 isotopologues of glutamate, from [13C5]glutamine. (D)
Oxidative glutamine metabolism, determined by the ratio of the M4 isotopologues of citrate
to the M5 isotopologues of glutamate, from [13C5]glutamine. Error bars indicate the standard
deviation and are calculated from at least two independent replicates. Statistical significance
between control and the treatment was determined by a two-tailed t-test. * denotes P6 0.05,
** denotes P6 0.01, and *** denotes P6 0.001.
in reductive glutamine metabolism while oxidative glutamine metabolism was slightly de-
creased (Figure 3.8 C-D). These data suggest that HIF-1α might have some metabolic ef-
fects, although HIF-1α protein expression was low under normoxia and barley detectable on
a Western blot.
Furthermore we found that HIF-1α knockdown under hypoxic conditions results in a partial
recovery of the typical hypoxia-mediated metabolic effects. We observed that the pyruvate
flux through PDC was enhanced, the reductive glutamine metabolism was decreased while ox-
idative glutamine metabolism was increased (Figure 3.8 C-F). While HIF-1α silencing under
hypoxic conditions partially recovered the hypoxia-mediated phenotype, a normoxic metabolic
phenotype could not be restored. While we cannot exclude that the HIF-1α silencing effi-
ciency was insufficient, it is more probably that other limiting factors, such as the oxygen
availability itself prevent a full recovery. Unlike for hypoxia-mediated metabolic effects, we
found that silencing HIF-1α in OSM-treated PH5CH8 cells under normoxia led to an almost
completely abolished OSM-mediated metabolic response (Figure 3.8 C-F).
Contrarily to our observations in HCC cell lines, these findings support the hypothesis that
OSM induces hypoxia-like metabolic effects via HIF-1α protein induction in immortalized
hepatocytes. To this point, the exact difference between OSM-mediated HIF-1α induction in
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HCC cells and in immortalized hepatocytes remains to be clarified. Furthermore we showed
that the mechanisms underlying OSM- and hypoxia-induced metabolic changes shared the
common feature of HIF-1α induction, while other factors might further contributed to the
strong metabolic effects under hypoxia.
3.2.7 OSM-induced metabolic effects are partially dependent on PDK1
Under hypoxia, the HIF-1α target gene PDK1 coordinates the metabolic switch from oxida-
tive phosphorylation towards a more glycolytic metabolism. [Kim et al., 2006, Papandreou
et al., 2006, Roche et al., 2001]. We were interested to validate whether PDK1 also plays
a role in the mediation of the OSM-induced metabolic phenotype. As previously described,
OSM-stimulation resulted in PDK1 upregulation which however did not translate into differ-
ential PDC phosphorylation in PH5CH8 cells (Section 3.2.3).
In PH5CH8 immortalized hepatocytes we showed that HIF-1α silencing reduced PDK1 ex-
pression under normoxia and hypoxia and furthermore prevented OSM-mediated PDK1 up-
regulation (Figure 3.9 A). This proved that PDK1 expression is at least partially under the
control of HIF-1α in these cells. Furthermore, we observed that PDK1 silencing abolished
both OSM- and hypoxia-mediated PDK1 upregulation on mRNA and protein level (Figure
3.9 B-C).
When we silenced PDK1 under normoxia, glucose-derived carbon contribution to citrate
increased by 14%, underlining a high influx of glucose-derived carbon into the TCA cycle
(Figure 3.9 G). In line, we observed that PDC activity was increased as reflected, in this
particular case, by an increased fraction of M4 citrate isotopologues. The very high influx of
fully labelled acetyl-coA into the TCA cycle consequently generated a high relative fraction of
M2 oxaloacetate isotopologues which in turn were condensed with fully labelled acetyl-coA,
thus increasing the abundance of M4 citrate isotopologues (Figure 3.9 G). As a consequence
of increased isotopic enrichment of the TCA cycle intermediates and in particular oxaloac-
etate, the relative proportion of unlabelled oxaloacetate was diminished and thus the relative
fraction of M2 citrate decreased (Figure 3.9 E, G). Furthermore, we measured an increased
abundance of M3 citrate isotopologues when PDK1 was silenced which suggested that PC
was allosterically regulated by increased acetyl-coA levels (Figure 3.9 E, G). Moreover, we
observed that following PDK1 silencing the fraction of the M5 citrate isotopologues was in-
creased thus further providing evidence for the increased influx of pyruvate into the TCA cycle
(Figure 3.9 F). PDK1 silencing in HCC cell lines had similar effects on glucose metabolism
(Supplemental figure A.5).
In addition to its effects on glucose metabolism, we observed that silencing PDK1 under
normoxia had a impact on glutamine metabolism. We measured that reductive glutamine
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Figure 3.9: The metabolic effects of PDK1 silencing on the OSM-induced hypoxia-like
metabolic phenotype in PH5CH8. SiRNA-mediated PDK1 knockdown (siPDK1) was per-
formed on PH5CH8 cells grown under normoxia or hypoxia. A non-targeting siRNA (siCtrl)
was used as control. PH5CH8 cells were stimulated for 36 h with 50 ng/mL OSM or left
untreated and grown in the presence of [13C6]glucose or [
13C5]glutamine. (A) qPCR on
PDK1 under HIF-1α knockdown conditions (B) qPCR on PDK1 under PDK1 knockdown
conditions (C) Westernblot on PDK1 (D) The enzymatic activity of PDC determined from
the M2 citrate isotopologues normalized to the M3 lactate isotopologues, from [13C6]glucose.
(E) PC activity determined from the M3 citrate isotopologues normalized to the M3 lactate
isotopologues, from [13C6]glucose. (F) Combined PDC and PC activities determined from
the M5 citrate isotopologues normalized to the M3 lactate isotopologues, from [13C6]glucose.
(G) Citrate MID from [13C6]glucose. (H) Reductive glutamine contribution to citrate, de-
termined by the ratio of M5 isotopologues of citrate to M5 isotopologues of glutamate, from
[13C5]glutamine. (I) Oxidative glutamine contribution to citrate, determined by the ratio
of M4 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine. Er-
ror bars indicate the standard deviation and are calculated from at least two independent
replicates. Statistical significance between control and the treatment was determined by a
two-tailed t-test. * denotes P6 0.05, ** denotes P6 0.01, and *** denotes P6 0.001.
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metabolism has inhibited while oxidative glutamine metabolism was enhanced (Figure 3.9 H,
I).
When we silenced PDK1 under hypoxic conditions, we observed drastic effects on cellular
metabolism, underlining its strong regulatory potential. We measured a drastic increase of
the glucose flux through PDC and PC (Figure 3.9 D-F) while reductive glutamine metabolism
was inhibited and oxidative decarboxylation of glutamine increased (Figure 3.9 H-I).
As a consequence of PDK1 silencing in OSM-treated PH5CH8 cells, we attenuated OSM-
mediated metabolic effects. While OSM-induced reduced PDC activity and OSM-mediated
changes in glutamine metabolism were impaired when PDK1 was silenced, they were not
fully abolished. This suggests that either the PDK1 knockdown was insufficient or that yet
other regulators are involved (Figure 3.9 D-F). Taken together, our results show that PDK1 is
necessary to mediate OSM-induced metabolic reprogramming, while we cannot exclude that
yet other HIF-1α target genes are involved.
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Figure 3.10: The metabolic effects of PDK1 silencing on cell proliferation and
intracellular metabolite levels. SiRNA-mediated PDK1 knockdown (siPDK1) was per-
formed on PH5CH8 cells grown under normoxia or hypoxia. A non-targeting siRNA (siCtrl)
was used as control. PH5CH8 cells were stimulated for 36 h with 50 ng/mL OSM or left
untreated. (A) Effects of PDK1 silencing on the proliferation of PH5CH8 cells (B) α-
ketoglutarate to citrate ratio. Intracellular metabolite levels of (C) α-ketoglutarate and
(D)citrate. GC-MS derived signal intensities were normalized to the internal standard and
to cell count. Error bars indicate the standard deviation and are calculated from at least
two independent replicates. Statistical significance between control and the treatment was
determined by a two-tailed t-test. * denotes P6 0.05, ** denotes P6 0.01, and *** denotes
P6 0.001.
Finally, we were interested if PDK1 silencing effects cell proliferation and intracellular metabo-
lites levels. We observed that PDK1 silencing significantly affected cell proliferation under
hypoxia underlying the importance of PDK1 under low oxygen tension (Figure 3.10 A). Next
we analysed intracellular metabolite levels and were especially interested in the ratio between
intracellular α-ketoglutarate and citrate levels. The ratio between these two metabolites was
shown to be determinative to induce reductive glutamine metabolism [Fendt et al., 2013]
where an increase in α-ketoglutarate to citrate ratios correlates with an increase in reductive
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glutamine metabolism. First we considered intracellular α-ketoglutarate and citrate levels in-
dividually. Both, hypoxia and OSM treatment led to increased intracellular α-ketoglutarate
levels while citrate levels remained unchanged (Figure 3.10 C). When we silenced PDK1,
OSM and hypoxia induced increased α-ketoglutarate levels dropped while intracellular cit-
rate levels increased (Figure 3.10 C, D). Both, OSM stimulation and hypoxia led to increased
α-ketoglutarate to citrate ratios supporting our finding that reductive glutamine metabolism
is induced (Figure 3.10 B). Silencing PDK1 abolished both the OSM- and the hypoxia-
mediated increase in α-ketoglutarate to citrate ratios (Figure 3.10 B). These results reinforce
our finding that OSM induces reductive glutamine carboxylation and show that PDK1 is
crucial regulator, both under normoxic and under hypoxic conditions.
3.2.8 Oncostatin-M induces a hypoxia-like metabolic phenotype in other
PH5CH clones
Next, we aimed to validate that OSM-mediated hypoxia-like metabolic changes are not re-
stricted to PH5CH8 cells. Therefore we performed OSM stimulation and PDK1 silencing
in conjunction with metabolic tracer analysis in the PH5CH clones PH5CH1 and PH5CH7
under normoxic conditions. We validated that HIF-1α and PDK1 expressions were increased
in response to OSM treatment in both PH5CH clones (Supplemental figure A.6 A, B and sup-
plemental figure A.7 A, B ) and validated the efficiency of the PDK1 knockdown on protein
level (Figure 3.11 A).
We observed in both PH5CH clones, that OSM stimulation decreased glucose-derived carbon
contribution to citrate due to a reduced activity of PDC (Figure 3.11 B,C and Figure 3.11
D,E). PDK1 silencing in PH5CH1 and PH5CH7 immortalized hepatocytes abolished OSM-
mediated effects on PDC activity (Figure 3.11 D-E). Comparable to PH5CH8 cells, PH5CH1
and PH5CH7 cell lines reacted to OSM treatment with a decrease in oxidative glutamine
metabolism while a higher proportion of glutamine undergoes reductive carboxylation. By
silencing PDK1, OSM-mediated metabolic effects on glutamine metabolism were dampened
but not fully abolished (Figure 3.11 G-F). Similar to PH5CH8, OSM stimulation led to in-
creased α-ketoglutarate to citrate ratios in PH5CH1 and PH5CH7 immortalized hepatocytes,
while this effect could be abolished when PDK1 was silenced (Figure 3.11 H). We can con-
clude that OSM-mediated metabolic reprogramming is a more common feature and can be
observed in all tested PH5CH clones.
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Figure 3.11: The metabolic effects of PDK1 silencing on the OSM-induced
hypoxia-like metabolic phenotype in PH5CH1 and PH5CH7 cells. PH5CH1 and
PH5CH7 immortalized hepatocytes were stimulated for 36 h with 50 ng/mL OSM or left
untreated in the presence of [13C6]glucose or [
13C5]glutamine. PDK1 was knocked down us-
ing siRNA (siPDK1) while non-targeting siRNA was used as control (siCtrl). (A) qPCR on
PDK1. (B) PDK1 Westernblot. (C) The enzymatic activity of PDC determined from the
M2 citrate isotopologues normalized to the M3 lactate isotopologues, from [13C6]glucose. (D)
PC activity determined from the M3 citrate isotopologues normalized to the M3 lactate iso-
topologues, from [13C6]glucose. (F) Reductive glutamine contribution to citrate, determined
by the ratio of the M5 isotopologues of citrate to the M5 isotopologues of glutamate, from
[13C5]glutamine. (E) Oxidative glutamine contribution to citrate, determined by the ratio
of the M4 isotopologues of citrate to M5 isotopologues of glutamate, from [13C5]glutamine.
(G) α-ketoglutarate to citrate ratio. Error bars indicate the standard deviation and are
calculated from at least two independent replicates. Statistical significance between control
and the treatment was determined by a two-tailed t-test. * denotes P6 0.05, ** denotes P6
0.01, and *** denotes P6 0.001.
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3.2.9 Long-term OSM treatment effects cellular metabolism in hepatocel-
lular carcinoma cells and immortalized hepatocytes
Our previous experiments were based on acute OSM treatments (36 h). However, we aimed
to study the effect of long-term OSM treatment which better simulates inflammation. For
this purpose, we continuously exposed PH5CH8 immortalized hepatocytes and JHH-4 HCC
cells to 25 ng/mL OSM for up to 11 days.
Surprisingly, chronic OSM treatment led to metabolic changes not only in PH5CH8 but also
in JHH-4 HCC cells. After 5 and 11 days of treatment, we detected a decrease in glucose-
derived carbon contribution to citrate while glutamine-derived carbon was increased (Figure
3.12 B,I).
In PH5CH8 cells, the metabolic effects of long-term OSM stimulation were stronger than
those observed by acute treatment. In PH5CH8 cells, we observed reduced PDC and PC
activities. Furthermore, reductive glutamine carboxylation was increased while oxidative
glutamine decarboxylation was decreased (Figure 3.12 C-G, J-M).
Unlike in PH5CH8 cells, chronic OSM treatment did not effect PDC activity in JHH-4 cells
(Figure 3.12 C), while we measured reduced PC activity and an increased reductive glutamine
metabolism while oxidative glutamine metabolism was decreased (Figure 3.12 F-G, L-M).
Interestingly, long-term OSM treatments did not induce HIF-1α in JHH-4 cells, suggesting
that metabolic effects are HIF-1α independent (Figure 3.12 A, H).
Chapter 3. Results 59
5G
da
ys
G
11
Gd
ay
sG
0
0.2
0.4
0.6
0.8
1
Ctrl OSM
Ca
rb
on
Hc
on
tr
ib
ut
io
nH
(3
)
0
0.2
0.4
0.6
0.8
1
Ctrl OSM
Ca
rb
on
Hc
on
tr
ib
ut
io
nH
(3
)
JHH-4 PH5CH8
Others
Glutamine
Glucose
*
** ***
** **
** *
A
HIF-1α
pSTAT3
C
trl
O
S
M
C
trl
O
S
M
PH5CH8 JHH-4 B
Ctrl
OSM
0
0.2
0.4
0.6
0.8
JHH4 PH5CH8
0
0.02
0.04
0.06
JHH4 PH5CH8
0
0.2
0.4
0.6
0.8
1
JHH-4 PH5CH8
0
0.2
0.4
0.6
JHH-4 PH5CH8
M
2H
Ci
tr
at
e/
M
3H
La
ct
at
e
M
3H
Ci
tr
at
e/
M
3H
La
ct
at
e
M
5H
Ci
tr
at
e/
M
5H
Gl
ut
am
at
e
M
4H
Ci
tr
at
e/
M
5H
Gl
ut
am
at
e
Ctrl
OSM
Ctrl
OSM
Ctrl
OSM
ns *** ***
***
***
***
***
C D E F
Ca
rb
on
Hc
on
tr
ib
ut
io
nH
(3
)
Ca
rb
on
Hc
on
tr
ib
ut
io
nH
(3
)
JHH-4 PH5CH8
0
0.2
0.4
0.6
0.8
1
Ctrl OSM
0
0.2
0.4
0.6
0.8
1
Ctrl OSM
Others
Glutamine
Glucose
*
** ***
****
ns *
HIF-1α
pSTAT3
C
trl
O
S
M
C
trl
O
S
M
PH5CH8 JHH-4G H
Ctrl
OSM
M
2H
Ci
tr
at
e/
M
3H
La
ct
at
e
M
3H
Ci
tr
at
e/
M
3H
La
ct
at
e
M
5H
Ci
tr
at
e/
M
5H
Gl
ut
am
at
e
M
4H
Ci
tr
at
e/
M
5H
Gl
ut
am
at
e
Ctrl
OSM
Ctrl
OSM
Ctrl
OSM
0
0.2
0.4
0.6
0.8
JHH4 PH5CH8
0
0.02
0.04
0.06
JHH4 PH5CH8
0
0.2
0.4
0.6
0.8
1
JHH-4 PH5CH8
0
0.2
0.4
0.6
JHH-4 PH5CH8
ns *** ***
*** **
ns
***
***
I J K L
Figure 3.12: Long-term OSM stimulation in PH5CH8 and JHH-4 cells. PH5CH8
and JHH-4 cells were treated with 25 ng/mL OSM over 11 days. Metabolites were extracted
after 5 days (A-G) and 11 days (H-M) of chronic treatment. (A,G) HIF-1α Westernblot.
(B,H) Glucose- and glutamine-derived carbon contribution to citrate. (C,K) PDC activity
determined from the M2 citrate isotopologues normalized to the M3 lactate isotopologues,
from [13C6]glucose. (D, J) PC activity determined from the M3 citrate isotopologues nor-
malized to the M3 lactate isotopologues, from [13C6]glucose. (E,K) Oxidative glutamine
contribution to citrate, determined by the ratio of M4 isotopologues of citrate to M5 iso-
topologues of glutamate, from [13C5]glutamine. (F,L) Reductive glutamine metabolism,
determined by the ratio of M5 isotopologues of citrate to M5 isotopologues of glutamate,
from [13C5]glutamine. Error bars indicate the standard deviation and are calculated from at
least two independent replicates. Statistical significance between control and the treatment
was determined by a two-tailed t-test. * denotes P6 0.05, ** denotes P6 0.01, and ***
denotes P6 0.001.
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3.3 Results summary
In summary, we showed that:
• OSM mediated HIF-1α protein induction in various HCC cell lines and in immortalized
hepatocytes under normoxia. In most of the tested HCC cell lines OSM-induced HIF-
1α upregulation was transient and restricted to early stimulation time points. Few
HCC cell lines and in particular immortalized hepatocytes displayed continuous HIF-
1α expression over 36 h.
• OSM induced hypoxia-like metabolic effects in immortalized hepatocytes which were char-
acterized by a reduced entry of glucose-derived carbon into the TCA cycle and the
induction of reductive glutamine metabolism.
• In immortalized hepatocytes, OSM-mediated metabolic effects were coordinated by HIF-1α
and partially dependent on the HIF-1α target gene PDK1. Silencing HIF-1α abolished
OSM-induced effects on central carbon metabolism, while under PDK1 silencing con-
ditions, OSM-dependent effects were dampened.
• OSM did not exert metabolic effects on central carbon metabolism in any of the tested
HCC cell lines, despite the fact that HIF-1α was induced.
• Chronic OSM treatment in the HCC cell line JHH-4 resulted in HIF-1α-independent
metabolic effects. As a consequence of chronic exposure to OSM these cells exposed
an increased reductive glutamine metabolism while the entry of glucose-derived carbon
via PDC remained unaffected.
Chapter 4
Discussion and Perspectives
4.1 Discussion
The fact that HCC development and progression are frequently accompanied by chronic in-
flammation suggests that this microenvironment favours malignant transformation and sup-
ports uncontrolled growth [Fausto, 1999]. In HCC, constitutive STAT3 activation is common,
despite the absence of genetic alterations [Calvisi et al., 2006, He et al., 2010, Spannbauer
and Trautwein, 2009]. This suggests that external stimuli, such as cytokines, present within
the inflammatory microenvironment lead to aberrant STAT3 activity [He and Karin, 2011].
While STAT3 activation by inflammatory mediators protects cells during inflammation, the
exact same pathways might drive neoplastic growth [Hodge et al., 2005]. In this context,
the cytokines IL-6 and OSM seem to play an important role and thus levels are increased in
the serum and in liver tissue of patients with cirrhosis and HCC [Giannitrapani et al., 2006,
Liang et al., 2012, Mantovani et al., 2008, Uhle´n et al., 2015, Wong et al., 2009, Znoyko et al.,
2005]. Neoplastic growth generally goes hand in hand with changes in cellular metabolism
that support high proliferation rates [DeBerardinis et al., 2008].
Based on the finding that IL-6 type cytokines induce the expression of the key metabolic
regulator HIF-1α [Vollmer et al., 2009], we hypothesized that the activation of STAT3 by in-
flammatory cytokines redirects cellular metabolism towards a more proliferative phenotype.
A multitude of studies describe that cytokines and growth factors upregulate HIF-1α un-
der normoxia [Fukuda et al., 2002, Laughner et al., 2001, Treins et al., 2002, Vollmer et al.,
2009]. While the metabolic consequences of HIF-1α stabilization under hypoxia are well
understood, we aimed to elucidate the metabolic effects of cytokine-induced HIF-1α upreg-
ulation under normoxic conditions using stable-isotope assisted metabolomics. The use of
uniformly labelled [13C6]glucose and [
13C5]glutamine is a very robust and sensitive method
that allows to trace changes in metabolic states and permits to unravel both changes in
61
Chapter 4. Discussion 62
enzyme activities and alterations in the usage of carbon sources [Liu et al., 2014, Roberts
et al., 2012, Zamboni and Sauer, 2009]. The direct interpretation of 13C labelling patterns
in metabolites confers a straightforward method that allows to monitor enzymatic activities,
qualitative changes occurring in metabolic pathways and the contribution of various nutri-
ments to metabolite synthesis [Buescher et al., 2015]. Using this method we were able to
profile central carbon metabolism and determine global metabolic changes occurring under
hypoxia and OSM treatment in immortalized hepatocytes and HCC cell lines. In line with nu-
merous other metabolomics studies we derived the relative activity of PDC from the relative
proportion of the M2 citrate mass isotopologues when using a [13C6]glucose tracer [Aguilar
et al., 2016, Grassian et al., 2011, Meiser et al., 2016]. This method has numerous advantages
when compared to other methods used to determine PDC activity: (1) it allows to profile
the metabolism on -omics level, (2) does not require the usage of radioactive 14C and (3) is a
high throughput and quick technique. However, it should be noted that results from stable-
isotope assisted metabolomics, at least in what concerns PDC activity, could be validated
using a different method such as PDC specific enzymatic assays [Scrutton and White, 1974,
Warren and Tipton, 1974]. While we put our major emphasis on the determination of PDC
activity under the various experimental conditions, TCA cycle anaplerosis via PC was also
accessed. With our extraction method, oxaloacetate cannot be measured as a consequence
of its chemical instability [Zimmermann et al., 2014]. Thus we used the relative abundance
of M3 citrate mass isotopologues to access PC activity in this study. While this method
is less biased by TCA cycle cycling products, such as the case when using M3 malate, M3
aspartate and M3 fumarate, it has to be noted that this mass isotopomer is generated by the
condensation of [13C3]oxaloacetate with unlabelled acetyl-coA and thus might be biased by
drastically changed unlabelled acetyl-coA pools. Other tracers can be used to complement the
information derived from a [13C6]glucose tracer in order to further investigate PC in a more
targeted manner. Additional tracers, such as a [1-13C1]pyruvate tracer or a [3,4-
13C2]glucose
tracer can be used which loose their 13C atom when metabolized via PDC while it is retained
when undergoing PC activity. Subsequent metabolization through the TCA cycle will lead
to the loss of the 13C atom allowing the unbiased determination of PC activity [Cheng et al.,
2011, Niklas et al., 2011].
4.1.1 The metabolic phenotype of HCC cell lines and immortalized hepa-
tocytes
The HCC cell lines and the immortalized hepatocytes that we used in this study were pro-
liferating cells. The contribution of glucose-derived carbon to citrate accounted for less than
50% (Figure 3.1 A-C). This might imply that the influx of pyruvate into the TCA cycle is
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relatively low and that a high proportion of glucose-derived carbon fuels other biosynthetic
pathways and/or is secreted after conversion to lactate. The relatively low contribution of
glucose-derived carbon to citrate might furthermore be explained by the fact that a substantial
fraction of citrate is generated from glutamine in these cells (Figure 3.1 A-C). Furthermore,
the proportion of glutamine-derived carbon into the TCA cycle intermediates downstream
of citrate was higher than that observed for citrate itself. This could be explained by glu-
taminolysis where glutamine-derived α-ketoglutarate enters the TCA cycle and is metabolized
oxidatively, and thereby diluting the contribution of glucose-derived carbon to the TCA cycle
intermediates (Figure 3.1 A-C).
While nutrient uptake is tightly regulated in quiescent cells, proliferating cells adapt metabolic
features that support the synthesis of anabolic precursors to sustain unlimited growth [Hsu
and Sabatini, 2008, Vander Heiden et al., 2009]. Cell proliferation is controlled by signal trans-
duction pathways that can be activated by growth factors and cytokines, and tumour cells
often acquire oncogenic mutations that render growth-stimulating pathways constitutively ac-
tive [Edinger and Thompson, 2002]. When cellular metabolism switches to aerobic glycolysis,
proliferating cells take up more glucose and convert it to lactate at near stoichiometric levels,
and consequently deviate the glycolytic flux away from oxidative phosphorylation [Metallo
et al., 2011, Semenza, 2011, Warburg, 1928, 1956]. Moreover, in proliferating cells, TCA cycle
intermediates, such as citrate serve as biosynthetic precursors that support high proliferation
rates, resulting in an eﬄux of carbon from the TCA cycle [DeBerardinis et al., 2008]. The low
contribution of glucose-derived carbon to the TCA cycle intermediates in the cell lines used
in this study, might reflect their proliferative nature (Figure 3.1 A-C). We furthermore found
that glutamine-derived carbon is an essential component of the TCA cycle intermediates in
HCC cells and immortalized hepatocytes. Glutamine was preferentially metabolized in an
oxidative rather than a reductive manner and thus might compensate for the eﬄux towards
biosynthetic pathways (Figure 3.1 A-C, and Figure 3.2 H-I). This underlines the importance
of glutamine as carbon source for TCA cycle intermediates in proliferating cells [DeBerardinis
et al., 2007].
Interestingly, we detected differences in glucose and glutamine metabolism between the cell
lines. How far these differences correlate with phenotypic features such as proliferation was
beyond the scope of this work. However, it is becoming more and more clear that each tumour
has an individual molecular signature which is accompanied by specific metabolic alterations
[Galluzzi et al., 2013, Halama et al., 2015, Mishra and Ambs, 2015]. In HCC cells, for exam-
ple, a high eﬄux of citrate from the TCA cycle towards cholesterol synthesis is proportional
to their proliferation rate [Parlo and Coleman, 1984b, 1986].
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4.1.2 Hypoxia inhibits glucose-derived carbon entry into the TCA cycle
and induces reductive glutamine metabolism
First we studied the metabolic consequences of hypoxia-mediated HIF-1α stabilization in
HCC cell lines and in immortalized hepatocytes. As expected, we found that hypoxia in-
duced HIF-1α stabilization in all cell lines (Figure 3.5 B, C) and consequently led to the
upregulation of the HIF-1α target gene PDK1 while PDP2 was downregulated (Supplemen-
tal figure A.2 A-C and supplemental figure A.3 A-C). As a consequence of this, we observed
that PDC phosphorylation on all three serine residues was enhanced (Supplemental figure A.2
B, E and supplemental figure A.3 B). In line with PDC inactivation under hypoxia, we found
that the pyruvate flux through PDC was decreased and that glucose- and glutamine-derived
carbon oxidation within the TCA cycle was drastically reduced (Figure 3.1 A-C and Figure
3.2 D-F, H-I). Reduced glucose-derived carbon entry into the TCA cycle was compensated
by an increased contribution of carbon derived from glutamine where glutamine was pref-
erentially metabolized reductively and used to generate lipogenic citrate (Figure 3.2 H-I).
The molecular mechanisms by which hypoxia reduces respiration are well understood and
support our findings in HCC cell lines and immortalized hepatocytes. Under hypoxic condi-
tions, HIF-1α is stabilized and upregulates PDK1 expression [Kim et al., 2006, Papandreou
et al., 2006, Roche et al., 2001]. In turn, PDK1 phosphorylates and thereby inactivates PDC
which results in a decreased entry of glucose-derived carbon into the TCA cycle [Kim et al.,
2006, Papandreou et al., 2006, Roche et al., 2001]. Consequently, the mitochondrial citrate
pool is depleted and glutamine-derived α-ketoglutarate is carboxylated to generate lipogenic
citrate [Fendt et al., 2013, Metallo et al., 2011, Wise et al., 2011]. We furthermore showed
that PC activity was reduced under hypoxia which might be a consequence of low acetyl-coA
levels that in turn allosterically regulated PC activity [Jitrapakdee et al., 2008] (Figure 3.2 E).
4.1.3 OSM does not induce a hypoxia-like metabolic phenotype in HCC
cell lines
While numerous cytokines and growth-factors can induce HIF-1α upregulation under nor-
moxic conditions, it remained to be elucidated if ”normoxic HIF-1” has metabolic effects
that are comparable to those observed under hypoxia. Thus, we investigated whether OSM-
mediated HIF-1α induction under normoxic conditions resulted in a hypoxia-like metabolic
phenotype in HCC cells. Unlike under hypoxia, cytokine-mediated HIF-1α induction results
from STAT3-induced increased HIF-1α transcription and not HIF-1α stabilization [Vollmer
et al., 2009]. Vollmer et al. described that several IL-6 type cytokines are potent inducers of
HIF-1α expression [Vollmer et al., 2009]. Among all tested cytokines, OSM-induced HIF-1α
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induction was strongest, and thus it was the focus of this work. Despite continuous STAT3
activation, we found that OSM-mediated HIF-1α induction was transient and restricted to
early stimulation time-points in most HCC cell lines (Figure 3.5 A-D). This was in contrast
to HIF-1α stabilization under hypoxia which was a continuous and strong event. It is thus
likely that cytokine-induced HIF-1α proteins underwent oxygen-dependent degradation in
the vast majority of the HCC cell lines. In HepG2 cells, for example, we detected contin-
uous OSM-induced HIF-1α upregulation on mRNA level over the full length of the time
course, while HIF-1α protein levels decreased after 24 h (Figure 3.5 A-C). However, when
we stimulated HepG2 cells with OSM under hypoxia, HIF-1α protein levels were more abun-
dant than those induced by hypoxia alone and persisted until later stimulation time points
(Figure 3.5 B-D). This suggested that, at least in HepG2 cells, OSM-induced HIF-1α was
indeed degraded in an oxygen-dependent fashion under normoxia, while under hypoxia OSM-
induced HIF-1α was stabilized and thereby further increased HIF-1α protein levels. Our data
suggests that, at early stimulation time-points, OSM indeed upregulated HIF-1α on protein
level, while degradation mechanisms caught up and cytokine-induced HIF-1α proteins were
degraded in an oxygen-dependent manner at later time points. Vollmer et al. described that
in contrast to hypoxia-stabilized HIF-1α, OSM-induced HIF-1α proteins carried hydroxyla-
tions and ubiquitinylations [Vollmer et al., 2009]. This finding is in line with the hypothesis
that OSM-induced HIF-1α is targeted by VHL-mediated and oxygen-dependent degradation
in many HCC cell lines [Cockman et al., 2000, Maxwell et al., 1999, Stickle et al., 2004].
VHL is frequently mutated in renal clear cell carcinomas (RCC), consequently HIF-1α and
HIF-2α are expressed under normoxia [Krieg et al., 2000]. As a result, RCC cells express high
levels of the HIF-1 target genes VEGF and GLUT1 [Krieg et al., 2000]. Furthermore, RCC
cells have high glucose uptake and lactate secretions rates and exhibit a decreased flux of
pyruvate through PDC [Minton et al., 2015]. These effects are directly attributed to HIF-1α
expression [Minton et al., 2015]. These findings in RCC cells show that the interruption of
VHL-mediated HIF-1α degradation is sufficient to induce a hypoxia-like metabolic features
under normoxic conditions.
In concordance with our finding that OSM-treatment led to a transient induction of HIF-1α
in HepG2 cells under normoxia, we consequently did not detect metabolic effects on cel-
lular metabolism after a 36 h treatment (Figure 3.3 A-B and Figure 3.4 D-F, H-I). The
HCC cell lines HepG2-C3A and SK-Hep1, however, showed HIF-1α induction 8 h and 36 h
post-OSM stimulation suggesting that in these cells OSM-induced HIF-1α did not undergo
oxygen-dependent degradation and thus might exert metabolic effects (Figure 3.5 A, F). De-
spite a strong induction of HIF-1α under normoxic conditions, we did not detect changes in
metabolism which suggested that OSM-induced HIF-1α was an inactive transcription factor,
at least in what concerns the regulation of metabolic genes (Figure 3.6 B-E, G-J). This ob-
servation suggests that oxygen-dependent mechanisms might render OSM-induced HIF-1α
inactive under normoxia (Figure 4.1). While the exact mechanisms remain to be elucidated
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in further research, it is probable that post-translational modifications inactivate HIF-1α un-
der normoxia in the HCC cell lines Sk-Hep1 and HepG2-C3A: (1) Under normoxia, HIF-1α
can be hydroxylated by FIH on its carboxy-terminal transactivation domain which prevents
the interaction of HIF-1α with the transcriptional co-regulators such as p300 and the CREB
binding protein and thus interferes with its transcriptional activity [Masson et al., 2012,
Stolze et al., 2004]; (2) OSM-induced HIF-1α is hydroxylated by PHDs and recognized by
VHL which might interfere with HIF-1-mediated transcription; (3) ARD1 acetylates HIF-1α
on lysine 532, enhances the interaction with VHL and thus supports HIF-1α degradation un-
der normoxia [Jeong et al., 2002]; (4) other posttranslational modifications of HIF-1α include
phosphorylations, S-nitrosylations and SUMOylation, all of which might play important roles
for its activity under normoxic (reviewed in [Dimova and Kietzmann, 2010]). While we showed
in this work that OSM-induced HIF-1α induction does not have the expected effects on cel-
lular metabolism in HCC cells, Vollmer et al. showed that OSM-induced HIF-1α proteins
are active transcription factors. They validated the transcriptional activity of OSM-induced
HIF-1α in reporter gene assays and based on the upregulation of the endogenous HIF-1 target
genes VEGF and PAI [Vollmer et al., 2009]. However, VEGF and PAI are not only HIF-1
but also STAT3 target genes, rising the question whether OSM-mediated upregulation was
not rather directly regulated by STAT3 [Dauer et al., 2005, Niu et al., 2002, Vollmer et al.,
2009, Wei et al., 2003].
Our observation that OSM stimulation under hypoxia led to higher HIF-1α proteins levels
than hypoxia alone suggested that OSM-induced HIF-1α was stabilized by hypoxic conditions
in HepG2 cells. Thus, we studied whether this also translates into a more pronounced hy-
poxic metabolic phenotype. However, our data showed that despite increased HIF-1α protein
levels, OSM-treatment did not further boost the metabolic effects under hypoxia (Supple-
mental figure A.4 D-G). It is possible that the metabolic effects under 1% hypoxia were so
profound that OSM-induced HIF-1α was insufficient to further enhance hypoxia-mediated ef-
fects. To validate this hypothesis, it would be of interest to study whether OSM-stimulation
under milder hypoxic conditions results in more pronounced metabolic effects in HepG2 cells.
Vollmer et al. described that a combinatorial treatment of hypoxia (5%) and OSM further
increased the expression of the HIF-1 target genes VEGF and PAI when compared to hy-
poxia alone [Vollmer et al., 2009]. However, as discussed above, it remains to be elucidated
if this observation is not a consequence of both, STAT3 and HIF-1 dependent transcriptional
regulation.
Based on our findings, we hypothesize that OSM-induced HIF-1α in HCC cells (1) is targeted
by oxygen-depended degradation mechanisms under normoxia, thus is only transiently upreg-
ulated in the vast majority of the tested cell lines and (2) is an inactive transcription factor,
at least in what concerns the regulation of metabolic genes. In this context, gene expression
microarrays were carried out on the HCC cell lines HepG2, JHH-4 and Huh-7 stimulated
with OSM, grown at 1% hypoxia and subjected to a combinatorial treatment for 24 h and
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48 h [Zimmer, 2015]. As expected, hypoxia strongly effected the expression of genes coding
for enzymes within central carbon metabolism, although to various degrees when comparing
all three cell lines. OSM treatment, however, did not induce a clear HIF-1α-dependent tran-
scriptional signature [Zimmer, 2015]. Moreover, a combinatorial treatment of hypoxia and
OSM did not further enhance the transcriptional regulation [Zimmer, 2015]. These observa-
tions further supported our finding that OSM-induced HIF-1α upregulation under normoxic
conditions in HCC cell lines does not induce hypoxia-like metabolic features.
Although it becomes clear from our data that OSM-induced HIF-1α is not required for
metabolic reprogramming in HCC cells under inflammatory conditions, other roles of HIF-1α
in this context remain to be studied.
4.1.4 OSM induces hypoxia-like metabolic changes in immortalized hepa-
tocytes
Contrarily to our findings in HCC cell lines, OSM induced significant metabolic effects in
PH5CH8 immortalized hepatocytes. In these cells, OSM stimulation resulted in HIF-1α up-
regulation on mRNA and protein level, where OSM and hypoxia-mediated HIF-1α protein
levels were comparable after a 36 h treatment (Figure 3.5 A-C). Consequently the HIF-1α
target gene PDK1 was upregulated on mRNA and protein level, although OSM-induced
PDK1 upregulation was less strong when compared to hypoxia (Supplemental figure A.3 A-
C). We did not detect a significant downregulation of PDP2 and consequently no pronounced
changes on PDC phosphorylation while PDC phosphorylation under hypoxia was increased
(Supplemental figure A.3 A-C). In line with increased HIF-1α and PDK1 expression levels in
OSM-stimulated PH5CH8 cells, we detected OSM-induced metabolic changes. We observed
that OSM treatment reduced glucose-derived carbon entry into the TCA cycle and negatively
impacted oxidative glutamine metabolism while reductive glutamine metabolism was induced
(Figure 3.3 C and Figure 3.4 D-F, H-I) (Figure 4.1). These changes were similar to those
induced by hypoxia, although weaker in magnitude (Figure 3.3 C and Figure 3.4 D-F, H-I).
In the context of STAT3-mediated metabolic effects on cellular metabolism, Demaria et al.
have reported similar findings. They showed that the expression of constitutively active
STAT3 (STAT3C/C) in MEFs induced aerobic glycolysis [Demaria et al., 2010]. The expres-
sion of STAT3C/C in these cells led to HIF-1α-mediated upregulation of PDK1 and correlated
with increased glucose uptake and lactate secretion under normoxia, while PDC activity was
reduced. In subsequent work, the same group showed that STAT3C/C expressing MEFs were
more prone to undergo spontaneous immortalization. Immortal STAT3C/C cells proliferated
faster when compared to their wild type counterparts and were less sensitive to apoptotic
stimuli [Demaria et al., 2012]. When HIF-1α was silenced in STAT3C/C expressing MEFs,
their transformed phenotype was partially reversed i.e. cell proliferation and the ability of
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cells to form colonies on soft agar was decreased but not abolished [Demaria et al., 2012]. The
authors concluded that STAT3C/C can serve as first hit in carcinogenesis and that STAT3
induced HIF-1α expression supports higher proliferation rates by inducing aerobic glycolysis
[Demaria et al., 2012]. In contrast to these studies, we found that OSM stimulation did not
effect cellular proliferation in PH5CH8 cells, which might be explained by different cellular
origins and by the fact that we used OSM to activate STAT3 while Demaria et al. used cells
that express STAT3C/C and thus specifically targeted STAT3 regulated mechanisms. Fur-
thermore, the effects of OSM on cell proliferation were described to be cell-type dependent
and to induce both stimulatory and inhibitory effects [Halfter et al., 1998, Horn et al., 1990,
Klausen et al., 2000, Nair et al., 1992, Zarling et al., 1986]. In the HCC cell line HepG2, OSM
was described to inhibit cell proliferation [Klausen et al., 2000]. The underlying mechanism,
however, was found to be regulated by OSM-induced STAT5 and ERK activation [Klausen
et al., 2000]. Based on our observations in OSM-treated PH5CH8 cells, we derived that
OSM-induced HIF-1α induction further enhanced aerobic glycolysis which however had no
effect on proliferation although it probably could support higher proliferation rates [Vander
Heiden et al., 2009]. It can be hypothesised that cytokine-mediated metabolic reprogram-
ming plays a supportive role in the context of cancer-promoting inflammation by stimulating
aerobic glycolysis in pre-malignant cells and thus might favour proliferation in conjunction
with malignant genetic alterations.
Although hypoxia and OSM treatment induced comparable levels of HIF-1α protein in
PH5CH8 cells, the metabolic effects we observed under hypoxia were more pronounced. This
suggests that yet other mechanisms contribute to the strong metabolic changes observed un-
der hypoxia. The exact reasons behind this observation remain to be elucidated, however
it is possible that the availability of oxygen by itself plays a role. While PDC activity is
reduced in OSM-treated immortalized hepatocytes, the oxygen supply in these cells remains
unaffected and oxidative phosphorylation keeps running. Under hypoxia and in addition to
a decreased PDC activity, oxygen availability becomes scarce which might effect mitochon-
drial metabolism independently of HIF-1α. Interestingly, it was shown that mitochondrial
oxygen consumption is in part maintained under hypoxia, although to a much lesser extend
than under normoxia, while NAD+/NADH ratios consequently are lowered [Frezza et al.,
2011]. While it is remains to be tested if OSM treatment effects NAD+/NADH ratios, it is
possible that the altered redox-state in hypoxic cells further contributes to the strength of
the hypoxia-induced metabolic phenotype in PH5CH8 cells. The fact that OSM stimulation
under normoxia did not result in a more pronounced phosphorylation of PDC, despite the
fact that PDK1 was upregulated, furthermore supported our observation that OSM-induced
metabolic changes are less pronounced than those induced by hypoxia. Since PDK1 activity
can be regulated by the cellular redox-state, low NAD+/NADH ratios under hypoxia might
further increase PDK1 activity [Kerbey et al., 1976].
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4.1.5 OSM-induced metabolic reprogramming in immortalized hepatocytes
is HIF-1α-dependent
In line with the findings from Demaria et al. in STAT3C/C expressing MEFs [Demaria et al.,
2010], we found that silencing HIF-1α in OSM-treated PH5CH8 cells led to a full abolishment
of OSM-mediated metabolic effects, which shows that OSM-driven metabolic reprogramming
is clearly HIF-1α-dependent (Figure 3.8 A-D).
However, when HIF-1α was silenced under hypoxic conditions, hypoxia-mediated metabolic
effects were abolished, a normoxic metabolic state was however not resorted (Figure 3.8 A-
D). The fact that PDK1 was not upregulated under hypoxic conditions when HIF-1α was
silenced showed that HIF-1α silencing was efficient and that the metabolic effects resulted
from HIF-1α-independent mechanisms (Figure 3.9 A). The absence of HIF-1α upregulation
under hypoxia probably resulted in an unrestrained influx of glucose-derived carbon into the
TCA cycle and as a consequence of hindered respiration in the accumulation of NADH and
depletion of NAD+. Consequently, metabolic reactions that are NAD+-dependent might be
thermodynamically inhibited while NADH-dependent enzymatic reactions might be favoured.
Furthermore, it might be possible that HIF-2α supports some of the metabolic adaptation
under hypoxia when HIF-1α is silenced, although it was shown that HIF-1α and not HIF-2α
regulate the glycolytic pathway under hypoxia [Hu et al., 2003].
4.1.6 OSM-induced metabolic reprogramming in immortalized hepatocytes
is partially dependent on PDK1
While the HIF-1α target gene PDK1 is essential to regulated the metabolic switch from
oxidative phosphorylation towards a glycolytic metabolism occurring under hypoxia, we in-
vestigated whether OSM-mediated metabolic reprogramming was also dependent on PDK1
and thus silenced PDK1 in OSM-treated PH5CH8 cells. When PDK1 was silenced we could
dampen, however not fully abolish OSM-mediated metabolic effects, despite a high silencing
efficiency and the absence of PDK1 upregulation after OSM treatment (Figure 3.9 B-E). This
finding suggests that PDK1 is not the only regulator involved in OSM-mediated metabolic
reprogramming. Although PDK1 is mostly discussed in terms of HIF-1α-mediated inhibition
of PDC under hypoxia, the regulation of PDC by PDKs is highly complex and not only depen-
dent on PDK1. While PDKs exists under 4 isoforms they exhibit a tissue specific expression
pattern and isoform-specific differences in their affinity for the different phosphorylation sides
on PDC [Bowker-Kinley et al., 1998]. It is thus possible that in the absence of PDK1, other
PDK isoforms coordinate PDC phosphorylation which would explain why OSM-mediated
metabolic effects are not fully abolished. Based on our observation that HIF-1α silencing
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fully abolished OSM-induced metabolic effects while PDK1 silencing only dampened these,
it is fairly possible that yet other HIF-1α target genes coordinate the effects of OSM on cel-
lular metabolism. While HIF-1 diminishes the entry of glucose-derived carbon into the TCA
cycle via PDK1 upregulation, it also exerts direct effects on the mitochondrial respiratory
chain [Fukuda et al., 2007]. Fukuda et al. described that HIF-1α regulates a switch in the
composition of the cytochrome c oxidase (COX) subunit 4 [Fukuda et al., 2007]. HIF-1 was
shown to upregulate the expression the COX4-2 isoform while inducing the degradation of
the COX4-1 isoform via the protease LON. This change in subunit composition of COX4 is
suggested to optimize the efficiency of oxygen utilization under hypoxic conditions [Fukuda
et al., 2007]. The expression of the COX4 isoforms in the context of cytokine induced HIF-1α
was not yet investigated while this mechanism could explain our finding that PDK1 silencing
is not sufficient to fully abrogate OSM-mediated metabolic effects.
We furthermore validated our finding that OSM induces metabolic reprogramming in addi-
tional cell lines. OSM stimulation in PH5CH1 and PH5CH7 cells resulted in HIF-1α upreg-
ulation on mRNA and protein levels (Supplemental figure A.6 A-B and supplemental figure
A.7 A-B). Furthermore, PDK1 was upregulated while PDP2 expression was not consistently
downregulated (Supplemental figure A.6 A-B). In line with our findings in PH5CH8 cells,
the phosphorylation status of PDC remained unaffected by OSM treatment (Supplemental
figure A.7 A-B). As a consequence of OSM-mediated HIF-1α and PDK1 induction in these
cells, we detected a decreased pyruvate flux through PDC, a reduced oxidative glutamine
metabolism, while reductive glutamine metabolism was enhanced (Figure 3.11 D-F). When
we silenced PDK1 in PH5CH1 and PH5CH7 cells, we could reduce but not abolish OSM-
mediated metabolic, furthermore suggesting that other regulators could be involved.
4.1.7 Long-term OSM treatment results in HIF-1α-independent metabolic
changes in the HCC cell line JHH-4
To study the metabolic effects of OSM in this project, we generally used acute OSM stimula-
tions although these do not reflect a chronic exposure to inflammatory mediators. In order to
study the metabolic consequences of long-term OSM treatment, we performed a chronic OSM
treatment in PH5CH8 and JHH-4 cells. As expected, we observed that chronic OSM treat-
ment in PH5CH8 cells induced HIF-1α and let to similar although more profound metabolic
changes when compared with acute OSM treatments (Figure 3.4 D-F, H-I and Figure 3.12
C-F, I-L ). Interestingly, chronic OSM treatment induced a strong reduction in PC activity,
this effect, however was not consistently observed under acute OSM stimulation. Since PC
activity is allosterically regulated by acetyl-coA, the strongly reduced activity of PDC might
result in lower intracellular acetyl-coA and consequently in a lowered PC activity.
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Figure 4.1: Model of OSM-mediated HIF-1α upregulation and effects on
metabolism. (A) In immortalized hepatocytes, OSM activates the transcription factor
STAT3, which in turn upregulates HIF-1α. Due to the presence of oxygen, PHDs and FIH
remain active which results in the degradation of HIF-1α. However, OSM-induced HIF-1α
upregulation seems sufficient to overwrite oxygen-dependent HIF-1α degradation and results
in the formation of transcriptionally active HIF-1 complexes. HIF-1 upregulates PDK1 and
most probably other target genes and thereby mediates hypoxia-like metabolic changes un-
der normoxia. The entry of glucose-derived carbon into the TCA cycle is reduced while
reductive glutamine metabolism is enhanced. (B) In HCC cell lines, OSM-induced HIF-1α
is a ”metabolically inactive” transcription factor. If OSM-induced HIF-1α in HCC cells reg-
ulates other target genes remains to be elucidated. Furthermore it remains to be clarified
which mechanisms render HIF-1α inactive. Possible explanations are PHD and FIH regu-
lated hydroxylations of HIF-1α under normoxic conditions and HIF-1α complexation with
VHL.
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While central carbon metabolism of JHH-4 cells remained unaffected by acute OSM stim-
ulations, we showed that chronic OSM treatments indeed induced metabolic changes. Sur-
prisingly, we did not detect HIF-1α protein induction in JHH-4 cells which suggests that
metabolic changes are HIF-1α independent (Figure 3.12 A,G ). In line with absent HIF-1α
induction by chronic OSM treatment in JHH-4 cells, we did not detect an altered PDC ac-
tivity. However, chronic OSM treatment drastically changed glutamine metabolism in JHH-4
cells (Figure 3.12 E-F, K-L ). We detected that reductive glutamine metabolism was in-
creased, while less glutamine underwent oxidative decarboxylation (Figure 3.12 K-L). In line,
the relative contribution of glutamine-derived carbon to citrate was increased, which suggests
that more glutamine is used to generate lipogenic citrate (Figure 3.12 B, H). To this point,
it remains unclear if OSM-mediated metabolic effects in JHH-4 cells are mediated by STAT3
or yet another OSM-induced signalling cascade such as MAPK or PI3P [Arita et al., 2008,
Van Wagoner et al., 2000]. Few studies report on the effects of OSM on metabolism. OSM
was described to upregulate the expression of the low density lipoprotein receptor (LDLR) in
the liver, suggesting its potential involvement in cholesterol metabolism [Grove et al., 1991].
Another study describes the involvement of OSM in the regulation of fatty acid metabolism
[Zhou et al., 2007]. Zhou et al. show that OSM stimulation in HepG2 cells results in the up-
regulation of ACSL 3 and 5 thereby stimulates β-oxidation [Zhou et al., 2007]. This effect was
dependent on ERK and not on STAT3 signaling [Zhou et al., 2007]. Furthermore, OSM can
downregulate the expression of the metabolic enzyme carnitine palmitoyltransferase (CPT1)
which is involved in β-oxidation [Henkel et al., 2011]. In the liver, Kupffer cells secrete OSM
and it is hypothesised that OSM then acts in a paracrine manner on hepatocytes and thereby
increases lipid accumulation and decreases insulin sensitivity [Elks and Stephens, 2015].
4.1.8 Conclusions
Inflammation plays an important role in HCC development and progression [Fausto, 1999].
Malignant transformation requires both, oncogenic mutations that favour uncontrolled growth
and a metabolism that meets the requirements of proliferating cells [DeBerardinis et al.,
2008, Edinger and Thompson, 2002]. Although it remains unclear if aerobic glycolysis is a
cause or a consequence of proliferation, the metabolic switch observed in proliferating cells
supports cellular proliferation by providing the necessary metabolic precursors to sustain un-
limited growth [DeBerardinis et al., 2008, Edinger and Thompson, 2002]. In this work we
showed that the inflammatory cytokine OSM induced metabolic changes that could support
higher cellular proliferation in immortalized hepatocytes. Although OSM-induced metabolic
changes did not correlate with increased proliferation rates, they might confer a metabolic
advantage in conjunction with a second growth promoting event. Thus, the inflammatory
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and pro-carcinogenic microenvironment driving HCC development, might assist carcinogen-
esis not only by promoting growth but also by regulating the appropriate switch in cellular
metabolism. In this study we delineated OSM-induced HIF-1α expression as trigger for
a cytokine-dependent metabolic switch in immortalized hepatocytes under normoxic condi-
tions and showed that the HIF-1α target gene PDK1 is one of the regulators involved in this
process. Since HIF-1α is expressed in a large variety of cancers, we provide evidence for an
interesting link between inflammation and malignant cellular transformation.
While cytokine-induced HIF-1α induction resulted in hypoxia-like metabolic changes in im-
mortalized hepatocytes, the metabolism of HCC cell remained unaffected, despite HIF-1α
induction. These observations show that HIF-1α is necessary but not sufficient to induce
cytokine-mediated metabolic reprogramming. Our findings suggest that the metabolic re-
sponse to IL-6 type cytokines might be cell-type dependent and point towards the fact that
cytokines rather exert HIF-1α-mediated metabolic effects in hepatocyte cell lines than in can-
cerous HCC cells. To this point, it remains to be clarified why OSM-induced HIF-1α induces
metabolic reprogramming in immortalized hepatocytes while the metabolism of HCC cells
remains unaffected.
While the metabolism of HCC cell lines remained unaffected by acute OSM treatments, we
provide evidence for that long term OSM stimulation significantly alters the metabolism of
JHH-4 cells. Unlike in immortalized hepatocytes, metabolic effects resulting from chronic
OSM treatments in HCC cells seemed to be HIF-1α-independent. While the exact mecha-
nisms remain to be fully understood, our observations suggest that chronic OSM exposure
stimulates fatty acid synthesis from glutamine. While acute OSM stimulations help to inves-
tigate early metabolic effects, long term treatments might better reflect chronic inflammatory
conditions that promote cancer development and progression.
4.2 Perspectives
In this study we showed that OSM-induced HIF-1 is a ”metabolically active” transcription
factor in immortalized hepatocytes, while in all tested HCC cells, OSM-mediated HIF-1α
induction was mostly transient and did not have effects on cellular metabolism.
From these observations the questions rises whether OSM-mediated HIF-1α induction is re-
quired as a regulator of cellular processes other than metabolism. Although OSM-induced
HIF-1α has no direct effects on central carbon metabolism at the time of extraction in HCC
cells, it might nevertheless be required as transcription factor for the regulation of other ge-
netic targets. Based on our observations we hypothesize that HIF-1α might be required for
a full transcriptional response to inflammatory stimuli. Interestingly, STAT3 and HIF-1α
can cooperatively act on gene expression, suggesting that HIF-1α can interact with other
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transcription factors [Pawlus et al., 2014b]. To tackle our question, gene expression profil-
ing in OSM-treated and HIF-1α-silenced HCC cells should be performed. Gene expression
profiles would consequently reveal whether HIF-1α expression is required for the response of
HCC cells to OSM and more generally to IL-6 type cytokines. Depending on the results,
chromatin-immunoprecipitation in combination with promoter-arrays or sequencing could be
used to validate HIF-1 target genes in response to cytokine signalling.
While it remains to be clarified whether HIF-1α induction is required for the full transcrip-
tional response in OSM-treated cells under normoxia, we started to investigate the effect of
OSM treatment under low oxygen tension, as these conditions might well reflect the pro-
inflammatory and hypoxic microenvironment in solid tumours. In this context, we performed
proteomics experiments in HepG2 cells and found that the stimulation of hypoxic HCC cells
with OSM resulted in the regulation of a unique set of proteins suggesting that a hypoxic
environment modulates the response to inflammatory mediators. Our collaborators carried
out microarray experiments and validated our finding that OSM treatment in conjunction
with hypoxia regulates a unique set of target genes which might point towards combinatorial
effects of STAT3 and HIF-1α [Zimmer, 2015].
Apart from the fact that HIF-1α induction by OSM does not induce metabolic effects in HCC
cells, we furthermore show that OSM-induced HIF-1α expression is transient and restricted
to early stimulation time points in many HCC cells. Based on these findings we hypothesise
that OSM-induced HIF-1α undergoes oxygen-dependent degradation. To this point, the exact
mechanisms that regulate the degradation of OSM-induced HIF-1α at later stimulation time
points remain to be studied. It is possible that oxygen-dependent degradation mechanisms
interfere with both, the stability of OSM-induced HIF-1α and its transcriptional activity. We
started to investigate into this direction and studied whether VHL silencing in HepG2 cells
was sufficient to induce HIF-1α under normoxic conditions, such as observed in RCC cells
[Krieg et al., 2000]. Although VHL expression was reduced by 50%, we did not detect HIF-1α
stabilization under normoxia nor effects on cellular metabolism. Probably, siRNA-mediated
VHL silencing was not powerful enough to sufficiently silence VHL expression. Thus it would
be better in this context to create VHL-knockout HCC cells or use VHL inhibitors to fully
abolish VHL-mediated HIF-1α degradation.
Apart from VHL-mediated HIF-1α degradation under normoxia, FIH-mediated HIF-1α hy-
droxylation might interfere with the transcriptional activity of OSM-induced HIF-1α. To
verify whether FIH-mediated HIF-1α hydroxlation interferes with the transcriptional activ-
ity of OSM-induced HIF-1α under normoxia, we established HepG2 cells that constitutively
express shRNA directed against FIH. Although FIH expression was reduced by 80% in HepG2
cells, no OSM-mediated metabolic changes were detected. This suggests that yet other mech-
anisms, eventually post-translational modification, might interfere with the transcriptional
activity of OSM-induced HIF-1α. A thorough investigation of the post-translational modifi-
cations of HIF-1α under normoxic conditions might help to better understand its regulation.
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While in this study we evaluated the metabolic effects of OSM on cellular metabolism of
HCC cells and immortalized hepatocytes, it remains to be studied how OSM effects central
carbon metabolism in primary hepatocytes. We focussed on proliferating cells, either derived
from HCC or generated by hepatocyte immortalization, thus these cells expose the metabolic
features of aerobic glycolysis. PH5CH cells were generated from primary hepatocytes immor-
talized with the Simian virus large T antigen, that consequently regulates immoralization by
binding tumour suppressors such as p53 and retinoblastoma [Ikeda et al., 1998]. Thus, it re-
mains questionable how well PH5CH cells still reflect the phenotype of hepatocytes. Based on
the observation from Nakamura et al. that OSM plays an important role in liver regeneration
by inducing hepatocyte proliferation, it would be highly interesting to study whether OSM
induces growth-promoting changes in cellular metabolism in hepatocytes and furthermore
determine if HIF-1α plays a key role in this context [Nakamura et al., 2004]. We started to
establish a protocol for the isolation of primary hepatocytes from mouse liver, however, due
to the time limitation of the project did not yet finalize protocol optimization.
While acute OSM treatment in JHH-4 cells did not affect cellular metabolism, the increased
reductive glutamine metabolism in JHH-4 cells subjected to chronic OSM-stimulation points
towards increased fatty acid synthesis from glutamine. In this context, fatty acid metabolism
should be more thoroughly investigated. This could be achieved by studying fatty acids as
fatty acid metyl esters by GC-MS and determine whether changes occur in their abundance
and in their MID in response to chronic OSM treatment.
While our metabolomics approach revealed that cytokine-induced HIF-1α expression does
not induce metabolic reprogramming in HCC cells, Demaria et al. described that the expres-
sion of STAT3C/C in MEFs confers a proliferative advantage. Thus it would be interesting to
study whether the constitutive STAT3 activation, rather than the cytokine-induced STAT3,
can further promote aerobic glycolysis in HCC cells [Demaria et al., 2012]. We are currently
generating HCC cell lines that express constitutively active STAT3 in an inducible fashion.
This will help us to better understand the role of STAT3 in HCC and conduct long-term
studies in more cell lines.
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Figure A.1: Glucose uptake and lactate secretion rates in PH5CH8. PH5CH8
immortalized hepatocytes were treated with OSM (50 ng/ml) under normoxia for 36 h. (A)
Glucose uptake rates. The signal intensity was normalized to cell count. (B) Lactate secretion
rates. The signal intensity was normalized to cell count. Figure published in [Battello et al.,
2016]
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Figure A.2: The effects of Hypoxia and OSM on PDK1 expression and PDC
phosphorylation in HepG2 and JHH-4. Cells were treated with OSM (50 ng/ml),
hypoxia 1% O2, a combinatorial treatment for the given timepoints. (A & D) qRT-PCR
of PDK1 and PDP2 after the indicated period of time and treatment, mRNA from three
biological replicates in HepG2 (A) and JHH-4 (D) cells. Fold change was calculated to the
untreated control. (B & E) Western Blot analysis of all three PDC phosphorylation sites
(S232, S293, S300) and PDK1 in HepG2 (B) and JHH-4 (D) cells. α-Tubulin was used as
a loading control and one representative α-Tubulin blot is shown. (C & F) PDK1 protein
levels in HepG2 (C) and JHH-4 (F) cells after the indicated period of time and treatment,
shown as percentage of the untreated control. All errorbars indicate the standard deviation
calculated from three biological replicates. Figure published in [Battello et al., 2016] This
data was kindly provided by Dr. Andreas Zimmer.
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Figure A.3: PDK1 expression and PDC phosphorylation in PH5CH8 cells.
PH5CH8 cells were treated with OSM (50 ng/ml), hypoxia (1% O2), or a combinatorial
treatment for the indicated periods of time. (A) Quantitative RT-PCR of PDK1 and PDP2
mRNA. The fold change was calculated relative to the untreated control (B) Western Blot
analysis for all three PDC phosphorylation sites (S232, S293, S300) and PDK1. α-Tubulin
was used as a loading control and one representative α-tubulin blot is shown. (C) Quantifi-
cation of PDK1 protein levels, shown as percentage of the untreated control. All error bars
indicate the standard deviation from three biological replicates. Figure published in [Battello
et al., 2016] This data was kindly provided by Dr. Andreas Zimmer.
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Figure A.4: Metabolic effects of OSM in combination with hypoxia in HepG2,
JHH-4 and PH5CH8. HepG2 and JHH-4 hepatocellular carcinoma cells and PH5CH8 im-
mortalized hepatocytes were cultured under hypoxia (1% O2) for 36 h and left untreated or
stimulated with 50 ng/mL OSM in the presence of [13C6]glucose or [
13C5]glutamine. (A,B)
Carbon atom transitions for pyruvate carboxylase (PC) and pyruvate dehydrogenase com-
plex (PDC) activities, from a [13C6]glucose tracer. (C) Carbon atom transitions for oxidative
and reductive glutamine metabolism, from a [13C5]glutamine tracer. (D) PDC activity de-
termined from the M2 citrate isotopologue normalized to the M3 lactate isotopologue, from
[13C6]glucose. (E) PC activity determined from the M3 citrate isotopologue normalized
to the M3 lactate isotopologue, from [13C6]glucose. (F) Reductive glutamine contribution
to citrate, determined by the ratio of M5 isotopologues of citrate to M5 isotopologues of
glutamate, from [13C5]glutamine. (G) Oxidative glutamine contribution to citrate, deter-
mined by the ratio of M4 isotopologues of citrate to M5 isotopologues of glutamate, from
[13C5]glutamine. Error bars indicate the standard deviation and are calculated from at least
two independent replicates. Statistical significance was determined by a two-tailed t-test. *
denotes P<= 0.05, ** denotes P<= 0.01, and *** denotes P<= 0.001.
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Figure A.5: The metabolic effects of PDK1 silencing in HCC cell lines. SiRNA-
mediated PDK1 knockdown (siPDK1) was performed in HepG2 and JHH-4 cells grown under
normoxia and grown in the presence of [13C6]glucose or [
13C5]glutamine. A non-targeting
siRNA (siCtrl) was used as control. (A) The enzymatic activity of PDC determined from
the M2 citrate isotopologue normalized to the M3 lactate isotopologue, from [13C6]glucose.
(B) PC activity determined from the M3 citrate isotopologue normalized to the M3 lactate
isotopologue, from [13C6]glucose. (C) Citrate MID from [
13C6]glucose. Error bars indicate
the standard deviation and are calculated from at least two independent replicates. Statistical
significance between control and the treatment was determined by a two-tailed t-test. *
denotes P<= 0.05, ** denotes P<= 0.01, and *** denotes P<= 0.001.
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Figure A.6: Response of PH5CH1 and PH5CH7 non-neoplastic hepatocytes to
OSM, hypoxia and a combination of both stimuli. PH5CH1 and PH5CH7 cells were
treated with OSM (50 ng/ml), hypoxia (1% O2) or a combinatorial treatment for the indi-
cated periods of time. Quantitative RT-PCR of PDP2, PDK1 and HIF-1α mRNA in (A)
PH5CH1 and (B) PH5CH7. Fold changes were calculated relative to the untreated control.
Figure published in [Battello et al., 2016] This data was kindly provided by Dr. Andreas
Zimmer.
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Figure A.7: Response of PH5CH1 and PH5CH7 non-neoplastic hepatocytes to
OSM, hypoxia and a combination of both stimuli. PH5CH1 and PH5CH7 cells were
treated with OSM (50 ng/ml), hypoxia (1% O2) or a combinatorial treatment for the in-
dicated periods of time. Western Blot analysis for HIF-1α, HIF-2α, PDK1 and all three
PDC phosphorylation sites (S232, S293, S300). Vinculin and α-Tubulin were used as loading
controls and one representative blot is shown. Figure published in [Battello et al., 2016] This
data was kindly provided by Dr. Andreas Zimmer.
Appendix B
Supplemental Material and
Methods
Table B.1: Metabolite Detector Settings
MD Settings
Centroid Peak threshold begin 10
Peak threshold end -5
Max. baseline distance 30
FWHM 0.5
Deconvolution Peak threshold 5
Max. peak hight 5
Bins/Scan 10 or 30
Deconvolution width (scans) 10
Required intensity 0
Required number of peaks 1
Identification Max. RI difference 2
Pure/Impure composition 0
Number of fragments 3
Min. number of identical fragments 1
Cutoff score 0.5
Similarity score RI+Spec
Mass filter 0-100
Quantification Min. distance between subseq. Ions 1
Min. required quality index 0.6
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Table B.2: MID Wizard settings
MID Wizard settings
Corrected using sum formula Carbon
Individual MIDs
∆ RI 2
Scoring method RI+Spec
Pure/Impure 0
Req. score 0.5
Compound reproducibility 0.5
Max peak disc. Index 100
Req. S/N 0
Min. # ions 1
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The role of HIF-1 in oncostatin
M-dependent metabolic reprogramming of
hepatic cells
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Abstract
Background: Hypoxia and inflammation have been identified as hallmarks of cancer. A majority of hepatocellular
carcinomas are preceded by hepatitis B- or C-related chronic infections suggesting that liver cancer development is
promoted by an inflammatory microenvironment. The inflammatory cytokine oncostatin M (OSM) was shown to
induce the expression of hypoxia-inducible factor-1α (HIF-1α) under normoxic conditions in hepatocytes and
hepatoma cells. HIF-1α is known to orchestrate the expression of numerous genes, many of which code for metabolic
enzymes that play key roles in the adaptation of cellular metabolism to low oxygen tension.
Results: Here, we show that OSM-induced upregulation of HIF-1α reprograms cellular metabolism in three clones of
the human hepatocyte cell line PH5CH (PH5CH1, PH5CH7, and PH5CH8) towards a hypoxia-like metabolic phenotype
but has no significant effect on cellular metabolism of HepG2 and JHH-4 hepatoma cells. Although we observed only
minor changes in glucose uptake and lactate secretion in PH5CH8 upon OSM treatment, we identified more
pronounced changes in intracellular fluxes based on stable isotope labeling experiments. In particular, glucose
oxidation in the tricarboxylic acid (TCA) cycle is reduced through pyruvate dehydrogenase kinase 1 (PDK1)-mediated
inhibition of the pyruvate dehydrogenase complex, thereby reducing the oxidative TCA cycle flux. As a result of the
impaired mitochondrial glucose and glutamine oxidation, the reductive isocitrate dehydrogenase flux was increased.
Conclusions: We provide evidence that connects the inflammatory mediator OSM to a hypoxia-like metabolic
phenotype. In the human hepatocyte cell line PH5CH, OSM-mediated upregulation of HIF-1α and PDK1 can induce
hypoxia-like metabolic changes, although to a lesser extent than hypoxia itself. Since PDK1 is overexpressed in several
cancers, it might provide a causal link between chronic inflammation and malignant cellular transformation.
Keywords: Oncostatin M, Inflammation, Stable isotope labeling experiments, Hypoxia-inducible factor, Pyruvate
dehydrogenase complex, Pyruvate dehydrogenase kinase
Background
Interleukin 6 (IL6)-type cytokines such as oncostatin M
(OSM) are key players in the regulation of the immune
response, the immune surveillance of tumor cells, and
in the development of cancer [1]. The main functions of
IL6-type cytokines are the induction of the acute phase
response by the liver, the stimulation of liver regeneration
*Correspondence: andre.wegner@gmx.com
†Equal contributors
1Luxembourg Centre for Systems Biomedicine, University of Luxembourg,
Avenue des Hauts-Fourneaux 7, L-4362 Esch-Belval, Luxembourg
Full list of author information is available at the end of the article
(by inducing hepatocyte proliferation), and the shift from
the innate to the adaptive immune response [2, 3]. Aber-
rant IL6 signaling is likewise able to induce a state
of chronic inflammation, as observed in many cancer
types and inflammatory diseases. Since hepatocellular
carcinoma (HCC) development can be promoted by an
inflammatory microenvironment, aberrant IL6 signaling
is implicated in the onset of HCC [4, 5]. Elevated IL6 and
OSM serum levels in HCC patients have been reported
to negatively influence disease outcome [6, 7]. A direct
link between IL6 and the onset of HCC was shown in a
study by Naugleret et al., where male IL6 knockout mice
© 2016 Battello et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Battello et al. Cancer &Metabolism  (2016) 4:3 Page 2 of 14
showed a vastly reduced development of HCC, depict-
ing IL6 as a key mediator in the onset of this cancer
[4]. All IL6-type cytokines signal via a homodimer of
the transmembrane receptor gp130 or a heterodimer of
gp130 with a second receptor chain (e.g., the OSMR or
LIFR for OSM), which bind and activate Janus kinases
(JAKs) upon cytokine binding. In turn, JAKs activate mul-
tiple signaling cascades mainly including STAT3 but also
MEK/Erk and the PI3K/Akt pathways [8]. Recently, we
have shown in non-neoplastic hepatocytes and HCC cells
that STAT3, activated by the IL6-type cytokine OSM,
upregulates HIF-1α expression under normoxic condi-
tions, via a transcriptional mechanism, leading to the
expression of vascular endothelial growth factor (VEGF)
and plasminogen activator inhibitor 1 (PAI) [9]. HIF-1α
regulates the expression of numerous target genes, many
of which code for metabolic enzymes that play key roles
in the adaptation of cellular metabolism to low oxygen
tension [10]. For example, HIF-1α promotes high gly-
colytic rates by upregulating the expression of glucose
transporters and many glycolytic enzymes [11]. In addi-
tion, pyruvate entry into the citric acid cycle is decreased
by HIF-1α-mediated upregulation of pyruvate dehydroge-
nase (PDH) kinase 1 (PDK1), leading to reduced pyruvate
dehydrogenase complex (PDC) activity which results in
reduced mitochondrial respiration and increased conver-
sion of pyruvate to lactate [12–14]. Apart from its function
in glucose metabolism, a strong impact of HIF-1α on glu-
tamine metabolism has been identified. Resulting from
reduced PDC activity, the mitochondrial citrate pool is
drastically depleted. Due to these concentration changes,
the actual free energy change of the isocitrate dehydro-
genase (IDH) reaction will become positive and thus,
reversing the IDH flux towards isocitrate. Consequently,
glutamine-derived α-ketoglutarate is reductively carboxy-
lated to isocitrate by IDH and eventually converted to
citrate [15–17]. Malignant cellular transformation and
proliferation goes hand-in-hand with reprogrammed cel-
lular metabolism [18, 19], mainly characterized by an
increased glucose uptake, a high glycolytic rate, and an
increased conversion of pyruvate to lactate, even under
normoxic conditions (Warburg effect). Most certainly,
this hypoxia-like metabolic phenotype favors increased
proliferation rates, as a high glucose turnover provides
necessary intermediates such as ribose-5-phosphate, ser-
ine, and glycine for macromolecule synthesis. A link
between inflammatory STAT3 activity, HIF-1α, and the
Warburg effect has been described recently. Demaria
and coworkers showed that constitutively active STAT3
induces the Warburg effect in mouse embryonic fibrob-
lasts [20] and renders the cells sensitive for malignant
transformation [21]. Based on our previous finding that
OSM mediates HIF-1α upregulation through increased
mRNA and protein levels in a STAT3-dependent manner,
we aimed to investigate the effects of OSM stimulation on
central carbon metabolism in hepatocytes and hepatoma
cells. Here, we (1) show that OSM induces the expres-
sion of HIF-1α in several HCC cell lines and immortalized
hepatocytes, (2) demonstrate that OSM stimulation leads
to a hypoxia-like metabolic phenotype in three clones of
the immortalized hepatocyte cell line PH5CH, (3) pro-
vide evidence that HIF-1α-mediated PDK1 upregula-
tion is necessary to induce OSM-dependent metabolic
reprogramming in PH5CH cells, and (4) show that OSM-
dependent HIF-1α upregulation is not sufficient to induce
metabolic reprogramming in the HCC cell lines HepG2
and JHH-4.
Methods
Cell culture and reagents
The hepatoma cell lines and the non-neoplastic, SV40
large T antigen-immortalized, hepatocyte lines, PH5CH1,
PH5CH7, and PH5CH8 [22] were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (AQMe-
dia, Sigma-Aldrich) supplemented with 10% fetal calf
serum (PAA), 100mg/l streptomycin, 60mg/l penicillin,
and 25mM HEPES (Lonza). The SV40 large T antigen-
immortalized human liver epithelial cells (THLE-2) were
cultured in LHC-8 medium supplemented with 70 ng/ml
phosphoethanolamine, 5 ng/ml epidermal growth factor,
10% FBS, 100mg/l streptomycin, and 60mg/l penicillin.
Cells were grown at 37 °C in a water-saturated atmosphere
at 5% CO2. Hypoxia treatment was performed at 37 °C
in a water-saturated atmosphere at 5% CO2 in a hypoxia
chamber (C-Chamber (C-274 & C-374) with a ProOx
C21 Static O2 & CO2 Controller from BioSpherix) at the
indicated oxygen percentage. HIF-1α and HIF-2α screen-
ing experiments were performed in an hypoxia incubator
(Heracell) from Thermo Scientific at 37 °C in a water-
saturated atmosphere at 5% CO2. Human oncostatin
M (227 a.a.) was from PeproTech. For all experiments,
cells were seeded together, stimulated for the indicated
periods of time, and harvested together at the latest
time point.
Western blot analysis and antibodies
Cells were lysed on the dish with ice-cold lysis buffer
containing 30mM Tris/HCl pH 6.7, 5% glycerol, 2.5 %
mercaptoethanol, and 1% SDS. Protein extracts were
separated by SDS-PAGE and analyzed by Western blot-
ting for the following proteins: HIF-1α and STAT3 (BD
Transduction Laboratories), phospho-STAT3, (Cell Sig-
naling), PDH-E1α (pSer232) and PDH-E1α (pSer300)
(Merck Millipore), HIF-2α (Novus Biologicals), PDK1
(Enzo Life Sciences) and α-tubulin (Thermo Fisher Scien-
tific), and PDH-E1α (pSer293) (Abcam). ECL signals were
detected and membranes stripped before re-probing as
previously described [23, 24]. The secondary antibodies
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IRDye 800CW and 680LT (LI-COR Bioscience) were used
for fluorescent Western blot detection with the Odyssey
Infrared imaging system (LI-COR Biosciences) of PDK1.
Quantification of PDK1 protein levels was done using
Image Studio Lite version 4.0 (LI-COR Bioscience). For
the evaluation the HIF-1α protein levels, densitometric
analysis was carried out using the Image-Lab software 4.0
(Bio-Rad Laboratories). The level of the target protein was
normalized to the α-tubulin protein level.
Quantitative PCR procedure
Total RNA was extracted using the NucleoSpin RNA
II kit (Macherey-Nagel) according to the manufacturer’s
instructions. The concentration of isolated RNAwasmea-
sured using a NanoDrop spectrophotometer. Five hun-
dred nanograms of total RNA was reverse-transcribed
with iScript (Bio-Rad Laboratories) in a final volume of
10μl, according to themanufacturer’s instructions. Quan-
titative real-time PCR (qPCR) was carried out on an iQ5
Real-Time PCR detection system (Bio-Rad Laboratories).
The reaction was performed in a total volume of 10μl
containing cDNA corresponding to 5 ng RNA template,
10 pmol of each forward and reverse primer, and 5μl
iTaq Universal SYBR Green Supermix (Bio-Rad Labora-
tories). Thermal cycling conditions for all qPCR assays
consisted of an initial enzyme activation step at 95 °C for
15min, followed by 40 cycles of denaturation at 95 °C, and
annealing and elongation at 60 °C for 30 s. The house-
keeping genes Cyclo A, HPRT, EEF1a, YWHAZ, and the
target genes were assayed in parallel for each sample. All
samples were run in triplicates. Gene-specific primers
for Cyclo A, HPRT, EEF1a, YWHAZ, HIF-1α, HIF-
2α, PDK1, and PDP2 were purchased from Eurogentec
(Belgium). The geometric mean of three housekeeping
genes was calculated, and a normalization factor for
each sample was generated using geNorm (VBA add-in
for Microsoft Excel). The normalization factor was used
to calculate the relative amount of each target in each
sample. Each sample was normalized to the untreated
control.
Total RNA extraction in HIF-1α silencing experiments
was performed using the RNeasy mini kit (QIAGEN)
according to the manufacturer’s instructions. Six hun-
dred nanograms of total RNA was reverse-transcribed
using SuperScript III reverse transcriptase (Invitrogen)
in a final volume of 20μl according to manufacturer’s
recommendations. qPCR was performed on a LightCy-
cler 480 (Roche) in a total volume of 20μl containing
cDNA corresponding to 6 ng RNA template, 5 pmol of
each forward and reverse primer, and 10μl iTaq Univer-
sal SYBRGreen Supermix (Bio-Rad Laboratories). Cycling
conditions were identical to those described earlier. Tar-
get gene expression was normalized to the housekeeping
gene L27.
siRNA-mediated silencing of HIF-1α and PDK1
For the siRNA-mediated HIF-1α knockdown, 3μl of
Lipofectamine RNAiMAX (Invitrogen) was diluted in
150μl 1× Opti-MEM I (Gibco by Life Technologies) and
1μl siRNA was added. The final concentration of non-
targeting (Dharmacon, Inc.) and HIF-1α siRNA (Santa
Cruz) was 15 nM. For the siRNA-mediated PDK1 knock-
down, 2.5μl of Lipofectamine RNAiMAX was diluted
in 200μl 1× Opti-MEM I and 1μl siRNA (Dharmacon,
Inc.) was added. The final concentration of non-targeting
and PDK1 siRNA was 20 nM. The Lipofectamine/siRNA
mix was incubated for 20min at room temperature,
then transferred into a 12-well plate and incubated for
another 5min. PH5CH1, PH5CH7, and PH5CH8 cells
were directly seeded onto the transfection mix. After 6 h,
the medium was changed to complete culture media and
cells were grown overnight.
Stable isotope labeling experiments
Cells were seeded and grown overnight. Complete
cell culture medium was then replaced with labeling
medium. For isotope labeling experiments using uni-
formly labeled glucose, cells were cultured in DMEM sup-
plemented with 10% dialyzed FBS (Invitrogen), 25mM
[13C6]glucose (Cambridge Isotope Laboratories), and
4mM glutamine (Sigma-Aldrich). For isotope labeling
experiments using uniformly labeled glutamine, cells
were grown in DMEM supplemented with 10% dialyzed
FBS (Invitrogen), 25mM glucose (Sigma-Aldrich), and
4mM [13C5] glutamine (Cambridge Isotope Laborato-
ries). Cells were stimulated with 50 ng/ml OSM (Pepro-
Tech) and grown for 36 h under normoxia or hypoxia
(1% O2) (Jacomex) at 37 °C, 5% CO2 and humidified
atmosphere. Metabolites were extracted as described
previously [25].
Extraction of extracellular metabolites
Extracellular metabolites from medium samples
were extracted using ice-cold extraction fluid (8:1
methanol/water) containing the internal standard
[13C5]ribitol (Omicron Biochemicals, Inc.) at a concen-
tration of 10μg/ml. Twenty microliters of the medium
was added to 180μl ice-cold extraction fluid, vortexed for
10 s, and centrifuged at maximum speed for 5min at 4 °C.
Fifty microliters of the medium extracts was transferred
to GC-MS glass vials and evaporated under vacuum to
dryness at −4 °C using the CentriVap Concentrator.
GC-MS analysis
Metabolite derivatization was performed using a Gerstel
MPS. Dried polar metabolites were dissolved in 15μl
of 2% methoxyamine hydrochloride in pyridine at
40 °C under shaking. After 60min, an equal volume of
MTBSTFA was added and held for 30min at 40 °C under
Battello et al. Cancer &Metabolism  (2016) 4:3 Page 4 of 14
continuous shaking. One microliter sample was injected
into an SSL injector at 270 °C in splitless mode. GC-MS
analysis was performed using an Agilent 7890A GC
equipped with a 30-m DB-35MS + 5-m Duraguard capil-
lary column. Helium was used as carrier gas at a flow rate
of 1ml/min. The GC oven temperature was held at 100 °C
for 2min and increased to 300 °C at 10 °C/min. After
3min, the temperature was increased to 325 °C. The GC
was connected to an Agilent 5975C inert XLMSD, operat-
ing under electron ionization at 70 eV. TheMS source was
held at 230 °C and the quadrupole at 150 °C. The detec-
tor was operated in single ion mode (see Additional file 1:
Table S1 for details). The total run time of one sample was
25.00min.
Mass isotopomer distribution analysis
All GC-MS chromatograms were processed using
MetaboliteDetector [26]. Chemical formulas for mass iso-
topomer distribution (MID) determination (Additional
file 1: Table S1) were taken from [27]. Weighted carbon
contribution was calculated with the following formula:
1
n ∗
n∑
i=1
Mi ∗ i, where n is the number of carbons of the
molecule of interest andMi the ith mass isotopomer.
Statistical analysis
Error bars represent the standard deviation unless other-
wise noted. Statistical significance was determined using
two-tailed Student’s t test. One asterisk denotes P < 0.05,
two asterisks denote P < 0.01, and three asterisks denote
P < 0.001.
Results
Oncostatin Mmediates induction of HIF-1α in hepatocytes
and hepatoma cells
Based on our previous observation that oncostatin M
(OSM) treatment induces HIF-1α expression in hepato-
cytes under normoxia, we first investigated whether the
OSM-mediated upregulation of HIF-1α is a general effect
for hepatocytes and hepatoma cells [9]. Therefore, we
evaluated HIF-1α protein levels after OSM stimulation
and hypoxia in 11 HCC and two non-neoplastic hepato-
cyte cell lines 8 and 36 h after treatment (Additional file 2:
Figure S1). After 8 h, we detected increased HIF-1α pro-
tein levels following OSM treatment in eight out of 11
cell lines, whereas after 36 h only five cell lines showed an
increase in HIF-1α protein levels (Fig. 1a). Compared to
OSM, the effect of hypoxia on HIF-1α protein levels was
generally more pronounced (Additional file 2: Figure S1).
In ten cell lines, we detected hypoxia-mediated HIF-1α
protein induction after 8 h and in nine cell lines after 36 h
(Fig. 1a).
We selected three of these cell lines for an in-depth
study of OSM-induced effects on cellular metabolism.
HepG2 and JHH-4 are hepatocellular carcinoma cell lines,
whereas PH5CH8 cells are immortalized hepatocytes.
In PH5CH8 and HepG2 cells, we observed that OSM
upregulates HIF-1α mRNA expression over the entire
time course, while we measured only a weak induction
of HIF-1α mRNA expression in JHH-4 cells (Fig. 1b).
In non-neoplastic PH5CH8 cells, we observed con-
tinuous OSM-dependent induction of HIF-1α protein
levels, comparable to those observed under hypoxia
(Fig. 1c, d). In HepG2 cells, we detected a transient
induction of HIF-1α protein levels, peaking around
12 h post-OSM treatment (Fig. 1c, d). Correlating with
the weak induction on HIF-1α mRNA, we did not
observed an increase in HIF-1α levels in JHH-4 cells
(Fig. 1b, c).
OSM stimulation reduces glucose oxidation via PDC
inhibition under normoxia in non-transformedhepatocytes
Based on the observed OSM-induced upregulation of
HIF-1α under normoxia, we hypothesized that this would
induce a pseudo-hypoxic metabolic phenotype. To inves-
tigate the effect of OSM stimulation on central car-
bon metabolism, we performed stable isotope labeling
experiments using [13C6]glucose and [13C5]glutamine and
quantified the isotopic enrichment in form of MIDs.
Therefore, we cultured PH5CH8 cells under normoxia
(18.6% O2), hypoxia (1% O2) either with or without
50 ng/ml OSM. We observed a significant decrease (P <
0.001) in glucose carbon contribution to citrate in OSM-
stimulated cells under normoxia as compared to the
control (Fig. 2a), although glucose uptake was slightly
increased (Additional file 3: Figure S2A). In line with a
reduced glucose carbon contribution to the TCA cycle,
we observed increased lactate secretion (Additional file 3:
Figure S2A). We next investigated whether the decreased
glucose contribution is a result of reduced anaplerosis via
pyruvate carboxylase (PC) or reduced PDC activity. Using
[13C6]glucose as a tracer, the two pathways can be dis-
tinguished by analyzing the M2 and M3 isotopologues of
citrate. Briefly, PDC activity generates [13C2]acetyl-CoA
from which M2 citrate is produced, whereas PC activity
yields [13C3]oxaloacetate leading to M3 citrate (Fig. 2b).
M5 isotopologues of citrate reflect the combined carbon
contribution of PC and PDC to citrate. To exclude bias
from the overall enrichment, we normalized the abun-
dance of the M2, M3, and M5 isotopologues of citrate to
the abundance of the M3 isotopologue of lactate. While
there was no difference in M3 and M5 isotopologues
(data not shown), OSM-stimulated cells exhibited a sig-
nificantly (P = 0.003) reduced M2-citrate-to-M3-lactate
ratio under normoxic conditions, pointing to reduced glu-
cose catabolism via PDC (Fig. 2c) and thus a reduced
oxidative TCA cycle flux. Reduced M2 isotopologues
propagated to all analyzed downstreammetabolites in the
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Fig. 1 OSM induces HIF expression in hepatoma cells and hepatocytes under normoxic conditions. a Eleven HCC cell lines and two non-neoplastic
hepatocyte cell lines (THLE-2, PH5CH8) were screened for the induction of HIF-1α protein levels by OSM treatment or hypoxia (green indicates
protein induction, red no HIF-1α protein induction). b–d HepG2, JHH-4, and PH5CH8 cells were selected for further analysis and treated with
50 ng/ml OSM, hypoxia (1% O2), or a combinatorial treatment for the indicated periods of time. b Quantitative RT-PCR of HIF-1α. The fold change
was calculated relative to the untreated control. Error bars represent the standard deviation of three biological replicates. cWestern blot analysis of
HIF-1α. α-Tubulin was used as a loading control, and one representative blot for α-tubulin is shown. S. Exp. indicates short exposure, L. Exp. long
exposure. d Quantification of HIF-1α protein levels in HepG2 and PH5CH8 cells after the different treatments. Statistical significance was determined
in comparison to the untreated control. *P <= 0.05, **P <= 0.01, and ***P <= 0.001
TCA cycle (Additional file 4: Table S2). Although HIF-1α
protein levels upon OSM treatment were comparable to
those under hypoxic conditions (Fig. 1d), we observed a
much stronger effect on cellular metabolism induced by
hypoxia. Specifically, PDC activity and consequently glu-
cose carbon contribution to citrate were almost reduced
to zero (Fig. 2a, c). OSM treatment did not further impact
glucose oxidation under hypoxia (Fig. 2a, c).
Since PDC links glycolysis and TCA cycle, it is
tightly regulated. Its activity is mainly controlled through
reversible phosphorylation of the PDH-E1α subunit.
An inhibition of the complex is mediated by its
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phosphorylation via pyruvate dehydrogenase kinases
(PDK1-4), whereas a dephosphorylation through pyru-
vate dehydrogenase phosphatases (PDP1-2) leads to an
increase in PDC activity. PDK1 is a direct HIF-1α tar-
get gene, and its upregulation has been implicated in
the metabolic switch induced by HIF-1α [13]. For that
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reason, we determined the effect of OSM treatment on
PDK1 and PDP2 mRNA levels. Furthermore, we analyzed
the degree of phosphorylation of all three serine phos-
phorylation sites of the PDH-E1α subunit by Western
blot. We observed an increase in the expression of PDK1
following OSM treatment, which was, however, weaker
compared to hypoxia and hypoxia in combination with
OSM treatment (Fig. 3a–c). The transcription of PDP2
was decreased under hypoxia at later time points but
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Fig. 3 PDK1 levels are increased upon OSM stimulation under
normoxia in PH5CH8 non-neoplastic hepatocytes. PH5CH8 cells were
treated with OSM (50 ng/ml), hypoxia (1% O2), or a combinatorial
treatment for the indicated periods of time. a Quantitative RT-PCR of
PDK1 and PDP2 mRNA. The fold change was calculated relative to the
untreated control. bWestern blot analysis for all three PDH
phosphorylation sites (S232, S293, S300) and PDK1. α-Tubulin was
used as a loading control, and one representative α-tubulin blot is
shown. c Quantification of PDK1 protein levels, shown as percentage
of the untreated control. All error bars indicate the standard deviation
from three biological replicates. Statistical significance was
determined in comparison to the untreated control. *P <= 0.05,
**P <= 0.01, and ***P <= 0.001
remained unaffected byOSM (Fig. 3a). Moreover, hypoxia
led to increased phosphorylation levels of the PDH-E1α
subunit at all three serine residues, whereas the results
for OSM were not as unambiguous. We did not observe
a clear effect on any of the three serine residues after
OSM treatment (Fig. 3b). Hypoxia led to higher PDK1
protein levels than OSM, correlating with the weaker
effect of OSM on PDC activity. Collectively, these data
indicate that OSM treatment reduces PDC activity under
normoxia in PH5CH8 cells but to a weaker extent than
hypoxia.
OSM stimulation increases reductive carboxylation of
α-ketoglutarate
Because of the observed reduced glucose oxidation in
the TCA cycle via PDC inhibition, we next sought to
investigate whether this reduction is compensated by an
increased glutamine contribution. To quantify the rela-
tive contribution of glutamine to the TCA cycle, we cul-
tured PH5CH8 cells in the presence of [13C5]glutamine.
We observed a modest increase of glutamine-derived
carbon in citrate under OSM-stimulation (Fig. 2a). Using
[13C5]glutamine as a tracer, the M4 isotopologue of cit-
rate results from a condensation of [13C4]oxaloacetate
and unlabeled acetyl-CoA (Fig. 2d), thereby providing
a readout of relative glutamine oxidation in the TCA
cycle. Although the fractional carbon contribution of glu-
tamine to citrate was increased, we observed a decreased
relative M4 isotopologue abundance when stimulating
PH5CH8 cells with OSM under normoxic conditions
(Fig. 2e), pointing to a decreased glutamine oxidation in
the TCA cycle upon OSM stimulation. This result sug-
gests that the glucose-derived acetyl-CoA pool is not fully
replenished by an alternative acetyl-CoA source such as
increased fatty acid oxidation or degradation of branched
chain amino acids. We also observed reduced M4 iso-
topologues in downstream metabolites including malate,
fumarate, and aspartate (Additional file 5: Table S3). Alter-
natively, citrate can be generated through reductive car-
boxylation of α-ketoglutarate via IDH, eventually yielding
M5 citrate (Fig. 2d). Reductive carboxylation was signif-
icantly increased (P < 0.001) in OSM-stimulated cells
compared to the control, as indicated by an increased
M5 isotopologue abundance (Fig. 2f). In agreement with
an increased relative reductive IDH flux, we observed
increased α-ketoglutarate levels together with decreased
citrate levels in OSM-stimulated cells (see Additional
file 3: Figure S2B). In line with the higher reduction
of PDC activity under hypoxia (Fig. 2c), we observed
a much stronger suppression of glutamine oxidation
(Fig. 2e) and a higher induction of reductive IDH activity
under hypoxia (Fig. 2f). However, OSM treatment did not
have any effect on glutamine metabolism under hypoxia
(Fig. 2e, f).
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OSM stimulation reduces glucose oxidation and increases
reductive glutamine metabolism in a
concentration-dependent manner
To investigate whether OSM affects cellular metabolism
in a dose-dependent manner, we cultured PH5CH8 cells
with 10, 25, and 50 ng/ml OSM. We found that OSM-
mediated HIF-1α protein induction steadily increased
with the OSM concentration (Fig. 2g). While we observed
the strongest effect on cellular metabolism with 50 ng/ml
OSM, we observed a reduction of glucose and glutamine
oxidation as well as increase of reductive glutamine
metabolism already with 10 ng/ml OSM (Fig. 2h–j).
HIF-1α-mediated PDK1 upregulation is critical for
OSM-inducedmetabolic reprogramming in PH5CH8 cells
To validate the hypothesis that OSM-induced metabolic
reprogramming is caused by increased HIF-1α activity,
we silenced HIF-1α expression in PH5CH8 using siRNA
(Fig. 4f). A scrambled siRNA was included as a con-
trol to exclude secondary effects of the transfection.
Silencing of HIF-1α almost completely prevented the
metabolic reprogramming induced by OSM. Specifically,
glucose-derived carbon in citrate increased under nor-
moxia and hypoxia (Fig. 4a) and was comparable to levels
of untreated cells (Fig. 2a). Glutamine carbon contribution
to citrate decreased in HIF-1α-silenced cells under nor-
moxia and hypoxia (Fig. 4b). Moreover, silencing of HIF-
1α decreased PDK1 expression (Fig. 4e), increased PDC
activity (Fig. 4c), and decreased reductive carboxylation
(Fig. 4d). Overall, these data suggests that HIF-1α is criti-
cal for OSM-dependent metabolic phenotype observed in
PH5CH8 cells.
Based on the observation that PDK1 expression is
increased by OSM treatment in an HIF-1α-dependent
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manner, we silenced PDK1 in PH5CH8 cells (Fig. 5a, b).
As a consequence of suppressed PDK1 expression,
previously observed OSM-mediated metabolic changes
were attenuated. Both the OSM-induced changes in PDC
activity and reductive carboxylation of α-ketoglutarate
were impaired when PDK1 was silenced (Fig. 5c, d).
Under hypoxic conditions, we detected a pronounced
increase in PDC activity and drastically reduced reduc-
tive glutaminemetabolism (Fig. 5c, d). Taken together, our
results show that the OSM-induced metabolic phenotype
in PH5CH8 cells is mediated by HIF-1α-dependent PDK1
upregulation.
OSM induces PDK1-dependent metabolic reprogramming
in other PH5CH clones
In order to show that OSM-mediated metabolic repro-
gramming is not a unique feature in PH5CH8 cells,
we aimed to validate our main findings in two other
PH5CH clones PH5CH1 and PH5CH7. In line with
our findings in PH5CH8, we detected continuous
OSM-dependent HIF-1α and PDK1 mRNA upregulation
and protein induction (Additional file 6: Figure S3A and
S3D), while PDP2 mRNA levels were downregulated.
HIF-1α protein levels were comparable to those found
under hypoxia (Additional file 6: Figure S3B and S3E).
Furthermore, OSM treatment reduced the entry of
glucose-derived carbon into the TCA cycle and induced
reductive glutamine metabolism (Fig. 5g, h). As already
observed in PH5CH8, silencing of PDK1 attenuated
the OSM-mediated metabolic changes in PH5CH1 and
PH5CH7 cells (Fig. 5g, h). Taken together, these results
confirm that PDK1 is required to induce a hypoxia-
like metabolic phenotype in PH5CH1 and PH5CH7
cells.
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OSM-dependent HIF-1α upregulation is not sufficient to
induce a hypoxia-like metabolic phenotype in two
hepatoma cell lines
Since aberrant IL6 signaling is implicated in the onset
of HCC development, we next sought to investigate the
effect of OSM on the two HCC cell lines HepG2 and
JHH-4. Although HIF-1α mRNAwas increased in HepG2
(Fig. 1b) and HIF-1α protein was transiently induced by
OSM treatment (Fig. 1c, d), we did not observe changes
in glucose and glutamine metabolism after 36 h of OSM
stimulation (Fig. 6a–c). To verify that OSM has indeed
no metabolic effect, we profiled cellular metabolism of
HepG2 at 6 and 15 h post-OSM stimulation (Additional
file 7: Figure S4). In line with HIF-1α mRNA and protein
expression levels in JHH-4 cells (Fig. 1b, c), we did not
observe OSM-mediated metabolic changes (Fig. 6a–c).
Under hypoxic conditions, however, glucose oxidation
was suppressed, while glutamine carbon contribution was
highly increased in both cell lines (Fig. 6a). In line with
these data, we observed decreased PDC activity under
hypoxia but no effect of OSM treatment under normoxia
(Fig. 6b). We observed the same for reductive carboxy-
lation of α-ketoglutarate, which was increased under
hypoxia but not significantly affected by OSM treatment
under normoxia (Fig. 6c). In agreement with the MID
data, we did not observe an induction of PDK1 (Fig. 7a,
c, d, f). Concordantly, phosphorylation at any of the three
serine residues of PDH was not induced after OSM stim-
ulation under normoxia in these two cell lines (Fig. 7b, e).
Taken together, these data show that, in HepG2 and JHH-
4, OSM did not induce the metabolic changes observed
in the three clones of the human hepatocyte cell line
PH5CH.
Discussion
Along with others, we reported that transcription of HIF-
1α, one of the master regulators of the cellular response
to hypoxia, is upregulated through IL6-type cytokine
(e.g., IL6 and OSM) signaling or other activators of the
JAK/STAT3 signaling pathway [9, 20]. Because HIF-1α is
heavily induced by hypoxia, we hypothesized that OSM
induces a hypoxia-like metabolic phenotype under nor-
moxic conditions. In this study, we provide insights in
how OSM affects transcriptional regulation of central
metabolism and how the transcriptional changes prop-
agate to redirect intracellular metabolic fluxes. First,
we demonstrated that OSM treatment under normoxia
leads to an upregulation of PDK1 in three clones of
the immortalized hepatocyte cell line PH5CH. Increased
mRNA levels of PDK1 translated to increased protein
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levels (Fig. 3a, c; Additional file 6: Figure S3C), which cor-
related with reduced PDC activity (Fig. 2c, Fig. 5g) and
therefore reduced glucose oxidation in the TCA cycle.
Reduced glucose-derived acetyl-CoA was not compen-
sated by an alternative acetyl-CoA source such as fatty
acid oxidation or degradation of branched chain amino
acids, leading to reduced glutamine oxidation (Fig. 2e,
Fig. 5h). As a result of the reduced glucose and glutamine
oxidation, the intracellular citrate levels decreased, trig-
gering reductive α-ketoglutarate carboxylation by mass
action [15, 28]. This is in line with a previous study by
Gameiro et al., showing that reductive carboxylation is
triggered by a deficient mitochondrial pyruvate oxidation
[16]. These results indicate that PDK1 plays an important
role in the OSM-induced metabolic phenotype. Together,
our current work shows that OSM treatment under nor-
moxic conditions induces an intermediate metabolic phe-
notype between hypoxia (1% O2) and normoxia (18.6%
O2) in PH5CH8 cells. This metabolic phenotype can sup-
port high proliferation rates. Although OSM was impli-
cated in increased hepatocyte proliferation in vivo after
partial hepatectomy (Nakamura et al. 2004), we did not
observe an effect on the growth rate of PH5CH8 cells (data
not shown).
Second, to confirm our hypothesis that the OSM-
induced metabolic changes are HIF-1α-dependent, we
demonstrated that silencing of HIF-1α almost completely
attenuated the OSM-dependent metabolic effects under
normoxia, showing that HIF-1α expression is critical for
OSM-dependent metabolic reprogramming. This depen-
dency on HIF-1α activity explains why although OSM
leads to increased HIF-1α protein levels under hypoxia, it
does not have any additional effect, as with 1% oxygen,
the amount of transcriptionally active HIF-1α cannot be
further induced through OSM. Interestingly, silencing of
HIF-1α under hypoxia increased glucose-derived pyru-
vate oxidation, suggesting that glucose-derived acetyl-
CoA and thus downregulated PDC activity is the limiting
factor and not only reduced O2 availability for respiration
under hypoxia.
Third, we identified PDK1 as a critical HIF-1α down-
stream regulator of the OSM-induced metabolic changes.
PDK1 knockdown, however, did not fully abolish OSM-
mediated effects on intracellular metabolic fluxes (Fig. 5c,
d, g, h). Possibly, our siRNA-mediated PDK1 silencing
was not sufficiently strong to fully abolish PDK1 activ-
ity, although PDK1 protein levels were not detectable by
Western blot anymore (Fig. 5b, f). Furthermore, it cannot
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be excluded that yet another regulator is involved in the
mediation of OSM-dependent metabolic reprogramming.
Finally, we demonstrated that in HepG2 and JHH-4,
OSM did not induce the metabolic changes we observed
in the PH5CH clones (Figs. 6 and 7). This is potentially
explained by the fact that OSM did not induce HIF-1α
in JHH-4 or solely in a transient way in HepG2. Even
in the PH5CH clones, where OSM-induced HIF-1α pro-
tein levels are similar to those induced by hypoxia, the
impact on PDK1 expression was less pronounced. In addi-
tion, the metabolic effect observed upon OSM in the
PH5CH clones was lower compared to the metabolic
changes induced by hypoxia. Taken together, these data
raise the hypothesis that OSM-induced HIF-1α is not
as potent in activating HIF downstream responses as
hypoxic HIF. This might be due to the fact that HIF-1α
is post-translationally regulated by the following mecha-
nisms: (1) Under normoxia, OSM-induced HIF-1α might
still be hydroxylated by PHDs on proline and asparagine
residues. Hence, VHL binds HIF-1α and tags it for
proteasomal degradation leading to a faster degrada-
tion as compared to stabilized HIF-1α under hypoxia.
VHL binding complexes might also interfere with HIF-
mediated transcription or lead to a reduced binding time
of HIF on promotors. In addition, factor-inhibiting HIF
(FIH)-mediated asparagine hydroxylation in the trans-
activation domain of HIF-1α prevents cofactor binding
(CEBP) and might thereby reduce effective transcription
[29, 30]. (2) HIF-1α might be modified by other post-
translational modifications upon hypoxia compared to
OSM-induced HIF-1α under normoxia and thus altering
its function. In addition to hydroxylation, HIF1α is known
to undergo acetylation, phosphorylation, S-nitrosylation,
and SUMOylation [31]. (3) Known cofactors of HIF-1α
(e.g., TAZ) found under hypoxia might not be present in
normoxic conditions [32].
We have previously shown, however, that at least the
HIF-1α target genes VEGF and PAI as well as HIF-1α-
dependent reporter gene constructs under the control of
the VEGF or the PAI promoter or of HRE elements are
upregulated upon OSM stimulation [9]. Hence, OSM-
induced HIF-1α can be an active transcription factor in
HepG2 cells. However, it remains unclear why we were
not able to detect HIF-1α-induced metabolic changes in
HepG2 cells in this study. VEGF was discussed to be
not only a HIF-1α but also a STAT3 target gene [33].
Therefore, it is possible that VEGF and PAI are regulated
by both transcription factors. In contrast to HIF, STAT3
might be able to recruit cofactors under normoxia that
HIF cannot, as it remains hydroxylated at asparagine. For
many metabolic genes (which are not STAT3 responsive
or mainly rely on HIF-1α for transcriptional regulation),
asparagine hydroxylation might prevent HIF from being
fully active.
Collectively, our data shows that HIF-1α is necessary
but not sufficient to induce OSM-dependent metabolic
reprogramming of hepatic cells.
Conclusions
Hypoxia and inflammation have been recognized as con-
ditions favoring carcinogenesis [18]. Both microenviron-
ments induce profound changes in cellular metabolism
towards a more glycolytic phenotype [34], and it is
assumed that high rates of glycolysis provide a selec-
tive growth advantage that promotes tumor progression
[35]. However, it is still debated whether these metabolic
changes are a consequence or a cause of carcinogene-
sis [35]. The OSM-induced metabolic changes described
in this study would support increased proliferation rates
and are similar to the metabolic adaptations described
in tumors [19]. Hence, OSM-dependent metabolic repro-
gramming might serve as a first hit in carcinogenesis,
which connects chronic infections to increased risks of
tumor development. On the other hand, our experiments
only applied acute treatments (50 ng/ml OSM, 18.6% O2,
and 1% O2) and certainly do not reflect chronic condi-
tions as encountered in a tumor. It will be interesting to
investigate whether long-term activity of the JAK/STAT3
pathway affects hepatocyte/hepatoma cell metabolism in
a different way.
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UponstimulationwithTh1cytokinesorbacterial lipopolysac-
charides, resting macrophages shift their phenotype toward a
pro-inflammatory state as part of the innate immune response.
LPS-activated macrophages undergo profound metabolic
changes to adapt to these new physiological requirements. One
key step tomediate thismetabolic adaptation is the stabilization
ofHIF1, which leads to increased glycolysis and lactate release,
as well as decreased oxygen consumption. HIF1 abundance can
result in the induction of the gene encoding pyruvate dehydro-
genase kinase 1 (PDK1), which inhibits pyruvate dehydrogenase
(PDH) via phosphorylation. Therefore, it has been speculated
that pyruvate oxidation through PDH is decreased in pro-in-
flammatory macrophages. However, to answer this open ques-
tion, an in-depth analysis of this metabolic branching point was
so far lacking. In this work, we applied stable isotope-assisted
metabolomics techniques anddemonstrate that pyruvate oxida-
tion is maintained in mature pro-inflammatory macrophages.
Glucose-derived pyruvate is oxidized via PDH to generate cit-
rate in the mitochondria. Citrate is used for the synthesis of the
antimicrobial metabolite itaconate and for lipogenesis. An
increased demand for thesemetabolites decreases citrate oxida-
tion through the tricarboxylic acid cycle, whereas increased
glutamine uptake serves to replenish the TCA cycle. Further-
more, we found that the PDH flux is maintained by unchanged
PDK1 abundance, despite the presence of HIF1. By pharmaco-
logical intervention, we demonstrate that the PDH flux is an
important node for M(LPS) macrophage activation. Therefore,
PDH represents a metabolic intervention point that might
become a research target for translational medicine to treat
chronic inflammatory diseases.
Macrophages are innate immune cells that differentiate from
monocytes, which circulate in the bloodstream. Upon differen-
tiation, they invade the surrounding tissue and become resident
macrophages (1).Macrophages can be activated by cytokines or
toll-like receptor agonists, e.g. lipopolysaccharide (LPS). In very
general terms, macrophage activation can result in rather pro-
inflammatory responses, serving as host defense mechanisms
or in wound healing responses and aiding in tissue repair and
remodeling. However, depending on the type of activation, very
different subtypes of activation occur (2). Upon activation with
LPS (M(LPS)) or the cytokine interferon- (M(INF)), macro-
phages undergo profound metabolic reprogramming, neces-
sary to activate cellular defense mechanisms as well as to cope
with differentmicro-environments in the inflamed tissue (3). A
marker for pro-inflammatory activation is high expression of
Irg1 (4, 5). We recently showed that Irg1 codes for the enzyme
cis-aconitate decarboxylase (IRG1/CAD) that catalyzes the syn-
thesis of the antimicrobial metabolite itaconate from cis-aconi-
tate (6). Therefore, metabolic reprogramming due to these
adaptations could affect the availability of substrate needed for
the synthesis of itaconate during host defense.
The reprogramming during macrophage activation shows
overlapping features with cancer cells; both have increased gly-
colytic rates and increased lactate release, known as aerobic
glycolysis or theWarburg effect (7, 8). Increased glycolytic rates
are observed in any cell type that exceeds the energy demand
derived from oxidative phosphorylation (9). In macrophages, it
has been revealed that this metabolic rewiring is mediated by
stabilization of HIF1 (10). A well described HIF1 target is the
gene encoding pyruvate dehydrogenase kinase 1 (PDK1), an
inhibitor of Pyruvate dehydrogenase (PDH)3 (11). When HIF1
is stabilized, the PDH flux can be inhibited by PDK1-mediated
phosphorylation, resulting in decreased pyruvate-derived
acetyl-CoA levels. In this case, reductive carboxylation of -ke-
toglutarate (KG) increases to provide sufficient acetyl-CoA
for lipogenesis, needed for cell proliferation (12–15). Increased
glycolytic rates, decreased PDH flux, and increased reductive
carboxylation can also be induced in any cell type when oxygen
tension is decreased or when oxidative phosphorylation is
impaired. In this case, NADH oxidation is compromised, and
citrate levels decrease. This decrease in citrate is linked to an
increase in NADH, which thermodynamically promotes the
metabolic adaptation to hypoxia by increasing reductive car-
boxylation of KG (13, 16, 17). However, it is currently unclear
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whether this full panel of metabolic consequences upon HIF1
stabilization is also true for pro-inflammatory macrophages.
Although it has been demonstrated that HIF1 can be stabi-
lized and activated by cytokines, e.g. TNF and IL1 (18, 19),
the detailed metabolic consequences are still uncertain.
HIF1 can bind to the promoter of the Tlr4 gene, thereby
acting through a positive feedback loop on the TLR4 defense
axis (20). Reactive oxygen species were shown to inhibit protea-
somal degradation of HIF1 (21), and recently, increased suc-
cinate levels in pro-inflammatory macrophages have also been
described to stabilize HIF1, by inhibiting prolyl hydroxylase-
mediated hydroxylation of HIF1 (10).
In this study, we asked whether the stabilization of HIF1 in
M(LPS) macrophages alters TCA cycle fluxes similarly to
hypoxic cells. We show that LPS-activated macrophages
exhibit a metabolic adaptation with overlapping features to
hypoxic cells, but also distinct differences, resulting in a unique
LPS-specific metabolic signature. The most striking difference
to hypoxic cells with stabilized HIF1 is that there is no
decrease in relative glucose flux through PDH and no increase
in reductive carboxylation of KG. The sustained PDH flux
provides sufficient acetyl-CoA for citrate production, which
keeps the rate of reductive carboxylation of KG at a low level,
as well as providing citrate that is needed for the synthesis of
fatty acids and itaconate. Upon LPS stimulation, high PDH
activity is maintained by a repression of Pdk1. As a result PDH
phosphorylation on Ser-232 and Ser-293 remains at a low level.
Finally, we demonstrate that the PDH flux is indeed important
to sustain M(LPS) activation in macrophages.
Experimental Procedures
Chemicals—UK5099 (Sigma, PZ0160) was first diluted in
DMSO and further diluted in medium to a working stock con-
centration of 10 mM and then added to the wells of the culture
dish to a final concentration of 100M. The final concentration
of DMSO did not exceed 1%; LPS (Escherichia coli, Sigma
L6529) was prepared as a working stock of 1 g/ml in glucose-
and glutamine-free DMEM and added 1:100 into the wells of
the culture dish for a final concentration of 10 ng/ml. Cells were
stimulated for 6 h; interferon  (mouse) (E. coli, Sigma I4777)
was prepared as a working stock of 5 mg/ml in glucose- and
glutamine-free DMEM and added 1:100 into the wells of the
culture dish for a final concentration of 50 ng/ml. Cells were
stimulated for 6 h.
Stable Isotope Tracing—13C stable isotope tracers were
obtained from Eurisotop as follows: glucose, CLM-1396; gluta-
mine, CLM-1822-H. The tracer medium was prepared in
DMEM without glucose and glutamine. [13C]Glucose (final 25
mM) and [12C]glutamine (final 4 mM) (or vice versa) was added
to the medium; pH was set to 7.3; 10% FBS and 1% penicillin/
streptomycin were added, and finally, the medium was sterile-
filtered. Tracer medium was prepared in advance and incu-
bated in the hypoxia chamber overnight to remove excessive
oxygen from the medium (only for hypoxia conditions). The
next morning, medium was replaced by tracer medium, and
cells were incubated for 24 h with the tracer medium to reach
isotopic steady state. LPS was added after 24 h and left on the
cells for an additional 6 h prior to extraction. For further infor-
mation regarding stable isotope-assisted metabolomics, see
also Refs. 22, 23.
Cell Culture—RAW 264.7 cells (ATCC TIB-71TM) were
obtained from ATCC and were cultivated according to the
manufacturer’s instructions. Briefly, cells were kept in
DMEM5796 with 10% FBS and 1% penicillin/streptomycin at
37 °C and 5% CO2 under atmospheric oxygen concentrations.
In the case of hypoxia, cells were cultivated in an incubator at
37 °C and 5% CO2 located in a closed hypoxia chamber with an
oxygen concentration of 2%. Cells were simultaneously seeded
in the afternoon at a density of 150,000 cells per well in 12-well
plates (Thermo Scientific, Nunc Multidish 12 Nunclon Delta
Si) and then either incubated either at 21 or 2% O2 overnight.
The next day, medium was replaced. In the case of hypoxia,
medium was already incubated in the hypoxia chamber over-
night to remove excessive oxygen from the medium. For com-
parison reasons,medium for normoxic conditionswas also pre-
pared the day before and incubated in a similar way under
atmospheric oxygen conditions. For LPS activation, LPS was
added 18 h after medium replacement. 24 h after medium
replacement cells were harvested.
Viability Assay—To assess cell viability, cells were trans-
ferred into tubes and analyzed using a Vi-CellTM XR (Beckman
Coulter) automated cell counter. To determine viability, cells
were incubated with trypan blue and number of stained cells
was determined.
cDNA Synthesis and Gene Expression Analysis—cDNA syn-
thesis and quantitative PCR was performed as described previ-
ously (6). Briefly, RNA was isolated from the interphase after
extraction of metabolites, using the Qiagen RNeasy mini kit.
0.5–1 g of RNA was used for cDNA synthesis using Super-
Script III (Invitrogen), following the manufacturer’s instruc-
tions. Quantitative PCR was performed using iQ SYBR Green
Supermix (Bio-Rad) as per the manufacturer’s instructions.
PCR was carried out on a Light Cycler 480 (Roche Applied
Science). Data analysis was performed using the analysis soft-
ware according to manufacturer’s instructions (Roche Applied
Science). Gene expression was normalized to the housekeeping
gene L27. For primer sequences, see Table 1.
Extraction of Intracellular Metabolites—Extraction was
according to Ref. 24. Briefly, cells were cultivated in 12-well
plates and washed with 1 ml of 0.9% NaCl and quenched with
TABLE 1
Primer sequences used for quantitative PCR
Gene 5 to 3 sequence
L27_F ACATTGACGATGGCACCTC
L27_R GCTTGGCGATCTTCTTCTTG
Irg1_F GCAACATGATGCTCAAGTCTG
Irg1_R TGCTCCTCCGAATGATACCA
Tnfa_F GGTTCTGTCCCTTTCACTCAC
Tnfa_R TGCCTCTTCTGCCAGTTCC
iNos_F AGCCCTCACCTACTTCCTG
iNos_R CAATCTCTGCCTATCCGTCTC
Pdk1_F TGCAAAGTTGGTATATCCAAAGCC
Pdk1_R ACCCCGAAGCTCTCCTTGTA
Il1b_F TGCCACCTTTTGACAGTGATG
Il1b_R TGATGTGCTGCTGCGAGATT
Cpt1_F TGGCAGTCGACTCACCTTTC
Cpt1_R CAAACAGTTCCACCTGCTGC
Hif1a_F TGACGGCGACATGGTTTACA
Hif1a_R AATATGGCCCGTGCAGTGAA
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0.2 ml of 20 °C methanol. After adding an equal volume of
4 °C cold water, cells were collected with a cell scraper and
transferred to tubes containing 0.2 ml 20 °C chloroform.
The extracts were shaken at 1400 rpm for 20 min at 4 °C
(Thermomixer Eppendorf) and centrifuged at 16,000 g for
5 min at 4 °C. 0.2 ml of the upper aqueous phase was col-
lected in specific glass vials with micro inserts and evapo-
rated under vacuum at4 °C using a refrigerated CentriVap
Concentrator (Labconco).
Gas Chromatography-Mass Spectrometry—Metabolite deriv-
atization was performed using a Gerstel MPS. Dried polar
metabolites were dissolved in 15 l of 2% methoxyamine
hydrochloride in pyridine at 40 °C under shaking. After 60min,
an equal volume of MTBSTFA was added and held for 60 min at
40 °C. 1l of sample was injected into an SSL injector at 270 °C
in splitlessmode. GC/MS analysis was performed using an Agi-
lent 7890A GC equipped with a 30-m DB-35MS  5-m Dura-
guard capillary column.Heliumwas used as carrier gas at a flow
rate of 1.0 ml/min. The GC oven temperature was held at
100 °C for 2 min and increased to 300 °C at 10 °C/min. After 3
min, the temperature was increased to 325 °C. The GC was
connected to an Agilent 5975C inert XLMSD, operating under
electron ionization at 70 eV. TheMS source was held at 230 °C
and the quadrupole at 150 °C. TheMSwas operated in selected
ion monitoring. The total run time of one sample was 25.00
min. All GC/MS chromatograms were processed by using
Metabolite Detector software (25). MIDs were determined and
corrected for natural isotope abundance using Metabolite
Detector software.
Measurement of glucose and lactate intensities was per-
formed by derivatization with an equal volume of MSTFA
(instead ofMTBSTFA) and held for 30min at 40 °C under con-
tinuous shaking. A 1-l sample was injected into an SSL injec-
tor at 270 °C in split 10mode. GC oven temperature was held at
90 °C for 1 min and increased to 300 °C at 15 °C/min for 8 min
to 320 °C. The total run time of one sample was 24.3 min. For
absolute quantification of glucose and lactate, a dilution series
of a standardmixwas included in the sequence andmeasured in
triplicate. For normalization, we used [U-13C]glucose and
[U-13C]lactate as internal standards (in this case, medium sam-
ples contained only [12C]carbon sources).
Quantification of Amino Acids—Quantification of amino
acids was performed on an Agilent 1100 HPLC system
equipped with a Diode Array Detector. Separation was carried
out on a ZORBAX amino acid analysis column (150 4.6 mm,
5 m) with a preceding ZORBAX amino acid analysis guard
cartridge (Agilent Technologies, Santa Clara, CA) at 40 °C in
gradient mode (see Table 1). The eluents used were 40 mM
Na2HPO4 (pH 7.8, eluent A) and a mixture of acetonitrile,
methanol, and water (45:45:10, eluent B). 0.02% sodium azide
was added to eluent A to prevent microbial growth. Primary
amines were automatically derivatized with ortho-phthalalde-
hyde in borate buffer (0.4 N in water, pH 10.2) and diluted in
eluent A prior to injection. The resulting ortho-phthalaldehyde
derivatives were subsequently detected at 338 nm (10-nm
bandwidth; reference wavelength, 390 nm; 20-nm bandwidth).
Allmedium samples were diluted 1:1with the internal standard
L-2-aminobutyric acid (final concentration, 300 M) to correct
for deviations resulting from the derivatization process. Exter-
nal calibration standards as well as referencemediawith known
concentrations were measured with every run to determine
sample concentrations and ensure stability of the analysis. Gra-
dient profile: 1.9 min, 0% eluent B; 18.1 min, 57% eluent B; 18.6
min, 100% eluent B; 22.3 min, 100% eluent B; 23.2 min,0% elu-
ent B; 26 min, 0% eluent B.
Western Blot—For preparation of whole cell extract, 1 106
cells were harvested, washed with ice-cold 1 phosphate-buff-
ered saline (PBS) (Invitrogen/Life Technologies, Inc., Europe
BV Belgium), lysed in 1M-PER, mammalian protein extrac-
tion Reagent (Thermo Scientific, Belgium) completed with 1
protease inhibitor mixture (Complete, Roche Applied Sci-
ence, Luxembourg), and further processed according to the
manufacturer’s instructions. A nanodrop analyzer was used to
measure the protein concentration. Proteins were separated by
size using SDS-PAGE (12%) and transferred to an Immo-
bilon-FL PVDF membrane (Merck Millipore) using the Mini-
PROTEAN Tetra Cell and PowerPac Basic Power Supply (Bio-
Rad, Belgium). The membrane was blocked in 5% nonfat milk
powder in PBS/Tween for 1 h at room temperature or overnight
at 4 °C. The antibodies used were as follows: anti-IRG1 (Sigma,
hpa040143) 1:750 in PBS-T 5% nonfat milk powder for 1 h at
room temperature; anti-PDK1 (rabbit) (Enzo catalog no. ADI-
KAP-PK112) 1:3000 in TBST 5% BSA, overnight at 4 °C; anti-
PDH-E1 (rabbit) (Ser(P)-232) (Millipore catalog no. AP1063)
1:1000 in TBST 5% BSA, overnight at 4 °C; anti-PDH-E1 (rab-
bit) (Ser(P)-300) (Millipore catalog no. ABS194) 1:1000 in
TBST 5% BSA, overnight at 4 °C; anti-PDH-E1 (rabbit)
(Ser(P)-293) (Millipore catalog no. ABS204) 1:10,000 in TBST
5% BSA, overnight at 4 °C; anti--tubulin (mouse) 1:5000 in
TBST 5% BSA, overnight at 4 °C; anti-rabbit HRP 1:5000 in
TBST 5% skim milk (Cell Signaling); anti-mouse HRP 1:5000
in TBST 5% skim milk (Cell Signaling). Visualization was done
using the ECL Plus Western blotting detection system Kit (GE
Healthcare, Netherlands). Signals were detected using the LI-
COR system. Quantification of band intensities was done using
the ImageStudioLight Software package.
Cell Imaging andDataAnalysis—Phase contrast imageswere
acquired using a10 objective on a Nikon Ti Eclipse inverted
microscope with motorized stage (Nikon Corp., Tokyo, Japan)
enclosed in a bench top incubator. Automatic microscope con-
trol, stage programming, and acquisition were done using the
OptoMorph version of MetaMorph 7.8.10 (Cairn Research,
Kent, UK). LPS-treated anduntreatedRAW264.7 cells growing
in 12-well Nunc plates (50,000 cells per well) were imaged in
positive phase contrast. Nine adjacent but non-overlapping
images were automatically acquired in a 3 3 grid around the
center of each well. The entire imaging experiment was per-
formed twice, resulting in 36 images acquired per condition.
One out-of-focus image and five containing cell aggregates
were excluded from further analysis. Surfaces of strongly
attached cells were estimated by thresholding in ImageJ 2.0.0-
rc-31/1.49v using the IJ_IsoData algorithm. Congruence of
thresholding results with cell contours was verified by visual
inspection. Cell sizes were calculated using the particle analysis
tool, allowing for areas from 50 to 5000 pixels and excluding
particles on the image edges. Average sizes were reported for
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each image. Halo and contrast effects resulting from the phase-
contrast imaging were analyzed to discriminate between
strongly and weakly attached cells. Strongly attached cells
appeared darker than background with a weak halo, although
weakly attached cells appeared brighter than backgroundwith a
strong halo. Histograms of pixel intensities of the entire field of
viewwere analyzed using custom software written inMATLAB
R2014b. First, the intensity peak corresponding to the back-
ground signal (cell-free surface) was identified and approxi-
mated by aGaussian function. The approximated peakwas sub-
tracted from the original histogram, and the weighted sum of
intensities below (dark) and above (bright) the background
peak was calculated, respectively. The ratio of dark-to-bright
values informs on the ratio of strongly-to-weakly attached cells.
Renormalization of this ratio by values obtained for individual
strongly and weakly attached cells yielded an adhesion index
with values from 0 (no cells attached) to 1 (all cells attached).
Statistical Analyses—To analyze a significant difference
between two groups, unpaired Welch’s t test was applied. p
values are indicated in each panel (*, p 0.01; or as indicated)
and was considered as significantly different with a p value
0.05. The number of independent replicates is indicated in
the figure legends. Each experiment was at least performed
three times with cells of a different passage. Each individual
experiment consisted of three wells per condition.
Results
M(LPS) Macrophages Show a Distinct Metabolite Sig-
nature—The macrophage environment is likely to be hypoxic,
as these cells infiltrate hypoxic tissues such as tumors, wounded
regions, or sites of inflammation. At the site of inflammation,
different oxygen tensions result from increased oxygen demand
as well as swelling or vascular damage (26, 27). To physiologi-
cally meet these challenging conditions, macrophages are well
adapted to hypoxia by their ability to adjust their gene expres-
sion profile and increase glycolytic activity (28). To study
whether the activation of macrophages reprograms metabo-
lism to a hypoxia-like phenotype, we cultivated the murine
macrophage cell line RAW264.7 under normoxia (21%oxygen)
and hypoxia (2%) and activated it with LPS for 6 h.We selected
this timepoint, because it reflects the highest expression level of
irg1/Cad, the enzyme that catalyzes the synthesis of the antimi-
crobial metabolite itaconate (6).
We analyzed intracellularmetabolite levels and revealed that
LPS stimulation resulted in increased levels of itaconate, succi-
nate, and lactate under normoxia (Fig. 1, A–C). These three
metabolites are marker metabolites for M(LPS) activation,
demonstrating a clear pro-inflammatory activation (6, 10, 29,
30). Moreover, we observed increased levels of the TCA cycle
associated metabolites malate and glutamate, whereas aspar-
tate and citrate levels remained unchanged (Fig. 1, D–G). The
amino acids glycine, serine, and alaninewere also elevated upon
LPS stimulation (Fig. 1, H–J). Compared with normoxia, LPS
treatment of hypoxic cells was unable to induce similar itacon-
ate and succinate levels (Fig. 1, A and B). As expected, lactate
levels further increased upon hypoxia as a result of reduced
respiration and concomitant increased glycolysis, known as the
Pasteur Effect. Non-activated hypoxic cells exhibited decreased
levels of the TCA cycle associated metabolites malate, aspar-
tate, glutamate, and citrate. However, LPS stimulation under
hypoxia resulted in increased levels of malate, aspartate, and
glutamate but not citrate (Fig. 1,D–G). The amino acids glycine
and serine were unchanged between hypoxia and normoxia.
Upon LPS activation of hypoxic cells, serine and alanine were
increased (Fig. 1,H–J). Interestingly, we also observed a trend of
increased levels of the branched chain amino acids isoleucine,
leucine, and valine under hypoxia for both non-stimulated and
LPS stimulated conditions (Fig. 1K; p value0.05).
We concluded from these results that LPS affects the metab-
olite profile of macrophages independent of the oxygen supply
and that this profile is clearly different from a pure hypoxic
profile. Intriguingly, we observed decreased abundance of the
antimicrobial metabolite itaconate under oxygen-limiting
conditions, which could have direct effects on the immune
response in tissues with low oxygen tension.
Decreased Itaconate Levels under Hypoxia Are Not the Result
of Decreased Irg1 Expression or Lower IRG1/CAD Protein
Abundance—To investigate whether the reduced levels of itac-
onate are caused by transcriptional repression, post-transcrip-
tional regulation, or post-translational regulation, we analyzed
gene expression and protein levels of the catalyzing enzyme
IRG1/CAD. We found that hypoxia does not significantly
reduce the gene expression level or the protein abundance of
IRG1/CAD, indicating a regulation at the post-translational
level or a result of decreased substrate concentrations (Fig. 2,A
andB). To confirmLPS activation ofmacrophages, we analyzed
gene expression of the pro-inflammatory marker genes Tnf,
iNos, and Il1 (Fig. 2, C–E). We found clear up-regulation
under both oxygen conditions when the cells were treated with
LPS. However, hypoxia resulted in a 20% reduction of Tnf
expression and3-fold higher expression of Il1 and iNos.
It has been reported in several recent publications that
HIF1 gets stabilized in M(LPS) macrophages compared with
resting macrophages (10, 21, 29, 31). Therefore, we also ana-
lyzed gene expression of Hif1, and we observed increased
expression of Hif1 in response to LPS treatment under
hypoxia (Fig. 2F), indicating thatHIF1 stabilization in hypoxic
M(LPS) macrophages can be a combined effect of increased
transcriptional expression and post-translational stabilization.
Under normoxia, no difference in Hif1 expression was
detected.
Based on these results, we conclude that the reduction of
itaconate under hypoxia is mostly a result of post-translational
effects such as alteredmetabolic fluxes, either due to an enzyme
modification that regulates its activity or by changing substrate
concentrations. To that end, we were interested to compare
cellular flux changes with LPS activation between hypoxia and
normoxia.
LPSActivation Promotes PyruvateOxidation via PDHbyPre-
venting Pdk1 Expression—Tomonitor intracellular glucose-de-
rived fluxes in M(LPS) macrophages, we incubated RAW 264
cells for 24 h in the presence of uniformly labeled [U-13C]glu-
cose to reach isotopic steady state conditions. During these
24 h, labeled glucose is metabolized within the cells and is
incorporated in cellularmetabolites downstreamof glucose. To
obtain the specific labeling patterns, intracellular metabolites
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were extracted and analyzed with gas chromatography/mass
spectrometry to determineMIDs (corrected for natural isotope
abundance), which reflect relative metabolic fluxes (Fig. 3A for
atom transitions) (22, 23).
As expected, stable isotope labeling revealed that hypoxia
resulted in decreased pyruvate flux through PDH, illustrated by
decreased M2 citrate isotopologues (Fig. 3B). Concomitant
with decreasing citrate M2 isotopologues under hypoxia, we
observed increased abundance of citrate M0 isotopologues,
representing citrate molecules derived from carbon sources
other than glucose (Fig. 3B). This decrease is a result of HIF1
stabilization and Pdk1 induction, where the PDK1 protein
FIGURE 1.Metabolome analysis of RAW 264macrophages in the context of LPS activation and hypoxia. Analysis of intracellular metabolite abundance
in RAW 264 cells, cultivated under normoxia (21%O2) and hypoxia (2%O2), unstimulated or stimulated with LPS. Metabolites were extracted and analyzed by
GC/MS. Signal intensities (peak area) are normalized to unstimulated cells under normoxia. Cells were treatedwith 10 ng/ml LPS for 6 h. Error bars indicate S.E.
(Welsh’s t test; *, p 0.01, n 3 wells). n.s., not statistically significant. One representative experiment with three individual wells per condition is presented.
The experiment was performed three times.
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inhibits PDH by phosphorylation (32, 33). Decreased pyruvate
oxidation under hypoxia promotes decreasing downstream
substrate levels, most probably resulting in the observed
decreased itaconate levels (Fig. 1A). However, HIF1 has also
been shown to be stabilized inM(LPS)macrophages under nor-
moxic conditions (10, 29). Therefore, it is speculated that pyru-
vate oxidation through PDH is decreased in M(LPS) macro-
phages, a similar phenotype to cancer cells with stabilized
HIF1 (3, 34). However, we did not observe decreased citrate
M2 isotopologues in normoxic M(LPS) macrophages, raising
the question whether PDH is inhibited under these conditions.
To analyze regulation of Pdk1 inmore detail, we investigated
geneexpressionandprotein abundanceofPDK1andphosphor-
ylation status of PDH (Fig. 3, C–H). In line with current knowl-
edge, hypoxia-mediated stabilization of HIF1 resulted in
increased Pdk1 expression (Fig. 3C), which complements our
observation of hypoxia-dependent, decreased glucose flux to
citrate (Fig. 3B). Intriguingly, we observed that LPS stimulation
resulted in a drastic reduction of Pdk1 expression at both nor-
moxia and hypoxia, indicating that PDK1-mediated inhibition
of PDH is reduced inM(LPS)macrophages (Fig. 3C).Moreover,
analysis of PDK1 protein abundance revealed similar PDK1 lev-
els in non-activated orM(LPS)-activatedmacrophages. Only in
hypoxia did we observe a significant increase of PDK1 abun-
dance (Fig. 3,D and E). To investigate whether the low levels of
PDK1 have an effect on PDH, we analyzed phosphorylation of
PDH on serine 232, 293, and 300 (Fig. 3,D and F–H). Phospho-
rylation of these residues has been reported to result in an inhi-
bition of PDH activity (33). As expected, hypoxia resulted in
increased phosphorylation of the three analyzed serine resi-
dues (not significant in case of Ser-300). However, and in line
with low PDK1 levels in normoxic M(LPS) macrophages,
LPS activation did not increase phosphorylation levels of
Ser-232 and -293. Regarding Ser-300, we observed signifi-
cantly increased phosphorylation upon LPS activation,
although there was no further significantly increased phos-
phorylation due to hypoxia. Whether Ser-300 specifically
has a unique function in the context of LPS activation in
macrophages remains to be determined in future work. Our
results from this part of the study reveal that HIF1-mediated
induction of Pdk1 can be attenuated by LPS stimulation,
which is in line with increased citrate M2 isotopologues
upon LPS activation (Fig. 3B).
In line with the results of PDK1 abundance and PDH phos-
phorylation status, our stable isotope analysis revealed that LPS
stimulation did not result in a decreased relative pyruvate oxi-
dation, both under hypoxia and normoxia (Fig. 3, B and I), indi-
cating that HIF1 did not mediate PDH inhibition upon LPS
stimulation. We observed increased citrate M2 isotopologue
levels, reflecting even higher relative pyruvate flux through
PDH (Fig. 3B). To normalize for upstreamchanges in glycolysis,
we determined the ratio of M2 citrate/M3 pyruvate and
observed an increase upon LPS stimulation, indicating
increased pyruvate flux through PDH in M(LPS) macrophages
(Fig. 3I). As a reduction of citrate M2 isotopologues was only
observed under hypoxic conditions, HIF1-mediated inhibition
of PDH depended only on the oxygen tension and not on the
macrophage activation status. Indeed, LPS activation can even
partially recover the HIF1- mediated PDH inhibition under
hypoxia (Fig. 3, B and I).
The M2 abundance of KG and malate was significantly
lower than in citrate (Fig. 3, J and K), suggesting that large
amounts of citrate, cis-aconitate, or isocitrate are either used
for pathways other than the oxidative TCA cycle or that other
carbon sources (e.g. glutamine) increase their contribution to
KG and malate. Stimulation with LPS as well as hypoxia fur-
ther decreased glucose contribution to KG andmalate, as can
be seen by a decreasing abundance of KG and malate M2
isotopologues (Fig. 3, J and K).
Next, we analyzed glucose uptake from the medium and cel-
lular lactate release, to evaluate whether M(LPS) macrophages
increase their glycolytic rate. Under normoxia, LPS-stimulated
macrophages increased glucose uptake and lactate release, and
under hypoxia, glucose uptake and lactate release were exceed-
ing the rate of M(LPS) macrophages under normoxia (Fig. 3L).
This effect was further enhancedwhen hypoxic cells were addi-
tionally stimulated with LPS (Fig. 3L). Under normoxia, the
lactate to glucose ratio was increased from 1.2 to 1.6 upon LPS
stimulation, indicating increased activity of lactate dehydroge-
nase, which is in line with the Warburg-like phenotype of
M(LPS) macrophages (3). However, 20% of the overall glucose
carbon pool is still available for othermetabolic pathways, indi-
cating that M(LPS) macrophages still contain sufficient pyru-
vate to maintain oxidation through PDH.
It has been shown before that STAT3-specific signaling can
inhibit PDHand thus block pyruvate oxidation through PDH in
primary fibroblasts and cancer cell lines (35). Therefore, we
investigated whether, and in contrast to LPS treatment, a
STAT3-dependent activation with the cytokine INF might
inhibit PDH. To this end, we treated the cells with INF or LPS
and analyzed the isotope enrichment in citrate. We did not
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FIGURE 2. Expression analysis of pro-inflammatory associated genes. A,
relative gene expression of Irg1. B, Western blot against IRG1/CAD, the pro-
tein that catalyzes the conversion of cis-aconitate to itaconate (no significant
difference (data not shown)). C–F, relative gene expression of Tnf, iNos, Il1,
and Hif1, normalized to normoxia control (LPS). Error bars indicate S.E.
(Welsh’s t test, *, p 0.01, n 3). Gene expression data represents the mean
over three independent experiments.
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observe a difference between LPS and INF treatment (Fig.
3M). In both cases, M2 citrate was significantly increased com-
pared with untreated controls. In line with LPS activation, we
also observed decreased expression of Pdk1 inM(INF)macro-
phages (Fig. 3N), indicating no inhibition of pyruvate oxidation
in M(INF) macrophages. In conclusion, sustained pyruvate
flux through PDH and its regulation by PDK1 seems to be inde-
pendent of TLR4 signaling.
LPS Activation Increases Glutamine Uptake but Does Not
Induce Reductive Carboxylation of KG —It has been demon-
strated that hypoxic cells metabolize increased amounts of glu-
tamine via reverse IDH activity to generate citrate by reductive
FIGURE 3. PDH flux analysis inM(LPS)macrophages. A, schematic of atom transitions in central metabolism using [U-13C]glucose as a tracer for determina-
tion ofMIDs to infer relative intracellular fluxes. 13C-carbons are in gray and 12C in black. The dotted line indicates endof one route.Aco, aconitase; Idh, isocitrate
dehydrogenase; Akgdh, KG dehydrogenase; OA, oxaloacetate. B, MID of citrate. M0 to M6 indicates the different mass isotopologues. C, gene expression
analysis of Pdk1. D–H, Western blot analysis of PDK1 and PDH phosphorylation on Ser-232, -293, and -300. -Tubulin serves as loading control. D shows one
representative Western blot of three independent experiments. -Tub, -tubulin. E–H shows quantification of three independent experiments. I, ratio of M2
citrate/M3 pyruvate indicating relative pyruvate oxidation through PDH. J and K, MID of KG and malate. L, absolute quantification of glucose uptake and
lactate release, and ratio of lactate release/glucose uptake to infer fractional lactate formation per glucose.M, activation of RAW264 cells with 10 ng/ml LPS or
50 ng/ml interferon- (INF) in medium with [U-13C]glucose. Presented are citrate M2 isotopologues as a readout for relative glucose flux through PDH. N,
relative gene expression of Pdk1 normalized to normoxia control (Ctrl) (LPS). Error bars indicate S.E. (Welsh’s t test, *, p 0.01, n 3). One representative
experiment with three individual wells per condition is presented. Each experiment was performed at least three times, except for C. Presented is themean	
S.E. over three independent experiments. (Welsh’s t test, *, p 0.01, n 3).
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carboxylation of KG (12–15). This pathway fuels the citrate
pool to provide sufficient acetyl-CoA for lipogenesis. Because
M(LPS) activation also results in a stabilization of HIF1 (10,
19, 21, 29) and increased glycolytic flux (see Fig. 3, I and L), we
investigated whether these cells exhibit increased reductive
carboxylation of KG. To that end, we applied a uniformly
labeled [U-13C]glutamine tracer and determinedMIDs of TCA
cycle metabolites (Fig. 4A for atom transitions).
As expected, under hypoxic conditions we observed a drop
in oxidative TCA cycle activity and a strong induction of
reductive carboxylation, inferred from decreased citrate M4
and increased citrate M5 isotopologues (Fig. 4, B–D). This
pattern was also reflected by decreasing malate M4 (oxidative
route) and increasing malate M3 (reductive route) isotopo-
logues (Fig. 4E). However, when cells were stimulated with LPS
at normoxic conditions, reductive carboxylation of KG was
not increased (Fig. 4D).
Using the glutamine tracer, we observed that the major
carbon source of KG was glutamine and that upon LPS
stimulation and under hypoxia the abundance of M5 isoto-
pologues increased, suggesting an increase in glutamine
influx and a decreasing glucose contribution (Fig. 4F).
Although hypoxia results in increased usage of KG for
reductive carboxylation and decreased KG oxidation (14,
15), we did not find evidence that LPS stimulation under
normoxia compromises the relative glutamine carbon flux
through KG dehydrogenase, indicated by a similar enrich-
ment pattern of KG and malate.
To analyze glutamine metabolism in more detail, we quanti-
fied glutamine uptake from the medium and glutamate release
from the cells. Although hypoxia did not result in increased
glutamine uptake, we observed a strong increase of glutamine
uptake upon LPS stimulation under both oxygen levels (Fig.
4G). Because glutamate is produced from glutamine and can be
FIGURE 4. Contribution of glutamine to central metabolism in M(LPS) macrophages. A, schematic of atom transitions in central metabolism using
[U-13C]glutamineas a tracer. 13C-carbonsare ingray, 12C inblack. Citratemoleculesderived fromreductive carboxylationofKGareM5 isotopologues,whereas
citrate molecules from the oxidative route of the TCA cycle are M4 isotopologues. The dotted line indicates end of one route. Aco, aconitase; Idh, isocitrate
dehydrogenase; Akgdh, KG dehydrogenase; Acly, ATP-dependent citrate lyase; FA, fatty acid. B,MID of citrate.M0 toM6 indicates the different mass isotopo-
logues. C and D, determination of oxidative TCA cycle activity: ratio of M4 citrate/M5 glutamate and ratio of M5 citrate/M5 glutamate indicating relative
reductive Idh flux. E and F, MID of malate and KG. G–I, absolute quantification of glutamine uptake, glutamate release, and uptake of the branched chain
amino acids (valine, isoleucine, and leucine). J, carbon contribution (%) of glucose, glutamine, and other carbon sources to citrate,KG,malate, and itaconate.
Carbon contributions are based onMIDs from [U-13C]glucose labeling (Fig. 3) and [U-13C]glutamine labeling. Carbon contribution to itaconate under non-LPS
conditions should not be considered because itaconate levels are negligibly low under these non-stimulated conditions (Fig. 1A). Error bars indicate S.E.
(Welsh’s t test, *,p0.01,n3).One representative experimentwith three individualwells per condition is presented. Eachexperimentwasperformedat least
three times.
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released from the cell, we quantified glutamate release to infer
glutamine anaplerosis to the TCA cycle. Although we observed
increased glutamate release upon LPS stimulation, the net
uptake of glutamine in LPS-stimulated cells was still higher
compared with untreated controls (control 12.84 versus LPS
20.5 fmol/cell/h) (Fig. 4,G andH). As indicated by the intracel-
lular metabolite levels (Fig. 1K), we also observed a trend of
increased consumption of branched chain amino acids from
the medium upon LPS stimulation (Fig. 4I). However, these
differences were only significant in the case of leucine. Never-
theless, we believe that the influence of branched chain amino
acids on central metabolism is higher upon LPS activation.
To better understand the impact of the different carbon
sources to the TCA cycle metabolites, we calculated the carbon
contributions of glucose and glutamine to citrate, KG,malate,
and itaconate (Fig. 4J).We observed a small decrease in glucose
contribution to citrate upon LPS activation. However, based on
the [U-13C]glucose-derived MIDs, this decrease mostly origi-
nated from decreased citrate cycling through the oxidative
TCA cycle (compareM3,M4, andM5 isotopologues in Fig. 3B)
or increased glutamine influx, rather than decreased pyruvate
flux through PDH (M2 isotopologue). Hypoxia resulted in a
stronger reduction of glucose contribution to citrate, whichwas
a result of PDH inhibition. Along with the decrease in glucose
contribution, the glutamine contribution to citrate was
increased uponLPS, especially under hypoxia, where glutamine
is the major carbon source of citrate. For KG and malate, the
glucose contributionwas significantly lower comparedwith cit-
rate, indicating that major parts of the citrate pool are not used
for further oxidation through the oxidative TCA cycle, but for
anabolic processes such as lipid synthesis or itaconate synthe-
sis. In line with this observation, we observed higher glucose
contribution to itaconate, compared with KG and malate.
Moreover, upon LPS stimulation, and especially with hypoxia,
we observed an increase of other carbon sources than glucose
or glutamine, which is in line with potentially increased uptake
of branched chain amino acids (Figs. 1K and 4I).
In summary, we observed that glutamine is themajor carbon
source of the TCA cycle in M(LPS) macrophages and is the
main substrate for TCA oxidation. Glucose carbon still enters
the cycle at citrate; however, significant amounts of the citrate
pool are not further oxidized through IDH but are distributed
to othermetabolic pathways.Glutamine serves to replenish this
lack of carbon by increased uptake upon LPS stimulation.
LPS Causes an Increase in Lipogenesis in RAW 264 Cells—
Besides transcriptional and metabolic adaptations to inflam-
mation, it has been described that pro-inflammatory macro-
phages also undergo morphological changes from small and
spherical to a larger andmore attached form (Fig. 5A). To dem-
onstrate the surface enlargement during LPS activation, we
monitored cell size by using two orthogonal microscopy
approaches (Fig. 5B), demonstrating an increase in cell surface
and thus pointing to an increased demand on lipids needed for
membrane formation. Furthermore, M(LPS) macrophages
increase intracellular and extracellular vesicle formation during
pathogen defense (36). Therefore, M(LPS) macrophages have
an increased demand for lipids, needed for morphological
changes and vesicle formation. To meet this demand, LPS-
activated macrophages need to prioritize their metabolism
toward lipogenesis and to repress lipid oxidation. In line with
this necessary metabolic shift, we observed decreased expres-
sion of carnitine palmitoyltransferase 1 (Cpt1), the gene of the
protein that imports palmitate into themitochondrion for lipid
oxidation and subsequent energy production (Fig. 5C). A
reduction of -oxidation is in line with reports of decreased
oxidative metabolism in M(LPS) macrophages (37) and sup-
ports the observed increased demand for lipids. High activity of
lipid degradation, simultaneously to their synthesis, would be a
waste of energy.
To generate lipids from central metabolism, cells export
mitochondrial citrate into the cytoplasmwhere it is hydrolyzed
via ATP-dependent citrate lyase to provide acetyl-coA for lipo-
genesis. In this preferred case, citrate utilization is for anabolic
processes rather than the TCA cycle. To analyze the contribu-
tion of glucose and glutamine to palmitate, an end point of fatty
acid synthesis, we determined theMIDs of and the carbon con-
tributions to palmitate after both the application of [U-13C]g-
lucose and [U-13C]glutamine as tracers in independent experi-
ments (Fig. 5, D and E). We observed that under normoxia,
nearly 50% of the carbon in palmitate originated from glucose.
Under hypoxic conditions, a shift in isotopologues indicated
that the glucose contribution was reduced while glutamine
contributionwas increased, suggesting increased reductive car-
boxylation under hypoxia, but not as a result of LPS stimula-
tion. Although dependent on the pool sizes of the metabolites,
increased production of itaconate and palmitate from glucose-
derived citrate in M(LPS) macrophages indicates reduced cit-
rate oxidation through the TCA cycle inM(LPS) macrophages.
Pyruvate Flux to Citrate Is Important for LPS Activation in
RAW264Cells—To investigate the importance of the PDH flux
in M(LPS) macrophages, we used a pharmacological approach
to impair pyruvate oxidation through PDH by inhibiting the
pyruvate transporter with the specific inhibitor UK5099 (38).
Using this inhibitor togetherwith the [U-13C]glucose tracer, we
observed a significant decrease of citrate M2 isotopologues,
indicating reduced relative pyruvate oxidation through PDH
(Fig. 6A). Addition of LPS to UK509-treated cells could not
restore the abundance ofM2 citrate, because pyruvate supply is
impaired by the inhibition of the transporter. Analysis of intra-
cellular metabolite levels revealed that inhibition of pyruvate
transport into the mitochondrion resulted in decreased
amounts of citrate, originating from reduced substrate levels
for citrate synthase (Fig. 6B). Intriguingly, we also observed
decreased amounts of the inflammatory marker metabolites
itaconate and succinate under pro-inflammatory conditions
(Fig. 6,C andD). Decreased amounts of itaconate and succinate
could either result from decreased glucose flux into the TCA
cycle, similar to hypoxia, or from a metabolic alteration in
M(LPS) macrophages. To analyze these hypotheses, we inves-
tigated the gene expression profiles of pro-inflammatory
marker genes (Fig. 6, E–H). Although Il1b gene expression was
not significantly decreased (Fig. 6E), we observed that UK5099
treatment of LPS-stimulated macrophages resulted in de-
creased expression levels of iNos, Irg1, and Tnf (Fig. 6, F–H),
indicating that in this case and in contrast to hypoxia, the
observed decreased itaconate level roots back to decreased Irg1
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levels. Moreover, application of UK5099 to LPS-stimulated
cells resulted in increased Cpt1 expression levels, similar to
untreated controls, although Pdk1 expression was still reduced,
due to the fact that pyruvate import into the mitochondrion
was inhibited and thus regulation of PDH not necessary (Fig. 6,
I and J). To exclude a potential toxic effect of UK5099 on RAW
264 cells, we performed a viability assay and did not observe
significant changes in viability (Fig. 6K). To further exclude the
possibility of timing effects due to simultaneous addition of LPS
and UK5099, we repeated the experiments with a modified
experimental setup, where we first activated the cells with LPS
for 3 h and then added UK5099 for an additional 6 h to investi-
gate whether this intervention can repress the pro-inflamma-
tory profile of M(LPS) macrophages (Fig. 6L). Following this
approach, we also observed significantly decreased citrate, itac-
onate, and succinate levels (Fig. 6, M–O) and significantly
decreased expression of Tnf, iNos, Irg1, and Il1b (Fig. 6, P–S).
These results indicate that inhibition of pyruvate import into
the mitochondrion can indeed suppress pro-inflammatory
responses in M(LPS) macrophages. Finally, we investigated
the effect of carbon contribution to palmitate for these con-
ditions, using [U-13C]glucose as a tracer, in combination
with UK5099. In line with decreased citrate, itaconate, and
succinate levels upon UK5099 treatment, we also observed
lower carbon contribution from glucose to palmitate (Fig. 6,
T and U).
In summary, these data demonstrate that the pyruvate flux
through PDH is important for LPS activation in macrophages.
Apparently, altered metabolic fluxes or changes in metabolite
concentrations enable a feedback mechanism to regulate cellu-
lar gene expression profiles. Hence, metabolic intervention can
be used to attenuate activation of M(LPS) macrophages.
Discussion
M(LPS) macrophages require extensive reprogramming to
enable host defense mechanisms. Although M(IL4) macro-
phages increase oxidative metabolism optimized for tissue
repair (39), M(LPS) macrophages develop aWarburg-like phe-
notype by increasing glycolysis and lactate release (3). It has
been demonstrated that pro-inflammatory activation results
in the stabilization of HIF1, HIF1 complex formation with
monomeric or dimeric PKM2, along with an increased
expression of M(LPS)-associated cytokines and bacterial
defense mechanisms (29). While under hypoxia HIF1 not
only increases the glycolytic activity but also represses PDH
activity through PDK1, it was speculated that glucose flux
FIGURE 5. Morphological changes upon LPS activation require sustained lipogenesis in macrophages. A, microscopy (bright field image) of RAW
macrophages unstimulated or stimulated with 10 ng/ml LPS for 6 h. White bar indicates 100 m. B, mean average of cell size (pixels) (left) and analysis of
adhesion index (right) of LPS-stimulated and -non-stimulated cells obtained from bright field microscopy. Analysis demonstrates morphological adaption of
macrophages during LPS activation. For further details regarding the analysis approach, see under “Experimental Procedures.” C, relative gene expression
of carnitine palmitoyl transferase1 (Cpt1) normalized to normoxia control (Ctrl) (LPS), indicating inhibition of-oxidation upon LPS stimulation.D and E,MID
of palmitate using [U-13C]glucose (D) and [U-13C]glutamine (E) as a tracer. Contribution of each carbon source is depicted in the top right corner of each panel.
Error bars indicate S.E. (Welsh’s t test, *, p 0.01,n 3). One representative experimentwith three individualwells per condition is presented. Each experiment
was performed at least three times, except for C. Presented is the mean	 S.E. over three independent experiments. (Welsh’s t test, *, p 0.01, n 3).
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through PDH is also repressed in M(LPS) macrophages (3,
40). However, this would diminish the carbon supply neces-
sary for lipogenesis and synthesis of the antimicrobial
metabolite itaconate.
In this work, we demonstrate that the PDH flux plays an
important role in maintaining full LPS-specific activation and
that pharmacological intervention to prevent pyruvate oxida-
tion represses pro-inflammatory activation. Although an active
PDH flux has been speculated for early macrophage differenti-
ation and for dendritic cells before (3, 41), our results demon-
strate that pyruvate oxidation through PDH is fully active in
mature M(LPS) macrophages and that this is even essential to
sustain LPS activation. Moreover, we discovered that this pro-
cess is facilitated by repressed Pdk1 expression and no increase
in PDK1 protein abundance, as well as significantly lower phos-
phorylation of PDH compared with hypoxic conditions, illus-
trating that M(LPS) macrophages sustain an active pyruvate
flux through PDH.
Under hypoxia, HIF1 decreases pyruvate oxidation through
PDH by inducing Pdk1 (32). In contrast to hypoxia, we demon-
strated that although glycolysis is increased and oxygen con-
sumption is decreased (29) in M(LPS) macrophages, pyruvate
oxidation through PDH is not inhibited, because PDK1 abun-
dance is not increased. Active PDH facilitates a stable citrate
pool, which in turn prevents increased reductive carboxylation
of KG by thermodynamic means (16). M(LPS) macrophages
have been shown to increase their expression of the mitochon-
drial citrate carrier to transport citrate from themitochondrion
into the cytosol (42), and we have shown that M(LPS) macro-
phages have an increased lipid demand. Because we demon-
strated that reductive carboxylation of KG is not increased,
the high demand of citrate has to bemostly supplied by glucose
through PDH.
WhenPDH flux is repressed, citrate is increasingly generated
by reductive carboxylation of KG, which is mostly derived
from glutamine (43). An increased demand on glutamine in
M(LPS) macrophages has been reported before (44). Here, we
describe in detail how this glutamine is utilized. In M(LPS)
macrophagesmost glutamine is preferentially used for glutami-
nolysis rather than for reductive carboxylation of KG. Besides
ATP-dependent citrate lyase-derived oxaloacetate, increased
glutaminolysis additionally provides oxaloacetate, which is
needed as an acceptor for pyruvate-derived acetyl-CoA and the
synthesis of citrate. It also replenishes the TCA cycle to com-
pensate for increased lipogenesis and the loss of carbon that is
used for the synthesis of itaconate.
It is known that LPS activation results in decreased oxygen
consumption, which suggests that TCA cycle activity is
decreased and would provide less NADH to be oxidized via the
ETC (29, 45, 46). However, we found evidence that the oxida-
tive TCA cycle is still running and is fueled by increased
amounts of glutamine. TCA cycle-derived NADH can be used
for alternative routes and would consequently not be oxidized
via the ETC and thus would also result in reduced oxygen con-
sumption rates. Mitochondrially derived NADH can alterna-
tively be converted to NADPH by nicotinamide nucleotide
transhydrogenase (17, 47), which is utilized by M(LPS) macro-
phages for ROS production via NADPH oxidase, needed for
antibacterial activity (48), or transferred to the cytoplasm (49)
where it is needed for lipogenesis. Therefore, it is possible that
M(LPS) macrophages use increased amounts of TCA cycle-
derived NADH for the generation of NADPH rather than oxi-
dizing it via the ETC, which fits to the reported decreased oxy-
gen consumption rates (6, 45, 46). Additionally, the ETC can be
directly inhibited by nitrosylation (50, 51) promoted by increased
expressionof iNos,whichwehaveshowntobe increaseduponLPS
stimulation.Therefore,decreasedoxygenconsumption inM(LPS)
macrophages due to decreased ETC activity is reasonable, but a
decreased ETC activity does not necessarily have to result in
decreased oxidative TCA cycle activity.
Although we could demonstrate that PDH activity is impor-
tant in M(LPS) macrophages, the mechanism of how Pdk1
repression is facilitated despite the presence of HIF1 needs
additional research. One possibility would be a weaker stabili-
zation because HIF1 is not as abundant as in hypoxic cells.
However, in this case, we would still expect a similar mode of
action and therefore a moderate induction of Pdk1. LPS activa-
tion exhibits distinct regulatory modules (2), and we conclude
that these specific networks overlap with the classical HIF1 signa-
ture tomediate LPS-specific activation. Becausewe demonstrated
thatM(LPS)macrophagesdependonthePDHflux to inducecyto-
kineexpressionandsynthesisof itaconate, it appears that a specific
HIF1-induced upstream regulator exists which specifically pre-
vents Pdk1 expression. In this way, increased glucose uptake and
lactate release can still be facilitated byHIF1,whereas PDK1 activ-
ity is prevented by an additional regulator. Overall, this points
toward a context-dependent HIF1 response.
With the hypoxia model, we demonstrated that the
decreasedpyruvate flux throughPDHresults indecreased levelsof
the antimicrobial metabolite itaconate as well as decreased levels
of succinate.However, geneexpressionof Irg1wasunchanged.We
conclude that, under hypoxia, decreased metabolite levels are a
FIGURE 6. Inhibition of pyruvate transport into mitochondria suppresses pro-inflammatory responses in M(LPS) macrophages. A, application of
the specific pyruvate transport inhibitor UK5099 to inhibit flux through PDH. Cells were treatedwith 100MUK5099 for 6 hwith or without 10 ng/ml LPS
at normoxia. Prior to treatment start, cells were cultivated for 24 h in [U-13C]glucose. Presented are citrate M2 isotopologues as a readout for relative
glucose flux through PDH. B–D, intracellular metabolite levels of citrate, itaconate, and succinate upon LPS stimulation and after application of 100 M
UK5099. Metabolite levels were determined using GC/MS and normalized to cell number. E–J, relative gene expression of Il1, iNos, Irg1, Tnf, Cpt1, and
Pdk1 normalized to normoxia control (Ctrl) (LPS), upon LPS stimulation and after application of 100 M UK5099 for 6 h. K, viability assay to test a
potential effect of UK5099 on cell viability. Assay was performed using trypan blue, dead and live cells were counted. L, to validate the effect of UK5099
a modified experimental setup has additionally been performed. Cells were first activated with 10 ng/ml LPS for 3 h and then UK5099 was added to the
cells for additional 6 h. In total, LPS activation was 9 h in this case. Non-UK5099 treated and non-activated cells served as control. M–O, intracellular
metabolite levels for citrate, itaconate, and succinate (analysis as in B–D). P–S, relative gene expression analysis of Tnf, iNos, Irg1, and Il1. T and U,MID
of palmitate using [U-13C]glucose as a tracer. Experimental setup as in A. U, glucose contribution to palmitate, determined from T. Error bars indicate S.E.
(Welsh’s t test, *, p 0.01, n 3). One representative experiment with three individual wells per condition is presented. Each experiment was performed
at least three times.
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passive effect of decreased pyruvate oxidation and decreased oxi-
dative mitochondrial metabolism. This also illustrates that HIF1-
mediated inhibition of PDHwould be disadvantageous toM(LPS)
macrophagesandthatpartsof theTCAcycleare indeed important
for M(LPS) macrophages, e.g. for the synthesis of lipids and
itaconate.
By inhibiting the pyruvate import into the mitochondria
of M(LPS) macrophages, we observed decreased metabolite
levels of itaconate and succinate, similar to hypoxia. Intrigu-
ingly, in the case of transport inhibition, gene expressions of
Irg1, Tnf, and iNos were decreased as well. All of these
genes are hallmarks of LPS activation, indicating a general
impairment of activation in matured M(LPS) macrophages.
Based on our observations, we can now extend the existing
metabolic model of M(LPS) macrophages (Fig. 7). 1) We
confirmed the findings of increased glycolysis and increased
lactate release. 2) Furthermore, reductive carboxylation of
KG is not increased in M(LPS) macrophages, but instead
glutamine is still oxidized through KG dehydrogenase. 3)
Finally, pyruvate is still oxidized through PDH, which turned
out to be essential for full LPS activation. Our work revealed
an LPS-specific metabolic feature that is essential for activa-
tion and that might be approached by further studies in the
light of translational medicine to develop novel therapies
against inflammatory dysfunctions.
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Abstract
Background: Metabolism gained increasing interest for the understanding of
diseases and to pinpoint therapeutic intervention points. However, classical
metabolomics techniques only provide a very static view on metabolism.
Metabolic flux analysis methods, on the other hand, are highly targeted, requiring
detailed knowledge on metabolism beforehand and cannot account for
unanticipated reactions.
Results: We present a novel workflow to analyze non-targeted metabolome-wide
stable isotope labeling data to detect metabolic flux changes in a non-targeted
manner. Furthermore, we show how similarity-analysis of isotopic enrichment
patterns can be used for pathway contextualization of unidentified compounds.
We illustrate our approach with the analysis of changes in cellular metabolism of
human adenocarcinoma cells in response to decreased oxygen availability.
Starting without a priori knowledge, we detect metabolic flux changes, leading to
an increased glutamine contribution to acetyl-CoA production, reveal biosynthesis
of N-acetylaspartate by N-acetyltransferase 8-like (NAT8L) in lung cancer cells
and show that NAT8L silencing inhibits proliferation of A549, JHH-4, PH5CH8
and BEAS-2B cells.
Conclusion: Differential stable isotope labeling analysis provides qualitative
metabolic flux information in a non-targeted manner. Furthermore, similarity
analysis of enrichment patterns provides information on metabolically closely
related compounds. N-acetylaspartate and NAT8L are important players in cancer
cell metabolism, a context in which they have not received much attention yet.
Keywords: stable isotope labeling; metabolomics; non-targeted; flux analysis;
mass isotopomer distribution analysis; NTFD; cancer; NAT8L; N-acetylaspartate
Background
Over the last decades, cellular metabolism gained increasing interest to pinpoint
potential therapeutic intervention points to treat complex diseases. Metabolomics
research, analyzing changes in metabolite levels, deepened our understanding of
cellular metabolism, which led to the discovery of unanticipated metabolites [1] and
disease biomarkers [2, 3]. However, metabolite levels alone provide only a very static
view on metabolism. For a systems understanding of metabolism, the underlying
metabolic fluxes are much more important and informative because they provide a
much closer functional link to an observed phenotype [4]. Metabolic fluxes through
these pathways do not only depend on metabolite concentrations, but are modulated
by intricate regulatory mechanisms [5]. For that reason, they cannot be deduced
from metabolite levels alone.
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To that end metabolic flux analysis techniques such as flux balance analysis (FBA)
and 13C metabolic flux analysis (13C-MFA) have been developed. FBA employs
genome-scale metabolic networks [6] and aims to balance cellular influxes and ef-
fluxes with an optimal set of intracellular fluxes [7, 8]. On the other hand, 13C-MFA
uses much smaller metabolic networks, but combines cellular influxes and eﬄuxes
with experimental data obtained from stable isotope labeling experiments [9, 10].
Isotopic labeling patterns are usually analyzed by mass spectrometry (MS) in the
form of mass isotopomer distributions (MIDs), which are the mass-aggregated rela-
tive isotopologue abundances. Since MIDs of metabolites from a given tracer within
a given metabolic network are solely a function of the metabolic fluxes, they can
be used to estimate these underlying fluxes [11, 12]. Using mathematical optimiza-
tion techniques, a set of fluxes is determined which can explain the experimentally
observed MIDs for a defined metabolic network model [9, 10].
A drawback, that all current metabolic flux analysis techniques have in common,
is that they rely on the exact topological knowledge of the metabolic network of
interest. However, knowledge of metabolic networks of most organisms is still not
comprehensive, as for example recently shown for mammalian macrophages which
were found to produce an unanticipated antimicrobial compound [1].
As stated above, MIDs from stable isotope labeling experiments hold metabolic
flux information. This is exploited in 13C-MFA, but only in a highly targeted man-
ner. However, there are methods available for the non-targeted MID determination
of compounds in complex mixtures after either gas chromatography MS (GC-MS)
[13, 14] or liquid chromatography MS (LC-MS) analysis [15–17]. These methods do
not rely on any biological knowledge, and thus, are able to account for any unan-
ticipated metabolite. To date, only very few studies performed non-targeted MID
analyses and obtained novel biological insights [15, 18]. Mostly, non-targeted detec-
tion of stable isotope labeling has been applied in a qualitative manner to separate
metabolites produced by the cell from analytical background [19–21]. One major
problem is still the lack of appropriate tools to extract biological information out
of the mass spectrometric data [22]. In particular, studies covering multiple exper-
imental conditions or time-points generate complex data and require proper tools
for efficient analysis and visualization of isotope labeling data.
In this article, we present a novel workflow for stable isotope labeling analysis that
allows for the non-targeted detection of 1) pathway activity, highlighting unexpected
parts of metabolism; 2) relative flux changes or differential pathway activity be-
tween conditions; and 3) the pathway contextualization of unidentified compounds
and their vicinity to other metabolites. This workflow can be used for data-driven
analyses and hypothesis generation which can be tested in subsequent targeted ap-
proaches. We illustrate our workflow by analyzing changes in cellular metabolism
of human lung cancer cells in response to varying oxygen availability ranging from
atmospheric 21% O2 down to 1% O2. Starting without a priori knowledge, we de-
tected metabolic flux changes, which led to an increased glutamine contribution to
acetyl-CoA, show that A549 lung cancer cells produce N -acetylaspartate, a com-
pound which is well known to have an important function in neuronal tissue, but
was until very recently[23] not known to be produced in other tissues, and show
that silencing its biosynthetic enzyme NAT8L exerts a negative growth effect.
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Methods
Chemicals
Stable isotope labeled tracers were bought from Cambridge Isotope Laboratories,
all other chemicals were bought from Sigma-Aldrich. All solvents were of grade
Chromasolv or higher.
Cell culture & stable isotope labeling
Human lung adenocarcinoma A549 cells (ATCC CCL-185, [24]) were cultivated in
D5030 medium (Dulbecco’s modified Eagle’s medium without glucose, glutamine,
phenol red, sodium pyruvate and sodium bicarbonate), supplemented with 10%
dialyzed fetal bovine serum and either 12.5 mM glucose, 12.5 mM [1,2-13C2]-D-
glucose and 4 mM glutamine, or with 25 mM glucose, 2 mM glutamine and 2 mM
[U-13C]-L-glutamine. Cells were seeded into 12-well multi-well plates at a density
of 3×105 cells in 0.75 ml growth medium and cultivated at 37 ℃, in an atmosphere
with 5% CO2 and 95% air with oxygen levels of 1%, 5%, 10%, 15%, and 21%. Before
applying the tracer-containing medium for 24 h, cells and media were equilibrated
to the respective oxygen levels for 24 h. Under each condition, 3–4 wells were used
for metabolite extraction.
Metabolite extraction and GC-MS analysis
Intracellular metabolites were extracted and polar metabolites were analyzed by
GC-MS as described in [25]. In short, a liquid-liquid extraction was performed
using chloroform:methanol:water. The quenching step using ice cold methanol was
performed at the respective oxygen levels. An aliquot of the polar phase was dried,
dissolved in pyridine containing methoxyamine hydrochloride and trimethylsilylated
using N -methyl-N -(trimethylsilyl) trifluoroacetamide (MSTFA).
GC-MS data processing and determination of isotopic enrichment
Deconvolution of mass spectra and targeted MID analysis were performed using
MetaboliteDetector version 2.820150209R [26]. The following MetaboliteDetector
peak picking and deconvolution settings were used: Minimum number of peaks: 25;
Peak threshold: 5; Minimum peak height: 5; Bins/scan: 10; Required base peak
intensity: 0; Deconvolution width: 3 scans. An even-numbered n-alkane mixture
(C10–C40) was measured for retention index calibration.
Non-targeted detection of stable isotope labeling and mass isotopolome anal-
ysis were performed using an in-house software based on the NTFD algorithm
[13, 14, 27]. For data analysis we considered all compounds which the NTFD algo-
rithm detected at least under one experimental condition two mass spectrometric
fragments with a coefficient of MID determination of R2 > 0.98,
∑ |Mi| < 1.05,
M0 abundance of 0.45 < M0 < 1 and minimal enrichment 1 −M0 ≥ 0.05. These
parameters are described in more detail in [27]. Because in non-targeted analysis the
maximal length of the MID vector is unknown, trailing mass isotopomer abundances
of below 0.01 have been considered as noise and been removed. Compounds were
identified based on RI and mass spectrum matching against an in-house reference
library. Known contaminants like siloxanes were excluded from further analysis. An-
alytes were identified based on RI and mass spectrum matching against an in-house
reference library.
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Mass isotopomer abundance variation
To detect compounds with most varying labeling patterns across different exper-
imental conditions, we analyzed the maximal standard deviation in relative mass
isotopomer abundance for every compound that was detected in at least three out
of five conditions:
variation score = maxσj | σj =
√√√√ 1
n
·
n∑
i=0
(pj − pj,i)2
where pi,j is the relative abundance of the Mj isotopologue of the given compound
in the i-th dataset and pj the average Mj abundance across all n datasets. The MIDs
of the heaviest common fragments across all conditions were used and the MIDs
of unlabeled compounds were not considered. Compounds with the top five MID
variation scores after [1,2-13C2]glucose and [U-
13C]glutamine labeling are shown in
Figure 3A (only one of two glutamate TMS derivatives is shown).
MID distance calculation
For calculation of MID distances, MIDs of the largest fragment with R2 > 0.95
of each compound was used. Correction for natural isotope abundance was per-
formed using the NTFD algorithm [27]. A Needleman-Wunsch alignment was per-
formed on the MID vectors minimizing the absolute differences in relative mass
isotopomer abundances using a gap penalty of 0.4 (Figure 1B). Subsequently,
the pairwise distances of all aligned MID vectors were determined (Figure 1A).
Therefore, the Canberra distance of two MID vectors A and B was calculated as
dA,B =
∑n
i=1
|Ai−Bi|
|Ai|+|Bi| and normalized by the sum of the dimensions of the MID
vectors (dnormA,B =
dA,B
dimA+dimB ). The most similar compounds are shown in Figure 4;
edge color represents the experimental condition at which the high similarity was
observed. In case of multiple TMS derivatives of the same metabolite only one is
shown.
MID deconvolution of aspartyl and acetyl moiety of N-acetylaspartate
The mass spectrometric fragment ions m/z 304 and m/z 245 of NAA 2TMS rep-
resent the [M-CH3]
+ and [M-CH3-CH3CONH2]
+ fragments, respectively (Supple-
mental Figure S5). The two fragments differ by the acetamido-group (CH3CONH2).
The MID of NAA (given by [M-CH3]
+) is the convolution or Cauchy product [12]
of the MIDs of the aspartyl moiety (MAsp, given by [M-CH3-CH3CONH2]
+) and
the acetamido moiety (MAc) of the molecule:

M0,NAA
M1,NAA
M2,NAA
M3,NAA
M4,NAA
M5,NAA
M6,NAA

=

M0,Asp 0 0
M1,Asp M0,Asp 0
M2,Asp M1,Asp M0,Asp
M3,Asp M2,Asp M1,Asp
M4,Asp M3,Asp M2,Asp
0 M4,Asp M3,Asp
0 0 M4,Asp

·
 M0,AcM1,Ac
M2,Ac

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This equation system was populated with the raw mass spectral intensities and
solved for MAc using a weighted least squares approach using the nlsLM routine
of the minpack.lm package (version 1.1-8) for the R statistics environment (version
3.1.2). The determined acetyl MIDs were corrected for natural isotope abundance.
siRNA transfection
For knockdown experiments, siRNA were reverse transfected into A549 cells
using Lipofectamine RNAiMAX (Invitrogen/Life Technologies). For each well
(12-well plate), 20 pmol siRNA were diluted in 200 µl Opti-MEM I reduced-
serum medium (Invitrogen/Life Technologies), supplemented with 2.5 µl Lipofec-
tamine RNAiMAX, gently mixed, and incubated for 20 min at room tempera-
ture. The prepared solution was spread in a well 5 min before 100,000 cells in
800 µl of DMEM 5796 growth medium containing 10% FBS were added. The
plate was gently mixed and incubated (37 ◦C, 5% CO2) for up to 72 h. ON-
TARGETplus non-targeting and NAT8L-targeting siRNA were obtained from
Dharmacon/GEHealthcare (see Supplemental Table S6 for target sequences).
Growth assay
For growth assays with A549 cells, cells were transfected and cultivated at 2%
oxygen as described above. After 72 h, cells were detached using trypsin, and cell
numbers and viability were determined using a Vi-CELL XR Cell Viability Analyzer
(Beckman Coulter). Cell viability was above 95% in all samples. Cell numbers are
presented as mean of three independent experiments, each consisting of 3-wells per
condition (Figure 5).
Human bronchial epithelial BEAS-2B cells (ATCC CRL-9609), human hepa-
tocellular carcinoma JHH-4 cells (JCRB Cell Bank) and non-neoplastic hepato-
cyte PH5CH8 cells [28] were transfected with non-targeting or NAT8L-targeting
siRNA as described above and cultivated at normoxia. Cells were seeded in 12-well
plates at densities of 95,000 cell/well for PH5CH8, 57,000 cells/well for JHH-4 and
100,000 cells/well for BEAS-2B. After 24 h, transfection medium was replaced by
DMEM 5796 growth medium containing 10% FBS (JHH-4 and PH5CH8) or LHC-9
medium (BEAS-2B). LHC-9 medium was prepared from LHC-8 media (Gibco) by
adding 33 nM retinoic acid (Lonza) and 2.75 µM epinephrine (Lonza). After 72 h,
cell numbers were determined as described above. Cell numbers are presented as
mean of three independent experiments, each consisting of three wells per condition.
Metabolome analysis
For semi-quantification of metabolite levels after NAT8L silencing (Figure 5), cells
were incubated at 21% O2 for two days after transfection. Metabolites were ex-
tracted and analyzed by GC-MS as described above. Data was analyzed using
MetaboliteDetector with settings as described above, but a deconvolution width
or 5 scans. Non-targeted batch quantification was performed over all data files and
mass spectrometric intensities were normalized to summed analyte signal of each
sample after exclusion of known contaminants. Replicates represent metabolite ex-
tracts from different cell populations (n = 3).
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Results
Mass isotopolome analysis
The starting point of our workflow is a stable isotope labeling experiment. After
mass spectrometric measurements of labeled and unlabeled metabolite extracts,
MIDs, corrected for natural isotope abundance, can be obtained in a non-targeted
manner [15, 16, 27]. We analyze these metabolome-wide MIDs, the mass iso-
topolome, to detect changes in metabolic fluxes and exploit MID similarity between
compounds for their pathway contextualization.
Locating flux changes by non-targeted mass isotopomer abundance variation
analysis
Since changes in MIDs can only be a consequence of altered metabolic fluxes, we
can reveal metabolic flux changes by detecting changes in the mass isotopolome
[29]. Therefore, MIDs of identical compounds are matched across different exper-
imental conditions to detect differences in relative mass isotopomer abundances.
As a measure of variation, for each isotopically enriched compound we calculate
the maximal standard deviation of relative mass isotopomer abundance across the
different experimental conditions (see Experimental Procedures). We assume that
large flux changes will lead to large changes in mass isotopomer abundances, al-
though this might neglect flux changes that make a small relative contribution to
a given metabolite pool. Thus, to find the most significant flux changes, we rank
metabolites by their aforementioned variation score. Like any MID analysis, this
approach is limited by the facts that 1) MIDs alone can only provide relative flux
information (flux ratios), and therefore, 2) not all changes in metabolic fluxes man-
ifest in MID changes. Furthermore, as in conventional metabolomics approaches,
metabolite pools of subcellular compartments are usually mixed during metabo-
lite extraction which might reduce their informative value. Apart from that, this
systematic analysis of relative mass isotopomer abundance variation detects flux
changes without the requirement of any biochemical a priori knowledge on the sys-
tem of interest or the identification of the respective compounds. It is only biased
by analytical restrictions and the choice of the isotopic tracer and will consider any
unanticipated reaction or metabolite which cannot be accounted for by current flux
analysis techniques.
MID-similarity assisted compound identification
For subsequent interpretation of the detected changes in mass isotopomer abun-
dances, the respective compounds need to be identified. This is usually achieved
by matching their mass spectra against reference libraries [30], but the available li-
braries are far from comprehensive. Although thousands of chromatographic / mass
spectrometric features, and among them at least several hundreds of metabolites
can be analytically detected [20, 31, 32], only a fraction thereof can be identified,
rendering compound identification a major bottleneck in current metabolomics re-
search [33]. When the detected features or at least their pathways or compound
classes are identified, they can provide more biological insights in addition to their
function as biomarkers. Hence, compound identification is, however cumbersome,
still highly important.
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For compounds that are not present in reference libraries, other means for iden-
tification are required. Here, we present an approach based on MID-similarity. As
described above, the MID of any metabolite is determined by those of its precursors
and the flux ratio of the producing reactions. Within linear pathways, the MIDs
of all compounds are identical, except if there are gains or losses of isotopically
enriched fragments of the molecules. Here we exploit the reverse conclusion, assum-
ing that compounds with identical or highly similar MIDs are more likely to be
intermediates of the same pathway or lie in the same area of the metabolic net-
work. Therefore, by analyzing the MID similarity of different compounds, they can
be grouped to metabolic pathways. Strictly speaking, this high MID similarity is
only granted in linear pathways. However, in converging pathways, if one flux is
much larger than the other, or there is only a dilution with the unlabeled isotopo-
logue, then the labeling pattern of the dominating precursor is mostly conserved in
the product MID and the reaction sequence can be seen as pseudo-linear. In this
case, the MID similarity is still significant. Empirically, this is the case for many
metabolic reactions.
To analyze MID similarity for pathway contextualization of unidentified com-
pounds, we pairwisely compare MIDs of all isotopically enriched compounds (Fig-
ure 1A). To account for potential losses or additions of isotopically enriched frag-
ments to the molecules which would shift the MIDs, we perform a Needleman-
Wunsch alignment [34] on the MID vectors prior to the similarity calculation (Fig-
ure 1B). As a similarity measure, we compare the Canberra distances of all pair-
wisely aligned MIDs. This pairwise comparison results in a distance or similarity
matrix. After applying an empirically determined distance cutoff, we create a net-
work of compounds with higher MID similarity. The resulting graph is likely to show
metabolically connected compounds. However, the MID similarity can — dependent
on tracer and pathways — be ambiguous. The specificity can be increased by us-
ing distinct tracers and multiple experimental conditions (Figure 1A). Edges in the
graph occurring in multiple conditions are more likely to be biologically meaningful.
In summary, MID similarity between compounds can indicate proximity within
the metabolic network. This can be used to associate unidentified compounds with
identified ones, and to map them to specific pathways. This itself is valuable informa-
tion and can furthermore be a strong hint for subsequent compound identification.
For both identified and unidentified compounds such an MID similarity analysis can
reveal new biosynthetic pathways or help to distinguish between different known
ones.
Method summary
The proposed workflow starts with stable isotope labeling experiments, mass spec-
trometric analysis, and the non-targeted detection of isotopically enriched com-
pounds (Figure 2B). In addition to MIDs, such an analysis yields, for each com-
pound, the labeled and unlabeled mass spectra, as well as the chromatographic
retention time, often normalized as retention index (RI). Qualitative analysis of
isotopic enrichment provides information on active fluxes and the general fate of
the metabolic tracer. MIDs from different experimental conditions are systemati-
cally analyzed to detect changes in metabolic fluxes. MID similarity may indicate
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metabolic proximity, hence, MIDs of compounds of interest are compared to all
other MIDs for pathway contextualization, discovery of potential precursors, or to
facilitate identification of unidentified compounds.
Overall, this non-targeted approach provides information on: 1) active pathways,
2) changed fluxes, and 3) compound identities. This information holds biological
insights itself and will furthermore generate hypotheses for subsequent analyses
(Figure 2A).
An additional advantage of non-targeted isotope labeling analysis is that, depend-
ing on the proper tracer choice, it clearly shows whether a given compound is formed
by the organism or was externally introduced as ingredient of an undefined growth
medium or as contamination and thus provides an additional quality control. Fur-
thermore, an advantage of the analysis of MIDs over metabolite levels is that they
are more robust to technical variation than metabolite levels.
Mass isotopolome analysis in hypoxic cancer cells
We illustrate the developed approach by analyzing human lung cancer cell
metabolism under different oxygen levels. We have chosen this condition, because
hypoxia induces strong changes in cellular metabolism which have been studied
intensively in cancer cells [35–39]. The large number of previous studies would al-
low us to readily confirm our findings and to validate our approach. Furthermore,
it was interesting to see if our approach was able to identify novels features. To
this end, we performed stable isotope labeling experiments with [1,2-13C2]glucose
and [U-13C]glutamine under oxygen levels ranging from 1% O2 to atmospheric 21%
O2. We chose glucose and glutamine as isotopic tracers because they are the major
carbon sources of most mammalian cells, and therefore, lead to a good metabolome
coverage of isotopic enrichment. After GC-MS analysis of the metabolite extracts,
we determined all isotopically enriched compounds along with their MIDs in an au-
tomated and non-targeted manner. We detected 24 compounds which were labeled
from [U-13C]glutamine and 60 labeled from [1,2-13C2]glucose (Supplemental Tables
S1–S2).
Non-targeted flux profiling reveals changes in intermediary metabolism
To detect hypoxia-induced metabolic flux changes in a non-targeted manner, we ap-
plied the aforementioned mass isotopomer abundance variation analysis and focused
on the 5 compounds with the highest variation resulting from [U-13C]glutamine and
[1,2-13C2]glucose labeling. Three compounds were common to both datasets, two
were unique to one set (Figure 3A, only one out of two glutamate TMS derivatives
is shown).
With decreasing O2 levels, the compounds with high MID variation after glu-
cose labeling showed an increase in the unlabeled (M0) fraction and a concomitant
decrease in the abundances of heavier mass isotopomers, indicating decreased glu-
cose contribution to their biosynthesis (Figure 3A). The compounds with changed
MIDs after glutamine labeling had an either relatively constant or slightly increas-
ing enrichment. Additionally, three of these compounds showed a switch of the
most abundant mass isotopomer indicating a change of their biosynthesis route
(Figure 3A).
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While the detection of these changes in labeling patterns was fully non-targeted
and did not require the compounds to be identified, the further interpretation re-
quires their identification, as well as detailed knowledge on the metabolic network,
including carbon atom transitions. Hence, to interpret the observed changes in
isotopic labeling, we tried to identify the corresponding compounds by matching
their mass spectra against an in-house reference library. We identified the highest-
ranking metabolites from glutamine labeling as the trimethylsilyl (TMS) derivatives
of malate, glutamate, citrate and N -acetylaspartate (NAA) (Figure 3A). From glu-
cose labeling we identified citrate and malate, NAA and adenosine monophosphate
(AMP). One compound remained unidentified; its mass spectrum could not been
found in any of the common mass spectrum reference libraries such as the Golm
Metabolome Database (GMD) or the NIST mass spectral library.
Citrate, malate, and glutamate and NAA are all associated with the citric acid
cycle. With decreasing O2 levels, their isotopic enrichment from [U-
13C]glutamine
changes significantly due to increasing reductive carboxylation of 2-oxoglutarate
by isocitrate dehydrogenase (IDH) [36, 37] (Figure 3B). This reductive IDH flux
increased severalfold with decreasing O2. At the same time, isotopic enrichment
from [1,2-13C2]glucose was significantly reduced, indicating a relative decrease in
glucose-carbon entering the citric acid cycle as a results of pyruvate dehydrogenase
(PDH) inhibition [40].
For this mass isotopomer abundance variation analysis we used the heaviest mass
spectrometric fragment that was detected as isotopically enriched. For malate, cit-
rate and glutamate, the selected fragment all contained the full carbon backbone of
the native metabolites. However, for NAA and AMP the MIDs represent only a sub-
structure of the analytes, so that interpretation is only possible if the fragmentation
is known. The MIDs shown for fragment m/z 169 of AMP 5TMS (Figure 3A) most
likely represent the ribose moiety of AMP [41]. These labeling changes might hint
towards changed fluxes through the pentose phosphate pathway, but require further
validation. The MIDs of fragment m/z 245 of NAA exhibited very high similarity to
malate, suggesting that this fragment contains only the aspartate moiety, but not
the acetyl moiety of NAA (Figure 3A). Combinatorial analysis of possible fragment
formulas using FFC [42] indicated that this fragment most likely arises from loss
of the acetamido-moiety of NAA which was confirmed by stable isotope labeling
(Supplemental Figure S5). This turned out to be of interest because it allows for
the deconvolution of the MIDs of the aspartyl- and acetyl-moiety of NAA and hence
can be used as a proxy to assess acetyl-CoA labeling under isotopic steady state
conditions (Figure 3C). The determined isotopic enrichment of the NAA acetyl-
moiety provides additional evidence for progressive increase of carboxylation of
2-oxoglutarate to provide acetyl-CoA for fatty acid biosynthesis under hypoxia [36].
MID-similarity assisted compound identification
Among the compounds with highly varying MIDs, as well as among the isotopically
enriched compounds in general, there were several compounds which we were not
able to identify using our in-house or any other commonly available reference library.
However, to be able to interpret the observed MID changes, knowledge on their
metabolic origin is imperative.
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To show that the aforementioned MID similarity analysis can be a valuable tool to
aid compound identification, we first performed MID similarity analysis on the al-
ready identified NAA. The compounds with the most similar labeling patterns after
[U-13C]glutamine labeling were aspartate, malate and pyroglutamate (Figure 4A),
and alanine and citrate after [1,2-13C2]glucose (Figure 4B). Aspartate is the di-
rect precursor of NAA and the other compounds are only a few reactions away,
demonstrating that MID similarity analysis can indeed provide valuable hints on
metabolically closely related compounds (Figure 4C).
Next, we performed the same analysis to aid identification of the yet unidentified
compound RI 2578 which popped up in the MID variation analysis (Figure 3A). The
heaviest fragment that was detected as isotopically enriched showed very high MID
similarity to citrate after [U-13C]glutamine labeling, suggesting that the unidentified
compounds must be closely related to citrate (Figure 4D). The compounds with high
MID similarity after [1,2-13C2]glucose labeling, glycerol 3-phosphate and pyrogluta-
mate, are very distantly related, and therefore, are less informative (Figure 4E). The
analyzed fragment m/z 363 has only about half the mass of the heaviest fragment
m/z 666 of the spectrum (Supplemental Figure S7). For the heaviest fragment, no
enrichment patterns could be determined due to its low abundance and low enrich-
ment. We assumed the heaviest fragmentm/z 666 was the [M-CH3]
+ ion, a fragment
ion that is commonly observed after electron ionization of TMS derivatives in place
of the molecular ion [M]+. In order to identify compound RI 2578, we searched
the HMDB database [43] for the mass of the native metabolite, assuming due to
its retention index 5 or 6 TMS groups in the molecule. Of the 38 database hits,
β-citrylglutamate (β-CG) was the candidate that could account for the observed
high MID similarity to citrate (Figure 4D,F). Unfortunately, there was neither an
authentic standard of β-CG commercially available to confirm this tentative iden-
tification, nor was there an electron ionization mass spectrum published. However,
as discussed below, there is biological evidence supporting this identification.
NAT8L-mediated NAA biosynthesis in lung cancer cells
We were intrigued by finding NAA in lung cancer cells, with its isotopic enrichment
clearly indicating its de novo biosynthesis there, although so far biosynthesis was
assumed to be restricted to neuronal tissue. Therefore, we followed up on this finding
to investigate whether NAA plays a significant role in cancer cells. The recent study
by Lou et al. [23], reporting some of the results presented below, was only published
during the preparation of this manuscript.
In neurons, NAA is known to be produced by NAT8L [44]. To confirm NAT8L
as the producing enzyme in A549 cells, we transfected them with NAT8L targeting
siRNA and analyzed polar metabolite extracts by GC-MS. Upon NAT8L silenc-
ing, NAA levels were drastically reduced (Figure 5A), confirming NAT8L-mediated
biosynthesis of NAA. Besides, NAA, we also observed production of another neu-
ropeptide, N -acetylaspartylglutamate (NAAG), by A549 cells. NAAG is synthesized
from NAA by RIMKLA and RIMKLB, the latter of which also catalyzes the forma-
tion of β-CG as alternative product [45]. Both RIMKLA and RIMKLB were found
to be expressed in A549 as determined by qPCR analysis (data not shown). Upon
transfection with NAT8L targeting siRNA, NAAG levels dropped below the detec-
tion limit (Figure 5B), whereas the levels of putative β-CG increased (Figure 5C).
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As mentioned above, there was unfortunately no authentic standard available to
confirm the identity of RI 2578 as β-CG. Yet, its identification is corroborated by
mass spectrometric fragmentation (Supplemental Figure S7), stable isotope label-
ing data as well as the correlation of NAT8L silencing with an increase in levels of
RI 2578.
Loss of NAT8L function impairs cell proliferation
Others have observed a positive correlation between NAA levels and malignancy of
prostate tumors [46] and identified NAA as a potential diagnostic blood biomarker
for cancer [23]. To determine whether NAA or NAT8L have an effect on cell prolif-
eration, we performed growth assays after siRNA-mediated NAT8L silencing. After
72h, the number of cells transfected with NAT8L-targeting siRNA was 28% lower
than the ones transfected with a non-targeting siRNA, suggesting a substantial role
of NAA or NAT8L in A549 cells (Figure 5D). To confirm this finding, we repeated
the experiments using bronchial epithelial BEAS-2B cells, hepatocellular carcinoma
JHH-4 cells and non-neoplastic hepatocyte PH5CH8 cells. All three cell lines showed
a similar reduction in cell numbers of about 20–30% after transfection with NAT8L
targeting siRNA (Figure 5E).
Discussion
Non-targeted data acquisition and analysis approaches are valuable tools to generate
initial hypotheses, especially when little a priori information is available on the
organism or subject of interest. We showed how stable isotope labeling experiments
and subsequent non-targeted mass isotopolome analysis can be used for metabolic
flux profiling and hypothesis generation (Figure 2A).
To demonstrate our novel non-targeted stable isotope labeling analysis workflow,
we performed stable isotope labeling experiments with human adenocarcinoma cells
incubated in the presence of 13C-labeled glucose and glutamine at various oxygen
levels and analyzed the resulting mass isotopolome. We illustrated that our approach
can be used to extract biologically meaningful information instead of mere statistical
differences. Although we applied our workflow on GC-MS data, it can also directly
be used in LC-MS experiments which may provide higher metabolome coverage.
We globally analyzed mass isotopomer abundance variation across different exper-
imental conditions to detect metabolic flux changes in a non-targeted manner. MIDs
after stable isotope labeling are determined by metabolic fluxes. This relationship
is already exploited in 13C-MFA, but only in a highly targeted manner. Here, we
applied a global differential MID analysis to detect metabolic flux changes without
considering the identity of the respective compounds. Therefore, even if such flux
changes occurred in yet unknown reactions, they would pop up in this analysis,
rendering compound identification dispensable at this stage of the analysis. Since
for many organisms or cell types the metabolic network is not fully known, such a
non-targeted and data-driven approach is highly desirable. It will not replace subse-
quent targeted experiments, but it can be a valuable scouting strategy to not miss
unanticipated reactions or metabolites and to validate the assumptions required for
example for 13C-MFA.
To demonstrate and validate our approach we analyzed cellular metabolism of
lung cancer cells at different oxygen levels. The data-driven analysis of isotopic
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enrichment correctly identified enhanced reductive carboxylation of 2-oxoglutarate
to isocitrate by IDH and subsequent cleavage of citrate by ACLY to produce cy-
tosolic acetyl-CoA which flows into increased fatty acid biosynthesis [36–38] (Fig-
ure 3). This inversion of IDH flux directionality is an important feature of cancer
cells since it allows for the generation of acetyl-CoA from glutamine under hypoxia
when acetyl-CoA production from glucose is strongly inhibited. The non-targeted
detection of these previously reported findings validate our approach.
We argued that, because MID similarity often correlates with metabolic prox-
imity, comparison of MIDs of different compounds can reveal metabolic similarity.
Addressing a current bottleneck in non-targeted metabolomics studies, we demon-
strated how the similarity in MIDs after stable isotope labeling can facilitate com-
pound identification. Knowledge of biochemically related compounds helps to con-
strain database searches and it can help to elucidate unknown biosynthetic path-
ways by revealing potential precursors. Although MID similarity analysis will not
always allow for compound identification, it can still be used to put unknown com-
pounds into the context of certain biochemical pathways or to provide hypotheses
on chemical substructures. MID similarity can, dependent on tracer and pathways,
sometimes be ambiguous. However, this ambiguity can be reduced by the use of dis-
tinct tracers and multiple experimental conditions as done in this study. Analysis
of MID similarity can additionally provide valuable hints on the composition of a
given mass spectrometric fragment, as shown above for NAA.
A related approach to our MID similarity analysis is the recently described
“metabolic turnover analysis” [47] which analyzes correlations in mass isotopomer
abundances to determine metabolic distances. Whereas Nakayama et al. [47] ana-
lyzed time-series data from a transient labeling experiment, we compare MIDs from
only one single time-point. The dynamic nature of metabolic turnover analysis has
the advantage, that it can reveal the sequence of intermediates of linear pathways,
an information that is lost in isotopic steady state. However, this extra information
comes at the cost of a more complex experimental setup.
We demonstrated the value of our MID similarity analysis in the case of the al-
ready identified NAA and an unidentified compound, the spectrum of which was
not present in any of the common reference libraries (Figure 4). This MID similarity
analysis constrained the database search for the given nominal mass to only one can-
didate structure. This putative identification is corroborated by mass spectrometric
fragmentation, isotope labeling and a gene silencing experiment.
Using stable isotope labeling and siRNA-mediated gene silencing we showed that
A549 lung cancer cells produce NAA and its downstream metabolite and neuropep-
tide NAAG (Figure 5). NAA is highly abundant in the brain and was long thought
to only be produced in neuronal tissues. Its functions are still not fully understood,
but several potential roles are discussed [48, 49]. In the context of cancer, NAA has
not received much attention, except for tumors of the brain where NAA concen-
trations are high per se. Increased levels of NAA were detected in ovarian tumors
[50–54] and a positive correlation between urinary NAA levels and malignancy of
prostate cancer cells has been observed [46]. Only during the preparation of this
manuscript, two independent studies focusing on NAA and NAT8L were published
[23, 55]. At the time of our study, it was not yet clear whether increased NAA levels
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in cancer cells are due to endogenous biosynthesis or accumulation of exogenous
NAA. Here, using 13C-labeling, we showed that lung adenocarcinoma cells are able
to produce this metabolite via the NAT8L enzyme. Production of NAA is not lim-
ited to A549 cells; we also detected NAA in prostate (RWPE-2) and liver (HepG2)
cancer cell lines and in bronchial epithelial cells (BEAS-2B) non-neoplastic hepato-
cytes (PH5CH8) (unpublished observations). Lou et al. investigated NAA levels and
NAT8L expression levels in lung cancer in parallel and independently of our studies
and their findings were published during the preparation of our manuscript [23].
Here we confirm their report on NAA production in A549 cells and show further-
more that the NAA downstream metabolite NAAG is produced and that NAT8L
silencing inhibits cell proliferation (Figure 5). Production of NAA and a negative
effect of NAT8L silencing on proliferation has also been reported by Zand et al. in
ovarian cancer cells [55]. Furthermore, they showed a lower survival rate of cancer
patients with higher NAT8L and NAA levels. These data hint towards a more inte-
gral role of NAA in cancer cells, more than a mere biomarker or byproduct, which
needs to be investigated further.
Nothing is known about the mechanistic role of either NAA, NAAG or NAT8L in
cancer yet. Exogenous NAA was found to increase proliferation of glioma stem-like
cells [56]. Pessentheiner et al. reported that NAT8L plays an important role in lipid
metabolism in brown adipocytes [57]. Its functional role there is yet unclear, but
the authors hypothesized an N -acetylaspartate-based acetyl-CoA shuttle across the
mitochondrial membrane, as suggested for neurons [58, 59] and similar to the inter-
cellular acetyl-transport observed in the brain [48]. In this model, NAA is exported
from the mitochondria, deacetylated by cytosolic aspartoacylase (ASPA) and the
resulting acetate is activated by cytosolic acetyl-CoA synthase (ACSS2). Such a
shuttling mechanism to provide cytosolic acetyl-CoA would also be advantageous
for cancer cells which are known to have increased fatty acid biosynthesis. NAA-
based acetyl-CoA shuttling would decouple acetyl-transport from citrate synthesis
for oxidation in the citric acid cycle. Furthermore, it would explain recent findings
on the importance of ACSS2 in cancer cells [60–62]. The inhibition of cell prolifera-
tion we observed here upon NAT8L silencing would be in line with NAA-mediated
acetyl transport. Lack of NAT8L could induce a shortage of cytosolic acetyl-CoA
for fatty acid biosynthesis and other metabolic processes which would eventually
reduce cell proliferation. More data are required to unravel the exact mechanism by
which NAT8L confers a growth advantage to these cells. This acetyl-shuttling relies
on mitochondrial NAA biosynthesis. However, there is no consent about subcellular
localization of NAT8L [63–68].
If NAT8L was only localized in the cytosol, NAA could still play an important role
as precursor of NAAG, which we also detected in A549 cells. NAAG was reported
as an agonist at type II metabotropic glutamate receptors [69, 70] which are also
expressed by cancer cells [71] and have been shown to promote cell proliferation [72].
The observed reduction in cell proliferation after NAT8L silencing could therefore
be due to reduced levels of NAAG.
An alternative product of RIMKLB, one of the NAAG-producing enzymes, is β-
CG [45] which we putatively identified in A549 cells. Very little is known about
the function of this metabolite. It was suggested to act as an iron carrier, able to
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reactivate aconitase activity and increasing cell viability [73]. It is unclear whether
β-CG plays a specific role in A549 cells, or whether it only forms as a side product
of RIMKLB.
Besides any biological role, NAA is of analytical interest because of its mass spec-
trometric fragmentation. Under isotopic steady state conditions, it can be used to
deduce labeling of the acetyl-CoA pool from which it is synthesized (Figure 3).
Acetyl-CoA is a hub of many anabolic and catabolic reactions, linking fatty acid,
carbohydrate and amino acids metabolism, and is a substrate for protein acetyla-
tion. Acetyl-CoA is not directly accessible via GC-MS measurements, but its iso-
topic enrichment can alternatively be deduced from labeling patterns of fatty acids
by isotopomer spectral analysis (ISA) [74]. However, this requires additional sample
processing and measurements and is further complicated by the fact that cellular
fatty acids can be derived from medium components directly or by elongation or be
synthesized de novo. When the localization of NAT8L is resolved, NAA may fur-
thermore provide a means to analyze isotopic enrichment of a compartment-specific
acetyl-CoA pool.
Analyzing isotopic enrichment of the acetyl-moiety of NAA at different oxygen lev-
els revealed that with decreasing oxygen availability, acetyl-CoA was progressively
increasingly derived from glutamine instead of glucose, whereas their combined con-
tribution was relatively stable.
Conclusions
We applied stable isotope labeling and illustrated a novel non-targeted mass iso-
topolome analysis approach to systematically analyze the metabolic hypoxia re-
sponse of human lung cancer cells. We employed non-targeted mass isotopomer
abundance variation analysis for non-targeted metabolic flux change profiling and
showed how MID similarity can assist compound identification, addressing a major
bottleneck of current metabolomics research. This approach can also account for
unknown or unanticipated reactions, thus bridging the gap between non-targeted
metabolomics and 13C-MFA. With this data-driven analysis we detected known
hypoxia-induced metabolic effects, validating our approach. Furthermore, this anal-
ysis led to the discovery of a potentially important role of NAA in cancer cell
metabolism, which needs to be investigated further. In summary, this non-targeted
approach provided biological insights and proved to be a fruitful methodology for
hypothesis generation for subsequent more targeted analyses.
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Figures
Figure 1 MID similarity analysis for pathway contextualization and detection of metabolically
related compounds.
A) The pairwise similarities of all MIDs is determined. A similarity threshold is applied, and
compounds with highly similar MIDs are visualized as network. Networks derived from different
experimental conditions can be overlaid for more information.
B) Before the distance calculation the MID vectors are aligned to account for gains or losses of
labeled fragments, which would otherwise conceal the metabolic proximity of these compounds.
Additional Files
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Figure 2 Workflow for non-targeted mass isotopolome analysis.
A) Non-targeted approaches are valuable for hypothesis generation. These hypotheses are
subsequently tested by more targeted techniques leading to refined hypotheses and biological
insights.
B) Data-driven analysis of non-targeted stable isotope labeling data. After stable isotope labeling
experiments active pathways and changed fluxes can be detected in a non-targeted manner from
metabolome-wide MIDs and changes therein. Compound identity and additional biochemical
knowledge is only needed for further interpretation. Analysis of MID similarity between
compounds can aid their identification or help to determine their biosynthetic pathways. Yellow
boxes highlight new analysis techniques presented in this article.
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Figure 3 Effects of different oxygen levels on MIDs and metabolic fluxes in lung cancer cells fed
with [1,2-13C2]glucose or [U-13C]glutamine. In total, 73 compounds were detected as isotopically
enriched under at least one experimental condition.
A) Compounds with the highest variation in relative mass isotopomer abundances. Non-targeted
analysis revealed that the MIDs of citric acid cycle associated metabolites and an unidentified
compound were most affected by changes in oxygen levels. Arrows indicate the mass isotopomers
abundances with the highest variation. Unidentified compounds are named by their
chromatographic retention index (RI). n.d.: not determinable. See also Table S3.
B) Simplified model of how these strong changes in MIDs at low oxygen can be explained by the
relative reduction of PDH flux and inversion of IDH flux directionality (see text).
C) NAA 2TMS can be used as a proxy to determine acetyl-CoA labeling under isotopic steady
state conditions. Mass spectrometric fragmentation of NAA 2TMS allows to deconvolute the
MIDs of the acetyl- and aspartyl-moiety (see also Figure S5). Isotopic enrichment of the
acetyl-moiety reflects changes in carbon origin of the acetyl-CoA pool from which NAA was
synthesized. Contribution from [U-13C]glutamine (blue) or [1,2-13C2]glucose (red) as well as their
summed contribution (grey) across different oxygen levels are shown. Enrichment was corrected
for the applied tracer ratio and partial labeling in the case of [1,2-13C2]glucose. Data are
represented as mean±SD (3 ≤ n ≤ 4).
Abbreviations: IDH/PDH: isocitrate/pyruvate dehydrogenase; ACLY: ATP-dependent citrate
lyase; CS: citrate synthase; Glc: glucose; Pyr: pyruvate; AcCoA acetyl-coenzyme A; Cit: citrate;
OAA: oxaloacetate; Mal: malate; NAA: N-acetylaspartate.
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Figure 4 MID similarity reflects metabolic similarity and can aid compound identification.
Application to an identified and an unidentified compound.
A,B) The networks show the compounds with the closest MIDs to N-acetylaspartate (NAA) after
(A) [U-13C]glutamine or (B) [1,2-13C2]glucose labeling. Edge color represents the experimental
condition at which the high MID similarity was observed.
C) Scheme of glycolysis and citric acid cycle showing those compounds with most similar MIDs to
NAA after [U-13C]glutamine (blue) or [1,2-13C2]glucose labeling (red).
D,E) Compounds with the closest MIDs to the unidentified compound RI 2578 after (A)
[U-13C]glutamine or (B) [1,2-13C2]glucose labeling.
F) Scheme of metabolic network showing those compounds with most similar MIDs to RI 2578
after [U-13C]glutamine (blue) or [1,2-13C2]glucose labeling (red), supporting its tentative
identification as β-citrylglutamate (β-CG).
Mal: malate; Asp: aspartate; Cit: citrate; Lac: lactate; Glu: glutamate; Gln: glutamine; Suc:
succinate; OAA: oxaloacetate; 2OG: 2-oxoglutarate; Pro: proline. See also Table S4.
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Figure 5 Effects of siRNA-mediated silencing of NAT8L.
Transfection of A549 cells with NAT8L targeting siRNA (siNAT8L) leads to a significant
reduction of A) NAA and B) NAAG levels, and C) an increase in β-CG as compared to
transfection with a non-targeting siRNA (siCtrl) or untreated cells (Ctrl). NAAG levels after
NAT8L silencing were below the detection limit (n.d.: not determinable).
D) Proliferation of A549 cells is significantly reduced upon transfection with NAT8L targeting
siRNA (siNAT8L) as compared to transfection with a non-targeting siRNA (siCtrl). Cell numbers
72h after siRNA transfection are normalized to average of siCtrl.
E) Proliferation of hepatocellular carcinoma cells (JHH-4), bronchial epithelial cells (BEAS-2B),
and non-neoplastic hepatocytes (PH5CH8) is significantly reduced upon transfection with NAT8L
targeting siRNA (siNAT8L) as compared to transfection with a non-targeting siRNA (siCtrl). Cell
numbers 72h after siRNA transfection are normalized to average of siCtrl.
Data are presented as means ± standard deviation of n = 3 replicates (A–C) or 3 independent
experiments with 3 technical replicates (n = 9); asterisks indicate Welsh’s t-test p-values of below
0.05 (*) or 0.01 (**).
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